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Abstract 
Introduction Streptococcus pneumoniae (or pneumococcus) is a common 
commensal (coloniser) of the human upper respiratory tract. Colonisation is likely a 
prerequisite for respiratory tract infections and invasive pneumococcal disease. 
Colonisation also has a significant role in the horizontal spread of this pathogen 
within communities, but paradoxically could also lead to boosting of the host’s 
immune system. We use the unique experimental human pneumococcal challenge 
(EHPC) model to study pneumococcal transmission and colonisation in healthy 
adults. This novel study design allows us to investigate bacteriological and immune 
factors associated with colonisation and to examine the density and duration of 
colonisation episodes.  
Project Aims 1) Investigation of the transmission dynamics of Streptococcus 
pneumoniae. Can the hands can be a vector for transmission of S. pneumoniae into 
the nasopharynx, leading to colonisation? Does concurrent asymptomatic viral 
infection affect transmission? 2) Investigation of the propensity of two 
pneumococcal serotypes to cause experimental pneumococcal colonisation, to 
improve the generalisability of the model and to investigate if immunological 
responses to serotype 6B are similar to other serotypes. We also wanted to 
investigate if colonisation is an asymptomatic process in healthy adults? How do the 
host’s polysaccharide specific antibody responses affect colonisation?  
Main findings Using our unique controlled human pneumococcal challenge model, 
we have demonstrated the viability of transmission of pneumococcus from the hand 
into the nasopharynx, leading to colonisation. We were unable to investigate the 
relationship between colonisation acquisition and concurrent viral infection due to the 
 xxx 
absence of viral infection in our participants. The data presented in this thesis showed 
that the experimental human pneumococcal carriage model can successfully 
investigate transmission dynamics of pneumococcus. We also demonstrated the 
varying propensity of two pneumococcal serotypes, 23F and 15B to experimentally 
colonise the nasopharynx of healthy adults. Nasopharyngeal colonisation was shown 
not to cause nasal symptoms; however, the data suggested that colonisation may 
cause a cough in healthy adults. No relationship was found between the level of serum 
IgG to 15B capsular polysaccharide at screening and colonisation outcome after intranasal 
inoculation. Nasopharyngeal colonisation with 15B was however, found to boost 
polysaccharide specific immunity; colonisation positive participants had a significant 
increase in serum IgG levels to 15B capsular PS.  
Implications Data presented in this thesis suggest that good hand hygiene practices, 
already known to reduce enteric bacterial and viral disease, may also prevent the 
spread of pneumococcus which is thought to be spread primarily through 
aerosolisation. Results support epidemiological studies which have shown the 
varying propensity of different pneumococcal serotypes to cause colonisation. We 
can build upon this work by investigating serotypes in vitro and in vivo to understand 
bacterial factors that impact the pneumococcus’ ability to colonise the nasopharynx 
in humans. The EHPC model will be useful in further studies to better understand the 
dynamics and drivers of pneumococcal transmission, bacterial factors which support 
successful colonisation and host responses to pneumococcal exposure and 
colonisation. 
 
 xxxi 
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This thesis focuses on investigating the drivers of nasopharyngeal pneumococcal 
colonisation. Two studies were conducted, and the clinical aspects of these studies 
will predominantly be discussed in this thesis. Both studies used the experimental 
human pneumococcal challenge model to answer research questions which are 
outlined at the end of the introduction. To form a rationale for these studies, a 
literature review was conducted on pneumococcal colonisation, transmission of 
Streptococcus pneumoniae and pneumococcal disease and is presented below along 
with description of gaps in the literature. Following this introduction, the methods 
section outlines the broad methods relevant to both studies described in this thesis. 
Chapter 3 and 4 describe the results of the two studies conducted as part of this MD 
project. The final chapter (Chapter 5) is a general discussion of the main findings of 
both studies, a methodological critique of the work conducted and the implications 
of the findings with an outline of possible future work in this field.  
1.1 Overview 
Streptococcus pneumoniae (or pneumococcus) is Gram-positive bacterium which is a 
common cause of respiratory tract infections and invasive disease worldwide. 
Pneumococcus is also a common commensal (coloniser) of the human upper 
respiratory tract. The majority of pneumococcal serotypes have a polysaccharide 
capsule (CPS) that surrounds the cell wall 1. There are over 90 different serotypes 
described, each with a biochemically unique polysaccharide capsule. In most 
Introduction 
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serotypes this capsule is attached to the cell wall of the pneumococcus by covalent 
bonds 2. Epidemiological studies have shown that most serotypes can cause disease, 
however, the majority of pneumococcal infections are secondary to a minority of 
serotypes 3. This thick layer of CPS improves the organism’s ability to evade the host’s 
defences and is required for invasive infection 4.  The mechanisms by which the 
capsule aids in evading the host’s defences include: 
• Repelling anionic mucus with it’s negatively charged polysaccharide capsule 
which allows the bacteria to escape the nasal mucus 5 6 
• Inhibition of phagocytosis by innate immune cells again by electrostatic 
repulsion 6 
• Helping to escape neutrophil net traps 6 
• Inhibition of complement and helps reduce recognition by immunoglobulins6 
The World Health Organisation (WHO) named Streptococcus pneumoniae as a 
priority pathogen in 2017 because it poses a high level of threat to human health 7. 
Invasive disease occurs when pneumococcus proliferates in areas of the body such 
as the middle ear, sinuses, blood stream and lungs (Figure 1) 8. Meningitis, sepsis and 
pneumonia are the predominant invasive diseases caused by pneumococcus and are 
more common in high risk groups including elderly people, patients with 
immunodeficiencies and young children 9.  
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Figure 1: Pathogenesis of pneumococcal disease  
Streptococcus pneumoniae colonises the nasopharynx, this often leads to clearance following a local 
immune response. Local spread and progression to otitis media is common in children. Children have 
the highest rates of nasopharyngeal pneumococcal colonisation.  Aspiration into normally sterile 
alveoli can lead to pneumonia or into the blood stream leading to bacteraemia. Complications such 
as meningitis and empyema can also occur. 1 9 
Transmission and acquisition of this pathogen and its colonisation in the nasopharynx 
is likely a pre-requisite for the development of infectious disease. Colonisation also 
has a significant role in horizontal spread of this pathogen within communities and 
could also lead to immune protection. Controlled human infection studies have 
shown that colonisation can be an immunising event; an increase in both anti-
pneumococcal antibody and T cell specific responses have been shown following 
colonisation 10.  
Introduction 
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Pneumococcus is a leading cause of lower respiratory tract infection and pneumonia 
worldwide. Definitive microbiological diagnosis is often difficult and antibiotic 
resistance is increasing. Strategies to prevent pneumococcal disease are becoming 
increasingly important. Therefore, this thesis focusses on investigating drivers of 
pneumococcal colonisation acquisition which may be blocked to reduce 
pneumococcal burden.  
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1.2 Colonisation  
 Pneumococcal colonisation 
Stable colonisation of the human nasopharynx with S. pneumoniae is a common 
human phenomenon with 40-95% of infants and 10-25% of adults colonised at any 
time11 12-15. The upper respiratory tract is also an ecological niche for many other 
bacterial species which colonise it, including the pneumococcus 16. Rates of 
pneumococcal acquisition and colonisation vary greatly by age, geographical location 
and socioeconomic background 9.  
Colonisation with pneumococcus is a dynamic process. Multiple pneumococcal 
serotypes can colonise the nasopharynx both simultaneously and sequentially but 
there is usually a predominant current colonising serotype 17. In addition, 
interspecies competition between resident flora such as alpha-haemolytic 
Streptococci inhibit potential colonisers including S. pneumoniae, H. influenzae and 
S. aureus. This leads to a constantly changing composition of the nasopharyngeal 
flora. I t is poorly understood why this leads to dynamism in the nasopharyngeal 
microbiome rather than a static state dominated by α haemolytic streptococci 9.  
Colonisation requires that the pathogen penetrates the mucous barrier which 
overlies the epithelium and avoids mechanical clearance mechanisms 5. Robust 
binding to host cellular carbohydrates and proteins is mediated by cell-wall 
associated proteins such as pneumococcal surface adhesins 5 . The bacterium must 
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also survive and replicate despite host cellular and humoral defences. Selective 
pressures have led to niche adaptation and may increase virulence (see Figure 2) 5. 
These local host responses play an important role in regulating all pathogens 
including pneumococcus in the upper airway. People who mount a poor mucosal 
immune response may subsequently develop persistent or recurrent colonisation 
episodes 18 19. Conversely a quick and efficient local immune response can result in 
elimination of colonisation and prevention of re-colonisation 18 19.   
 
Figure 2: The stages of pneumococcal colonisation of upper respiratory tract adapted from Siegel et 
al 5   
Streptococcus pneumoniae colonised the nasopharynx by initially entering at the nose and passes 
through a layer of mucus. When the bacteria reach the epithelial surface, they bind to surface 
carbohydrates and proteins. Following this, to allow for replication, pneumococcus obtains nutrients 
which can involve exploiting inflammation produced by the host. Persistence of pneumococcus also 
includes circumvention of both cellular and humoral immune responses. Following this the 
pneumococcus can use these responses to persist and lead to colonisation invade the host potentially 
leading to disease Evasion of host immune responses also allows for exit from the host which can drive 
transmission. In addition, growth during colonisation leads to increased bacterial densities which can 
increase the likelihood of transmission. Shifts in colonisation density, co-infection with viruses and 
interactions with other commensal and pathogenic bacteria in the nasopharynx can affect stages of 
this cycle. Viral co-infection increases bacterial load and mucus production and therefore leads to 
increased shedding 20. The success of the pneumococcus also requires interaction with 
nasopharyngeal microbiota, these interactions can either be co-operative or competitive 20. 
Pneumococcus enters 
nasopharynx and passes 
through mucus  layer  
Binding to the epithelial surface 
occurs by attaching to surface 
carbohydrates and proteins
Nutrients 
obtained from 
host 
Persistance of bacteria in 
nasopharynx by evading host's 
immune responses
Pneumococcus exploits 
host's immune responses 
which helps invasion or 
drives tranmission 
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 Pneumococcal colonisation and impact on immunity 
The highest rates of pneumococcal colonisation are observed in infants. Following 
this, colonisation rates decrease with increasing age. Interestingly, in low and middle-
income countries, the highest rates of colonisation are observed at 2 months of age 
(80%) with a gradual reduction observed until 3 years of age, followed by a more 
dramatic reduction in rates following this 13.  Conversely, in high-income countries, 
less than 50% of children under 1 year of age have been found to be colonised, a 
peak is observed at 3 years of age where colonisation rates of 60% have been 
reported 11. Differences in colonisation rates between high and middle-lower income 
countries continue into adulthood. High income countries report adult colonisation 
rates of approximately 10% compared to low-and middle-income countries reporting 
colonisation rates up to 40% 21.  
It is hypothesised that the reduction of colonisation rates with increasing age is due 
to the development of specific immunity which partially protects older children and 
adults against colonisation. General reduction in rates of pneumococcal colonisation 
and disease around the second and third years of life coincides with the development 
of humoral and cellular responses to pneumococcal capsular polysaccharides and 
protein antigens. This has been generally thought to be the immune response 
mounted in unvaccinated children in response to pneumococcal exposure 22. The fact 
that immunisation with a polysaccharide conjugate vaccine (PCV) has been shown to 
reduce pneumococcal colonisation and produces a serotype-specific antibody 
response supports this view 22. However, there is some evidence from longitudinal 
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follow up of children, during their first year of life, that colonisation protects against 
subsequent colonisation episodes 23. This protection is serotype-independent and is 
observed prior to maturation of capsule-specific antibodies. It is likely that a 
combination of serotype-dependent and serotype-independent immune 
mechanisms explain how colonisation is controlled with increasing age.  
Repeated exposure to pneumococcus and episodes of pneumococcal colonisation 
are likely to boost immune defences and contribute to lower rates of colonisation 
and disease 24. Murine models have shown that antigen specific T-cell and specific 
antibody responses develop during colonisation and protect against subsequent re-
colonisation 25-28. Mice who had been previously colonised with pneumococcus 
showed earlier clearance of the pathogen when re-colonised 25. This correlated with 
higher levels of luminal neutrophils compared to those observed in mice being 
colonised for the first time 25. A further study showed a high level of protection 
against fatal invasive disease in mice which had previously cleared a colonisation 
episode 26. This study reported that higher numbers of CD4+ cells and increased 
levels of interleukin 17A (IL17A) in the lungs were associated with a reduction the 
number of pneumococcal found in the lungs of pre-colonised mice 26. However, a 
conflicting murine study reported that a previous colonisation episode protected 
against death from subsequent severe pneumonia, mainly by reducing rates of 
bacteraemia 28. This protection remained when mice were depleted of CD4 cells prior 
to colonisation but was lost in antibody deficient mice. This suggests that the 
protection against bacteraemia following pneumonia may not be dependent on 
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CD4+ T-cells but could be related to antibody-mediated phagocytosis of the bacteria 
from the blood 28.  
Pneumococcal colonisation in children without any invasive infection is associated 
with higher serum levels of immunoglobulins against pneumococcal proteins and 
capsular polysaccharide 12 24 29. Controlled human infection studies, which have been 
developed over the last 10-20 years, have been able to improve the understanding 
of the immune responses resulting from pneumococcal colonisation 29 30. One of 
these models is the Experimental Human Pneumococcal Challenge model (EHPC) 
which has been established over the last 9 years at the Liverpool School of Tropical 
Medicine (LSTM). This model uses serotype 6B S. pneumoniae to establish 
colonisation in approximately 50% of healthy participants following nasopharyngeal 
challenge with 80,000 colony forming units (CFU) per nostril 10.  
One EHPC study showed that specific immune mucosal responses are elicited 
following exposure to pneumococcus even in the absence of colonisation. These 
results support the possibility that exposure to low doses of pneumococcus is 
potentially immunising at the mucosal surface 24. It also reported an increased anti-
pneumococcal polysaccharide immunoglobulin response (IgG and IgA) nasally in 
participants following inoculation and an increase in IgG levels found in fluid obtained 
from the lungs of these participants 24. 
A similar human controlled infection study showed that a previous colonisation 
episode was significantly protective against reacquisition of colonisation by the same 
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pneumococcal serotype (6B) 10. Following the initial pneumococcus exposure 
(inoculation) an increase in IgG to several pneumococcal proteins was observed in all 
participants, the largest of which were observed in colonisation positive participants 
24. Increased levels of IgG to the 6B anti-capsular polysaccharide were also found but 
only in colonisation positive participants 24. Ten colonisation positive participants 
were inoculated for a second time with the same serotype up to 11 months following 
clearance of the first colonisation episode (re-challenged). Eighty percent of 
participants (8/10) were found to have significantly increased level of IgG to both 
proteins and polysaccharides which protected against reacquisition of colonisation 
10. This is an important finding as it suggests that the immunising effect of a single 
episode of pneumococcal colonisation is functionally significant. These results can 
may have significant implications of future vaccine strategies; they support the 
development of pneumococcal mucosal vaccine strategies.  However, the relative 
importance of protection against pneumococcal colonisation and its association with 
the reduction of mucosal infections and invasive pneumococcal disease is still 
unclear.  
 Pneumococcal colonisation and disease 
Colonisation is important as it is believed to be a pre-requisite of infection and is the 
primary reservoir for transmission but can also be a source of immunising exposure 
and immunological boosting against pneumococcal infection in both children and 
adults 10 29 31. Most colonisation episodes will not lead to a subsequent disease 
episode. The progression from stable nasopharyngeal colonisation to invasive 
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disease is enhanced by local inflammation caused by cytokines such as interleukin 1 
and tumour necrosis factor (TNF). The inflammatory cascade that follows the 
production of these factors lead to a change in the number of receptors on epithelial 
and endothelial cells 20 32. Invasion of the pneumococci follows due to pneumococcal 
cell-wall choline binding to one of these upregulated receptors namely platelet-
activating-factor receptor, which in turn induces internalisation of the pneumococci 
20 32. In addition, choline-binding protein A (PspC) on the pneumococcus interacts 
with Ig receptors, on cytokine-activated human cells 9 33. This leads to increased 
migration though the mucosal barrier 33 .  
Colonisation by pneumococcus is often asymptomatic but it can progress to 
respiratory or even systemic disease 9. Observational studies show a direct link 
between pneumococcal disease and colonisation at the individual level 31. Most 
commonly this link is seen with mild mucosal infections (predominantly AOM) but 
some reports suggest a link between colonisation and pneumonia or invasive 
pneumococcal disease (IPD) 31. One study shows a disproportionally high prevalence 
of colonisation in children affected with pneumococcal disease 31. Another study set 
in Pakistan found that 94% (101/108) of children diagnosed with IPD were carrying 
the bacteria in their nasopharynx compared to 52% (69/133) colonisation rate in 
healthy controls 34.  the study found in 99% (69/70) of cases there was concordance 
between the serotype cultured from the nasopharynx and that causing invasive 
disease34. A similar study in The Gambia found comparable results; 90% (73/81) of 
children with IPD were found to have pneumococcal colonisation compared to 76% 
(86/113) colonisation rates in healthy controls (chi squared, 6.99; P<0.01)35. 
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However, it is difficult to prove a temporal relationship between pneumococcal 
colonisation and subsequent IPD. 
It is believed that pneumococcus is more likely to cause disease soon after 
colonisation of the upper airway before there is time for the body to mount a cell-
mediated response and for antibodies to develop. Longitudinal colonisation patterns 
were studied in a cohort from birth to 24 months of age; serial throat and 
nasopharyngeal swabs were taken to determine colonisation status 36. They found 
that infection usually occurred within 30 days of the acquisition of pneumococcal 
colonisation with a new serotype (74% of infections [23/31])  and found that disease 
following prolonged colonisation was rare 36.  
Evidence suggests that pneumococcal serotypes differ in their duration of 
colonisation and invasiveness. Some serotypes are rarely found in colonisation but 
have high invasiveness. For these serotypes it is hypothesised that they may only 
colonise the nasopharynx for a short duration which is difficult to see prior to disease 
and therefore difficult for temporal relationship to be proven 31. A further hypothesis 
is that these serotypes may colonise at lower densities and are therefore not 
detected in epidemiological studies 37. Using a meta-analysis, researchers showed 
that for some serotypes there is an inverse correlation between invasive disease and 
colonisation prevalence. In this study, the most invasive serotypes were the least 
likely to be found to colonise the nasopharynx and the most frequent colonisers were 
the least likely to cause invasive disease 37.  Research suggests that there may be a 
specific density needed for the transition from colonisation to disease or a common 
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factor which allows for both, one study found that patients with pneumococcal 
pneumonia had higher densities of pneumococcal nasopharyngeal colonisation 
compared to asymptomatic colonised controls 38.  
Recent technical advancements have also allowed more in-depth research into the 
dynamics of colonisation episodes with multiple pneumococcal serotypes. Evidence 
e suggests that children that are colonised with multiple pneumococcal serotypes 
have higher overall density of colonisation than those with a single serotype 
colonisation episode 39. A further study used lytA qPCR and molecular serotyping to 
investigate the prevalence of pneumococcal serotypes in colonisation episodes. They 
found that 30% of colonised children (89/299) were colonised with 2 or more 
pneumococcal serotypes 40. The authors concluded that multiple pneumococcal 
serotypes may be transmitted between children as a complex mixed community and 
colonise the nasopharynx in the same way rather than as a single serotype 40. High 
density colonisation has also been hypothesised as a risk for invasive disease. A 
surveillance study carried out in South Africa found that higher colonisation density 
was associated with viral co-infection (adjusted odds ratio [OR], 1.7; 95%CI, 1.1-2.6) 
and invasive pneumococcal pneumonia (adjusted OR, 2.3; 95% CI, 1.3-4.0) 41. 
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1.3 Transmission of Streptococcus pneumoniae 
Historically transmission of S. pneumoniae was thought to occur primarily due to 
inhalation of infected respiratory droplets from person-to person. However, spread 
of pneumococcus by various transmission methods are biologically plausible 
including aerosol, droplet or indirect contact. The relative frequency of these 
different modes of bacterial transmission and their links to pneumococcal 
colonisation or disease in humans is poorly understood 42. Epidemiological data 
suggest that transmission is enhanced when there is close contact with a carrier and 
is more likely to occur with concurrent viral respiratory tract infections 8 43. S. 
pneumoniae outbreaks have been well documented in day care centres, military 
camps, prisons and nursing homes 8. To allow for successful implementation of 
methods to reduce transmission we first need to understand better the mechanisms 
underlying pneumococcal transmission into the nasopharynx. 
It has been suggested that in young adults pneumococcal transmission may occur 
through saliva by sharing drinking glasses and bottles 44. This study investigated 
pneumococcal colonisation prevalence in an Israeli Army training base and possible 
risk factors for colonisation 44. They reported that sharing of a drinking glass/bottle 
was common practice with 48% of participants reporting frequent sharing. They 
reported that frequent sharing of a drinking glass/bottle was a strong and 
independent risk factor for pneumococcal colonisation. The study also concluded 
that there was no evidence of a correlation between hand wash frequency and 
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colonisation. The authors suggest that pneumococci may be transmitted in saliva in 
adults.   
More recently our understanding of the process of pneumococcal transmission has 
improved following the development of murine models which have successfully 
studied transmission dynamics. However, current understanding of the dynamics of 
human-to-human transmission is still poor and needs further investigation. A recent 
randomised controlled trial examined the effects of nasopharyngeal bacterial 
colonisation during a viral URT co-infection in 151 children. The study used the live 
attenuated influenza vaccine (LAIV) as a surrogate for mild URT viral infection. The 
results suggested that the use of this vaccine may increase bacterial densities in the 
nasopharynx 45. The authors suggest that due to the absence of safety concerns, 
following the widespread use of the LAIV, that LAIV could be used as a tool to 
investigate the dynamics of pneumococcal transmission in the future 45. 
 Rodent models investigating transmission 
Initial rodent models investigating the dynamics of pneumococcal transmission 
depended on influenza co-infection to increase pneumococcal transmission. One 
study in 2010 used a model of transmission in ferrets. The benefit of using ferrets for 
pneumococcal transmission studies lies in the fact that they sneeze which allows for 
airborne transmission 46. This study showed that ferrets which had previously been 
infected with influenza virus had higher rates of pneumococcal disease and 
transmission 46. In addition, in a further experiment they intranasally inoculated 
contact ferrets (no pneumococcal colonisation) with Influenza A virus prior to contact 
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with colonised ferrets. This pre-existing viral infection promoted pneumococcal 
acquisition and allowed acquisition of colonisation over longer distances 46. 
Other groups have studied transmission dynamics using murine models. One group 
analysed transmission from index pups colonised with pneumococcus at 4 days old 
to contact pups from the same litter who had previously been infected with influenza 
47. They found that younger age, close contact and viral co-infection all increased 
transmission 47. This group also found that influenza increased bacterial titres in both 
the inoculated donor mice and the index mice 47. Furthermore, using neutrophil 
depletion they showed that higher bacterial numbers during colonisation promoted 
transmission, as did nasopharyngeal inflammation in the contact pups 
(demonstrated by cytokine production) 48.  
More recently another group also using a murine model, suggest that increased 
transmission during concurrent influenza infection is likely secondary to increased 
bacterial shedding rather than solely due to higher bacterial titres in donor mice 
during viral co-infection 49. Shedding was found to increase with levels of 
inflammation observed in the upper respiratory tract in response to influenza 
infection 49. A further study supported this finding by reporting that reduction of 
inflammation using intra-nasal dexamethasone reduced shedding and transmission 
50.  
More recently a murine model has been developed which can investigate the 
transmission dynamics during pneumococcal mono-infection. This model allows for 
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examination solely of pneumococcal factors and host responses that can impact on 
transmission. In 2016 this model was published and showed that bacterial shedding 
peaked over the first 4 days post inoculation of index pups. This correlates with a 
peak of inflammation in the upper respiratory tracts due to colonisation 51. This study 
also reported that transmission within a litter was enhanced when there was a high 
ratio of colonised pups to un-colonised contact pups 51. Colonisation density 
significantly affected level of shedding and rates of transmission were proportional 
to the level of shedding observed 51.   
 Healthy carrier transmission  
There is evidence of S. pneumoniae spread within families. One study which looked 
at 64 families for a period of 8 weeks to 52 weeks found 25 episodes of transmission 
of a single serotype of S. pneumoniae from one family member to another 52. They 
also saw rapid spread of pneumococcus between family members if a new serotype 
was introduced to the family; 7/25 transmission episodes took place within 2 weeks 
of a new serotype entering the household 52. They also described 2 different and 
distinctive patterns of spread of S. pneumoniae in these families; (1) apparent 
concurrent acquisition of colonisation of a specific serotype of pneumococcus by two 
or more members of the family and (2) the prolonged colonisation by one member 
of the family with sudden spread to several others in the household 52. They 
suggested that a specific event could facilitate dissemination of the bacteria; they 
hypothesised that simultaneous viral illness could be this event, but this was difficult 
to investigate as there were three times more viral episodes as episodes of S. 
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pneumoniae colonisation 52. However, they did find that when evaluating the 25 
episodes of transfer of S. pneumoniae a presumed donor and recipient could be 
identified 52. Investigating these presumed donors, they found in 14 of the 25 
episodes the donor had symptoms of upper respiratory tract infections (URTI) during 
the 2-week period where transmission could have occurred 52. They hypothesised 
that increased production of respiratory secretions or another mechanism associated 
with presumed viral illness may play a role in increased transmission 52. 
Another study assessed pneumococcal transmission in Muslim pilgrims completing 
the Hajj 53. They took nasopharyngeal swabs and administered a questionnaire to 
3203 subjects (1590 at beginning-Hajj and 1613 at end-Hajj) they found that there 
was a statistically significant increase in nasal colonisation between the beginning 
and end of the Hajj (4.4 % vs 7.5%; prevalence ratio 1.7, 95% CI 1.3-2.3) but did not 
investigate the possible routes of transmission 53. This likely indicates there was 
increased transmission of pneumococcus during the Hajj from person-to person. An 
overall increase of colonisation was observed rather than the increase of a specific 
serotype which reduces the possibility that a single invasive clone could have 
expanded during the Hajj 53. They also found that there was a lack of association 
between duration of time at the Hajj and likelihood of colonisation 53. This is in 
keeping with results of the study above which suggest that transmission leading to 
colonisation happens relatively quickly following contact and that there may be an 
all-or-nothing protective response, however, further study is needed to understand 
this further  52.  
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 Disease transmission 
Patients with pneumococcal pneumonia are usually considered a relatively low 
contagion risk; hospitalised patients with pneumococcal infections are not treated 
under isolation and health care workers do not take increased infection control 
measures 8. However, there have been reports of epidemics previously in Africa and 
Canada 54-56. In Ghana there was a steady increase of incidence of pneumococcal 
meningitis from 2000-2003 55. The researchers concluded that the S. pneumoniae 
ST217 clonal complex showed a high propensity to cause meningitis and that 
evidence of increasing incidences suggested that the lineage had high epidemic 
potential 55. Following a review of cases with suspected bacterial meningitis between 
2002-2005 in Burkina Faso it was reported that pneumococcal meningitis was 
occurring in an epidemic pattern. An average of 38 cases of S. pneumoniae infection 
was identified each month during the meningitis epidemic season compared to 
average of 8.7 cases/month at other times of the year 56. Of the 48 pneumococci that 
were tested, 41% (21/48) were identified as serotype 1, with the remaining identified 
as 15 different serotypes 56. In Canada during 2000/2001 there was a report of 
pneumonia epidemic caused by a virulent strain of streptococcus pneumonia 
serotype 1 54. A total of 84 cases of pneumococcal pneumonia were identified, of 
these 34/84 (40%) occurred in adults aged 20-64 years and majority were severe 
infections with 75/84 needing hospitalisation 54.  
Another study investigated thirteen clusters of acute otitis media (AOM) in siblings 
and analysed the bacterial pathogens causing disease in these siblings 57. Following 
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comparison of the pneumococcal isolates from each sibling pair they found 100% 
homology between the siblings and antibiotic susceptibility testing were able to show 
homology between pairs of organisms from siblings 57. This provides evidence that 
there is person-to-person transmission among siblings with AOM, but what the 
current study could not show is what impact the disease process of AOM has on the 
transmission in these cases.  
Despite these reports, outbreaks of pneumococcal infection are generally 
uncommon and usually are observed in high risk populations such as nursing home 
residents 58, day care centres 59, prisons 60 and residents in homeless shelters 61. One 
interesting cohort study investigated an outbreak of multi-drug resistant 
pneumococcal pneumonia in an American nursing home in 1996 58. The study 
reported that 23% of residents and 3% of employees were colonised with a 
multidrug-resistant S. pneumoniae, serotype 23F. Evidence suggested that the 
transmission route was likely person-to-person transmission from staff to residents. 
This was due to two main reasons; firstly, residents that were colonised or had 
developed pneumonia from this bacterial serotype were randomly distributed 
throughout the facility and secondly two colonised residents were bedbound with no 
exposure to any other resident or visitors 58. However, they did not investigate how 
this transmission from staff to residents took place. They noted that one colonised 
staff member, who had widespread contact with residents, had a febrile respiratory 
illness during the period which was treated with antibiotics and hypothesised that 
working during this illness may have been the cause of the spread.  
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An outbreak of pneumococcal pneumonia in children was observed in the United 
Kingdom (UK) in 2006 57. Initially three cases of pneumococcal pneumonia were 
reported in an English primary school. Children were aged 4-5. Following 
identification of this outbreak, school contacts and those living in the same 
household of these children were given rifampicin chemoprophylaxis but 
unfortunately despite this intervention two further cases were reported from 
classmates in the same school 57. All five cases were caused by pneumococcal 
serotype 1 which supports the hypothesis that there was transmission between 
these subjects which lead to disease 57.  Following the second outbreak throat swabs 
were obtained from cases and contacts, only one further carrier of S. pneumoniae 
serotype 1 was identified 57. However, the authors conclude that this colonisation 
rate may be under-reported due to sampling technique. Colonisation was only 
determined from oropharyngeal swabs rather than nasopharyngeal swabs due to NP 
swabs being an unpleasant procedure for children 57. In many of these reported 
outbreaks of pneumococcal disease, close contact in crowded conditions was often 
hypothesised as a major risk factor for the transmission. 
 Streptococcus pneumoniae survival in the environment  
To better understand how pathogens are transmitted, it is important for us to 
understand how long pathogens can persist on inanimate objects. This is specifically 
important in the health care setting for deciding on the appropriate treatment of 
surfaces. The longer pathogens can persist on a surface, the longer it is a possible 
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source of transmission which can endanger patients or be further spread by health 
care workers 62.  
There is evidence to suggest that in the hospital environment many inanimate 
objects such as computer keyboards, bed rails and tap handles can be reservoirs for 
pathogen transmission 63 64. A study evaluated 144 samples from computer 
keyboards and tap handles in a medical intensive care unit to investigate if they were 
reservoirs of nosocomial pathogens 63. The colonisation rate for keyboards was 24%, 
and for taps was 11% 63. Pathogens recovered included Staphylococcus aureus (49%), 
Enterococcus 18% and Enterobacter 12%. A further study investigated survival and 
transfer of bacteria in laboratory conditions, they found a variable degree of 
pathogen transfer from contaminated objects to the hands, with the highest rates of 
transmission observed with E.coli, Salmonella spp., and Staph aureus 65.  
Kramer et al 62 found that most Gram-positive bacteria can survive on dry surfaces 
for months, and that Gram-negative bacteria have been reported to persist longer 
on average than Gram-positive bacteria. When evaluating environmental factors that 
prolonged persistence on objects they found that lower temperatures (4-6 degrees 
centigrade) and high humidity (>70%) were both associated with longer persistence 
for most bacteria 62.  
Data specific to S. pneumoniae are few. It has been reported that pneumococcus can 
persist for up to 28 days outside the human host 62 66(see Table 1). Prolonged survival 
was reported when the bacteria are stored in dry conditions and at lower 
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temperatures 66. More recently a study investigated the survival and infectivity of S. 
pneumoniae following desiccation 67. They found that direct contact with respiratory 
droplets containing pneumococci may not be needed for transmission of this 
pathogen 67. Desiccated pneumococci were recovered and following this were able 
to colonise the nasopharynx of mice following intranasal inoculation67. This suggests 
that inanimate objects could be a source of pneumococcal transmission 67. Only one 
study was found which specifically investigated pneumococcal survival time on hands 
and fomites 68. Pneumococcus was suspended in either serum broth (10% horse 
serum in Brain heart infusion broth) or Mueller-Hinton broth. Three volunteer’s 
hands were exposed to pneumococcus. They reported a significant reduction in 
pneumococcal counts after only 3 minutes 68. However, pneumococcus could still be 
recovered 3 hours after exposure when suspended in serum broth. Interestingly 
when testing pneumococcal survival on fomites, despite substantial loss of viable 
pneumococcus following exposure, pneumococcus could still be recovered from a 
glass plate up to 15 hours after exposure and from a plastic toy at the final eight-hour 
sampling point 68. 
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Table 1: Survival time of Streptococcus pneumoniae 62 66 
Origin of Streptococcus 
pneumonia bacteria 
Temperature 
stored at 
Stored in Dry 
conditions 
(Survival time in 
days) 
Stored in moist 
conditions 
(Survival time in 
days) 
Infectious human pus 
mixed with room dust 66 
15-20°C 12 but not 16 5 but not 8 
Infectious blood of a rabbit 
mixed with room dust 66 
15-20°C 1 but not 3 1 but not 3 
Infectious sputum from 
patient mixed with room 
dust 66 
15-20°C 20 but not 25 12 but not 16 
Infectious sputum from 42 
patients and divided into 2 
portions 66 
4°C 28 N/A 
Infectious sputum from 42 
patients and divided into 2 
portions 66 
Room 
temperature 
7 N/A 
 
Recently emerging evidence suggests that capsular type can also effect shedding and 
transmission of pneumococcus. A recent murine model examined whether 
pneumococcal capsule contributes to viability of pneumococcus outside the host 7. 
This study showed that the capsule supports pneumococcal viability during 
starvation conditions (24 hours in phosphate-buffered saline at 25°C) 7. 
Pneumococcal serotype affected viability during these nutrient-poor conditions and 
a decrease in capsule thickness and amount of CPS was observed following starvation 
7. It was confirmed that serotype differences in survival were due to capsular type, 
rather than a result of genetic background by testing capsular-switch mutants 7. This 
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study suggests a possible new role of the pneumococcal capsule; pneumococcus may 
be able to utilise their capsule as a nutrient source to maintain viability when the 
organism is being transmitted between hosts. A further murine study found that 
capsule type and amount affected shedding of pneumococcus during a colonisation 
episode and this was associated with the rate of host-to-host transmission 69. The 
authors highlighted that those specific serotypes which are strongly bound by mucin 
are shed less by the host and therefore are less likely to be transmitted 69.  
The results of these recent studies suggest that capsular type may lead to varying 
rates of pneumococcal transmission and could explain why different serotypes have 
varying propensity to cause outbreaks of disease. Serotypes which can survive for 
longer in the environment could increase the likelihood of acquisition, colonisation 
and potentially disease in a new human host.  
 Hand to nose transmission of S. pneumoniae 
Hand washing interventions can reduce the transmission of disease spread by the 
faecal-oral route, and is an effective and feasible means of reducing rates of 
gastroenteric infections in developing countries 70. Hand washing interventions may 
also be a promising intervention against acute respiratory infections. The hands can 
be vectors for respiratory microorganisms which are shed from the nose and mouth 
to a new host’s mucous membranes 70. A meta-analysis of 8 studies conducted in 
2006 showed that hand washing interventions could reduce the risk of acute 
respiratory infections (ARI’s) by around 16% (95% CI 11-21%) 70. However, the quality 
of the studies examined was poor and had geographical limitations; none of the 
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studies were conducted in developing countries and 6/8 studies were conducted in 
the USA. Therefore, the generalisability r of the findings are uncertain 70.  
When evaluating the possible impact of transmission of infection by self-inoculation, 
it is important to consider the prevalence of face-touching behaviour. Self-
inoculation is a type of contact transmission where contaminated hands make 
contact with other parts of the body such as the mouth, eyes and nostrils ,which 
subsequently introduces bacteria into those sites 71. An observational study from 
1973 monitored a total of  124 adults in a lecture theatre or Sunday school 
environment for 30-50 minute periods 72. They observed 29 episodes of nose picking 
(0.33 hr-1) and 33 episodes of eye rubbing (0.37 hr-1) 72. 
Two more recent studies reported much higher rates of hand to face contact 71 73. 
Nicas et al in 2008 conducted an observational study looking at the hand touching 
rate of 10 volunteers. Participants sat alone at a desk for a 3-hour period performing 
office-type work and the frequency of hand contact with the eyes, nostrils and lips 
was examined. The average total contact rate per hour was 15.7 73. They noted that 
there was significant inter-individual variability in total hand contact with facial 
membranes 73. This was shown by a 35-fold difference in the range limits (lowest 
total hand to face contacts 3 vs. highest 104) 73.  
Kwok et al 71 observed 26 students’ face touching behaviour during two 2-hour 
lectures. They found that on average each of the students touched their face 23 times 
per hour; of these 44% (1024/2346) involved contact with a mucous membrane 71. 
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Of the 1024 touches that involved mucous membranes, there was found to be a fairly 
even split between the mouth (36% 327/1024), nose (31% 318/10247 and eyes (27% 
273/1024) with 6% (61/1024) of touches being a combination of mucous membrane 
contact 71 (Figure 3). The students involved in this study were medical students who 
had previously had one 4-hour infection control lecture which involved teaching 
about hand hygiene, aseptic technique and transmission-based precautions. Kwok et 
al concluded that due to the high frequency of mouth and nose touching observed in 
this study, hand hygiene is an essential preventative method to break colonisation 
and transmission cycles 71. 
 
 
 
 
 
 
Figure 3: Average number touches of mucosal surfaces observed over 1 hour period adapted from 
Kwok et al 71 
Results from a behavioural study involving medical students in Australia. Face-touching behaviour was 
observed via videotape recording; frequency of hand to face contact was analysed.  
 
NOSE 
3 average 
touches/hour 
Average duration 1 
MOUTH 
4 average touches/hour 
Average duration 3 
second (range 1-12) 
EYE 
3 average 
touches/hour 
Average duration 1 
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The above studies support the hypothesis that hands could be an important vector 
for bacterial transmission to facial mucous membranes. S. pneumoniae colonises the 
upper airway; through touching of contaminated surfaces, sneezing, coughing and 
rubbing/picking of the nose pneumococcus could contaminate the hands. Due to this 
it is biologically plausible that hand to face contact could be a significant transmission 
pathway. There is very little research investigating the link between pneumococcus 
hand contamination and rates of nasal colonisation currently.  
Only two relevant studies in humans were found; the first found pneumococcal nasal 
colonisation in 83% (67/81) of children studied in Papua New Guinea with a 
corresponding hand contamination rate of 22% (18/81) 74. They also found that 17/20 
children who were found to have hand contamination with pneumococcus had the 
same serotype colonising their nasopharynx 74. In conjunction with testing children, 
the study also evaluated pneumococcal hand contamination of mothers; two 
mothers had pneumococcus recovered from their hands but there was no 
concordance  with the serotype found colonising their children’s nasopharynges 74.   
The second study compared the rates of pneumococcal hand contamination and 
nasal colonisation in two groups of children in Australia; a remote aboriginal 
community group (n=89) and an urban child care centre group (n=294) 42. They found 
a two-fold increase of nasal colonisation rates in the remote group compared to the 
urban group (90%, 80/89 positive for colonisation remote group vs. 43%. 125/294 
urban group) using nasal swabs 42. This correlated with higher hand contamination 
rates in the remote group; the remote group were >9 times more likely than the 
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urban group to have pneumococcal hand contamination (37%, 33/89 positive hand 
swab remote group vs. 4%, 13/294 urban group) 42. This suggests that pneumococcal 
shedding during a colonisation episode is possible and that the hands could be a 
possible vehicle for pneumococcal transmission in the community.  
Rodent models investigating pneumococcal transmission are adding to the current 
understanding of the extent of airborne transmission versus contact-dependent 
transmission. Transmission secondary to infected secretions from a person colonised 
with pneumococcus may involve direct person-to-person spread or may involve 
contaminated surfaces or fomites 20. A recent study demonstrated that an 
environmental reservoir of pneumococcus can facilitate transmission 50. In this study 
colonised mice were kept in separate cages from un-colonised mice. Both sets of 
mice had an uncolonised mother; three times per day mice were switched between 
cages but were never in contact with each other 50. Over 50% transmission rate was 
observed; the investigators concluded that contamination of the mother’s teats with 
pneumococcus was the source of transmission between the colonised and 
uncolonised mice.  They confirmed that the bedding was not an environmental 
source of pneumococcal transmission by doing a further experiment. When they 
moved the mothers between cages of colonised and uncolonised mice transmission 
was still seen suggesting that pneumococcus was likely acquired from the surface of 
the mothers 50.  
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 Reduction of transmission 
The benefits of hand washing for reducing the spread of respiratory bacterial 
pathogens is uncertain with the evidence currently available 42. Previous intervention 
studies using hand hygiene interventions to reduce viral transmission pathways 
support the hypothesis that both direct and indirect contact are important in 
transmission of viruses from person to person. A randomised control trial looking at 
the effect of infection control measures in child care centres showed only a 5% 
overall reduction of incidence of “colds” 75.  
There is limited research assessing whether hand hygiene interventions and infection 
control teaching can reduce upper respiratory bacterial pathogen transmission. A 
cluster randomised control trial (RCT) conducted in 20 child care centres in Australia 
investigated this question76. Ten centres (219 children) had one infection control 
training session for staff and had regular follow up visits by researchers to implement 
20 second hand washing, barrier nose-wiping, removal of contaminated toys and 
non-touch sunscreen application 76. The other 10 centres (235 children) acted as 
controls with no intervention given. The researchers found no reduction in 
transmission of bacterial pathogens (adjusted incidence rate ratio, IIR, 0.97 95% CI 
0.88, 1.08) or respiratory illness in the intervention group (adjusted IIR 1.00 95% CI 
0.93, 1.01) 76. Transmission of bacterial pathogens (S. pneumoniae and H. influenza) 
was assessed with nasal swabs undertaken every 2 weeks for 6 months and childhood 
illness was reported by parents. However, interpretation of these findings was 
limited by poor uptake of the hand hygiene practices in the intervention centres 
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(proportion of hygiene practices consistent with guidelines; weighted mean 
difference 14%, 95% CI 9, 19).  
1.4 Pneumococcal disease treatment and prevention 
 Pathogenicity  
Streptococcus pneumoniae was first described by George M Sternberg who isolated 
it in 1880 from a colonised individual 77. He also described recovery of the organism 
from the saliva of healthy students which established that the pneumococcus is part 
of the normal human microflora 77. S. pneumoniae was first described as a cause of 
lobar pneumonia in 1883 by Friedlander and Talamon. Diagnosis of pneumococcal 
pneumonia improved following the development of the Gram stain as a method to 
differentiate bacterial species in 1884. It is a Gram-positive bacterium which has the 
potential to cause invasive infections and is considered to be an extracellular 
bacterial pathogen 78. Extracellular pathogens can replicate or persist on mucosal 
surfaces in the human body or in tissues outside host cells. They can also spread 
quickly or establish an infection if they successfully contend with host humoral 
defences and cellular immune mechanisms (e.g. T cells and phagocytes) 78. Due to 
this, the ability of extracellular pathogens to evade clearance by the body’s humoral 
and cellular immune defence mechanisms is an important determinant of 
pathogenicity.  
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The pneumococcus can release a pore-forming toxin called pneumolysin; which at 
low levels can induce apoptosis of cells and high levels cause lysis of all cells with 
cholesterol in their membrane 79. This pathogen also has pro-inflammatory cell wall 
components such as C-polysaccharide and F-antigen. These release tissue damaging 
enzymes such as neuraminidase and have adhesins, such as pneumococcal surface 
protein A (PspA), that can bind to cell surface carbohydrates which play important 
roles in combating the host’s immune responses 80.  
The polysaccharide capsule surrounds the pneumococcal cell wall which is comprised 
of peptidoglycan and teichoic acid. This capsule protects the bacteria from 
phagocytosis by obstructing leukocyte fixation onto the cell wall 1. Pneumococcal 
serotypes each have chemically distinct capsules which can affect: 
• Tendency to cause outbreaks,  
• Antibiotic resistance profiles, 
• Likelihood of causing invasive disease (serotypes 1 and 7E are 
prominent serotypes for invasive disease),  
• Prevalence of mucosal disease or nasopharyngeal colonisation; 
different serotypes have varying propensity to cause colonisation and 
invasive disease  1 2.  
Geographical variation in serotypes is often dependent on the period studied and 
differences in age distribution between host’s; serotypes most commonly observed 
in young children include 6B, 9V, 14, 19F and 23F 1 2 80. These differences in serotypes 
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may be due to the quantity and degree of encapsulation of the polysaccharide 
capsule. Thicker capsules protect against neutrophil-mediated killing in vitro, and 
may prevent clearance of colonisation by the host 2. Other genetic factors relating to 
the pneumococcus are also likely to impact on virulence such as bacterial adhesins.  
 Pneumococcal disease  
Streptococcus pneumoniae is the most common cause of acute otitis media, sinusitis 
and pneumonia worldwide and also causes a significant number of cases of 
meningitis 81. Epidemiological studies have shown that there is an inverse 
relationship between the frequency and severity of types of pneumococcal disease 
(see Figure 4).  
The archetypal presentation of a patient with pneumococcal pneumonia has been 
historically described as symptoms including sudden onset of chills and pleuritic 
chest pain, closely followed by fever and rusty sputum production. However, many 
present with more non-specific symptoms especially in the elderly and in young 
children81. Pneumococcal pneumonia can progress to  pneumococcal bacteraemia in 
some patients, rates of bacteraemia have been  estimated at 20-25% 82 and mortality 
from bacteraemia has stayed high at 20-30% despite antibiotic treatment 83.   
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Figure 4: Burden of pneumococcal disease adapted from Edwards and Griffin 84.  
Estimated pneumococcal disease cases per year in adults and children in USA taken from CDC report 
2002 (www.cdc.gov/nip/publications/surv-manual/chapt09_pneumo.pdf) 
 
 
Pneumococcus is considered to be the most common cause of CAP worldwide and in 
the UK is the most common cause of CAP in children ≤2 years of age 85. Timely and 
effective management of pneumococcal pneumonia can be difficult. It is hindered by 
low rates of microbiological pathogen confirmation in patients with suspected 
pneumonia and lower respiratory tract infections (LRTI) 86 87. Following spread of the 
pneumococcus to a sterile site it can also cause IPD which encompasses a range of 
diseases including bacteraemia, meningitis, empyema and septic arthritis. 
Penicillin has been the mainstay of antibiotic treatment for any pneumococcal 
infection for over half a century 81. However, increasing antibiotic resistance is a 
growing problem worldwide.  S. pneumoniae is no exception to this and we have 
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observed increasing antibiotic resistance develop specifically in serotypes that have 
high prevalence in children for example serotypes 6, 14, 19 and 23. 
Due to these diagnostic difficulties and increasing problems with antibiotic 
resistance, strategies to prevent pneumococcal disease are becoming increasingly 
important.  
1.4.2.1 Burden in UK and worldwide and risk factors for disease 
The WHO estimates that 1.6 million deaths are caused by pneumococci annually, 
with over a million of these deaths attributed to pneumococcal pneumonia in 
children under the age of 5 in developing countries 81 88. The global pneumococcal 
disease burden in children, especially under 5 years of age is well documented. In 
2000 it was estimated that there were 13.9 million cases of pneumococcal 
pneumonia per year in this age group. The burden of pneumococcal disease in adults 
is less well known. 
Over the last 100 years, the incidence of pneumococcal pneumonia has stayed stable 
but a significant improvement in mortality rates has been observed following 
widespread antibiotic use 89. In the United Kingdom (UK) and high-income countries, 
the yearly incidence of community acquired pneumonia (CAP) is approximately 1% 
of which half is attributable to S. pneumoniae. 
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Overall incidence of pneumococcal pneumonia is 5 in 1000, with the incidence being 
significantly higher in high risk populations such as infants and the elderly 81. 
Pneumococcal pneumonia can progress to invasive pneumococcal disease (IPD) (e.g. 
bacteraemia). The annual incidence of this is 10-20 cases per 100,000 individuals 
annually in North America and Europe 81. The risk of IPD increases by more than 20 
times this rate in young children attending day care centres 90. In Western countries, 
the incidence of pneumococcal disease rises in the winter months and the increased 
rates of viral respiratory infections observed during this period could be the pre-
disposing factor for this 81. 
Both age and gender are found to be important risk factors for pneumococcal 
pneumonia 81. The incidence of pneumococcal pneumonia is up to 50 times higher in 
the elderly (over age of 65) and in the very young (under age of 2), with a male: 
female ratio of approximately 1.5-2:1 81. Many underlying co-morbidities have been 
found to pre-dispose patients to pneumococcal disease. A case- control study 
investigated this retrospectively. They compared 63 men with culture proven 
pneumococcal infections to 130 uninfected control patients and calculated relative 
risks using logistic regression analysis 91. They found that the following conditions 
were statistically significant independent risk factors (relative risks shown in 
brackets); dementia (5.82), seizure disorders (4.38), heart failure (3.83), 
cerebrovascular disease (3.82, institutionalisation (3.13) and chronic obstructive 
pulmonary disease (COPD; 2.38) 91. Concurrent respiratory tract infection, especially 
influenza viral infection, is also a risk factor for pneumococcal pneumonia 81.  
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 Pneumococcal disease prevention: current pneumococcal 
vaccines  
In the UK, there are currently three vaccine formulations licenced for the prevention 
of pneumococcal infections; the pneumococcal polysaccharide vaccine (PPV23) and 
two pneumococcal conjugate vaccines (PCV10 and PCV13) 92. See Table 2 for 
comparisons of these vaccines.  
Table 2: Comparison of currently licenced pneumococcal vaccine formulations in the UK 
Table reports specific aspects of the pneumococcal vaccines which have been, or currently are 
licenced for use in the UK. Further discussion about vaccine immunological profile and efficacy 
discussed in sections 1.4.3 and 1.4.4. 
 
 PCV 7 PCV13 PPV23 
Serotypes 
covered 
1, 4, 5, 6B, 7F, 9V, 
14, 18C, 19F, and 
23F. 
1, 3, 4, 5, 6A, 6B, 7F, 
9V, 14, 18C, 19A, 19F, 
and 23F. 
1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 
9V, 10A, 11A, 12F, 14, 
15B, 17F, 18C, 19A, 19F, 
20, 22F, 23F and 33F. 
UK Vaccination 
recommendation 
From 2006-2010 93: 
recommended for all 
children at 8 weeks 
old, 16 weeks old 
and 1 year old. 
Since 2010 93: 
recommended for all 
children at 8 weeks 
old, 16 weeks old and 
1 year old. 
Since 2003 93: 
recommended for all 
over 65’s and younger 
adults who have chronic 
illnesses that put them at 
higher risk of invasive 
pneumococcal disease. 
Effective against 
S. pneumoniae 
Invasive pneumococcal disease. 
Reduction in nasopharyngeal colonisation, 
leading to reduction in transmission of 
vaccine serotypes (in turn reduced incidence 
of mucosal disease). 
Moderately effective against mucosal disease 
such as pneumonia and AOM 94. 
 
Invasive pneumococcal 
disease. 
 
Non-conclusive evidence 
on protection against 
pneumococcal 
pneumonia or other 
mucosal infections92. 
 
Introduction 
39 
The currently used PPV contains polysaccharide from 23 different serotypes (PPV23). 
PPV23 elicits a T-cell independent, humoral immune response. Evidence suggests this 
protects against IPD but there is debate about this vaccine’s effectiveness against 
pneumonia 92. The immune response to PPV is not long lasting and does not show a 
booster response upon challenge with native polysaccharide. Due to this, protection 
induced by this vaccine is limited. A major limitation is lack of efficacy in infants under 
2 years of age whose immune systems are immature 95. PPV immunisation does not 
protect against nasopharyngeal colonisation by pneumococcus, therefore no herd 
immunity was observed after vaccine implementation. Herd immunity is the indirect 
protection against an infectious disease whereby individuals who are not immune 
can benefit and which occurs when many of the population are immune following 
vaccination. 
A meta-analysis which evaluated 25 studies ( 18RCTs and 7 non-RCTs) found strong 
evidence that PPV is effective against IPD with overall efficacy of 74% (95% CI 56% to 
85%) 96. No statistical heterogeneity was found when all RCTs were included in 
analysis However, there was a statistical difference between heterogeneity of studies 
conduction among different populations such as healthy adults in low-income 
countries (P <0.01) 96. Results of effectiveness against pneumonia were inconclusive 
96. Efficacy against all-cause pneumonia in low-income countries was reported (OR 
0.54, 95% CI 0.43 to 0.67) 96. However, this was not the case in high-income countries 
in the general population (OR 0.71, 95% CI 0.45 to 1.12) or those with chronic disease 
(OR 0.93, 95% CI 0.73 to 1.1) 96. A further meta-analysis supported this finding and 
concluded that PPV did not appear to be effective against pneumonia even among 
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elderly patients or adults with chronic disease for whom the vaccination is 
recommended 97.  
Some randomised control trials have found protective effect of the PPV against 
pneumonia; this prospective randomised study included 1006 nursing home 
residents. It reported a statistically significant reduction in pneumococcal pneumonia 
cases in the vaccine arm compared to control (14/502 ,2.8% vs 37/504, 7.3%; 
P<0.001) 98. Due to this specific study population (mean age of 84, nursing home 
residents many with co-morbidities), it is difficult to generalise the findings to larger 
population. In addition, a non-randomised observational study of 27,204 individuals 
aged ≥60 years in Spain reported that recent vaccination with PPV23 (<5 years ago) 
reduced risks of bacteraemic pneumococcal CAP (hazard ratio [HR], 0.38; 95% 
confidence interval [CI], .09–1.68) and non-bacteraemic pneumococcal CAP (HR, 0.52; 
95% CI, .29–.92)99. This was only observed following sub-analysis of patients who had 
received the vaccine within the last 5 years, when evaluating the full cohort, no 
protective effect was observed 99.  
PVC13 is the most commonly used polysaccharide conjugate vaccine worldwide; this 
vaccine covers pneumococcal 13 serotypes 100. PCV13 contains purified 
polysaccharides of the capsular antigens of each of the 13 pneumococcal serotypes 
covered. These are individually conjugated (coupled) with a nontoxic diphtheria toxin 
(CRM197, CRM cross-reactive material). The conjugation of the capsular 
polysaccharide to a carrier protein in PCV13, unlike PPV, activates a T-cell dependent 
antibody response which leads to mucosal immunity and immunological memory 92 
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101. Previous studies suggest that this leads to immunity for the individual user but 
also leads to herd immunity 92. Global vaccine strategies have been very successful, 
and 132 countries have introduced PCV into their national immunisation programs 
(see Figure 5. 
 
Figure 5: Worldwide current or planned implementation of PCV into national immunization 
schedule as of September 2016.  
Taken from World Health Organization, Immunization Vaccines and Biologicals Database, September 
2016. http://www.who.int/immunization/monitoring_surveillance/data/en 102 
 
Since the introduction of childhood PCV there has been a decrease in IPD and 
pneumonia in children and similar reduction in rates of IPD have been observed in 
older adults 92. A large randomised control trial, which included 85,000 adults aged 
65 years of age or older was conducted by a PCV vaccine manufacturer 103. This study 
showed 45.6% (95% confidence interval [CI]=21.8-62.5%) efficacy of PCV13 against 
all vaccine-type pneumococcal pneumonia and 75% (CI=41.4-90.8%) efficacy against 
vaccine-type IPD in adults ≥65 years of age 103.   
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 Rationale behind new vaccine development 
Despite the success of the PCV and PPV immunisations in reducing pneumococcal 
disease and mortality worldwide, the widespread use of these vaccines and addition 
into public immunisation programmes has highlighted several limitations 92 101 104. 
These include: 
• Protective immunity is limited to the specific serotypes contained in each of 
the PPV23 and PCV13 – there are currently over 90 known serotypes of S. 
pneumoniae. 
•  ‘Serotype replacement’ is a major limitation of the PCVs. Among 
asymptomatic carriers, the prevalence of non-vaccine serotypes ([NVT] non 
PCV 13 serotypes) has increased significantly (serotype replacement). 
However, there does not seem to be any impact of overall pneumococcal 
colonisation rates 105. A review, also reported an increase in NVT 
pneumococcal disease 105. The true amount of replacement may be 
underestimated due to biases in the pre-vaccine colonisation data. 
Surveillance systems may underestimate the prevalence of serotypes with 
lower invasive potential. Because these systems monitor invasive 
pneumococcal disease, serotypes which do not cause disease are likely to be 
underreported. Epidemiology studies can also underestimate prevalence of 
pneumococcal serotypes which have short colonisation durations. This is 
because surveillance tests for colonisation often are undertaken weekly or 
less frequently in these studies105. In addition, simultaneous colonisation with 
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multiple pneumococcal serotypes has been increasingly reported with 
improvements in molecular techniques for pneumococcal detection 40. Due 
to this, NVT may have been more prevalent colonisers but at lower density in 
a multiple serotype colonisation episode and therefore under detected.  
• Limited efficacy against certain serotypes covered in PCV13 (serotype 1 and 
5) 92. Clinical trials in South Africa 106 107 and The Gambia 108 109 failed to show 
evidence of efficacy of PCV against serotype 1. A further study, reported 
PCV13’s vaccine effectiveness at 62% and 66% against serotype 1 and 3 
respectively although confidence intervals spanned zero 110. A further study 
found that the vaccine effectiveness for serotype 3 was not significant (26%, 
95% CI, -69%-68%) 111. In developing countries serotype 1 and 3 continue to 
be prevalent serotypes causing IPD therefore the lack of efficacy is 
problematic.  
• Geographic variation in protection from both PCV13 and PPV23 due to 
varying serotype distribution worldwide. The current vaccines favour 
covering serotypes that are most prevalent in western countries such as USA 
or Europe rather than the serotypes that cause most of invasive disease in 
developing countries 9. This was a larger issue with the first PCV vaccine; PCV 
7 than for PCV13. 
• Hypo-responsiveness to the capsular polysaccharide is observed with PCV 
immunisation (serotype-specific) if children had an episode of pneumococcal 
nasal colonisation shortly before the first dose of PCV 112 113. This is only 
partially overcome after the 2nd or 3rd dose of the vaccine. There has also been 
reports that repeated doses of bacterial polysaccharides may induce a state 
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of immune tolerance or hypo-responsiveness. All studies, except one 114, 
reported that serotype-specific pneumococcal antibody concentrations were 
lower after the second dose of PPV compared the first dose 115-119 .  
• Complexity and high costs of protein-conjugate vaccines incurred by 
pharmaceutical companies and purchasers may impact on the future 
development of these vaccines to expand coverage to more serotypes 92.  
• Transient efficacy in healthy elderly. Clinical effectiveness of PPV in older 
adults is likely to diminish over time. The reduction in pneumococcal capsular 
antibodies over time following vaccination has been shown in PPV 120. 
Reduction in clinical effectiveness over time is also seen in other 
unconjugated polysaccharide vaccines 121 
• Lack of proven efficacy in very frail elderly or immunocompromised. 
Evidence suggests that PPV23 is effective in preventing invasive 
pneumococcal disease in healthy young adults and in the healthy older 
population 122. However, the vaccines effectiveness in the 
immunocompromised and very elderly has not been demonstrated 123 122 ,  
 Novel vaccine development  
Limitations of the current vaccines available for protection of pneumococcal disease 
have driven the development of novel vaccines some of which would be serotype-
independent. New vaccine approaches include new polysaccharide conjugate 
technologies, pneumococcal whole cell vaccines and vaccines which are based on 
highly-conserved noncapsular protein antigens 92 124 125. Due to the limitations 
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discussed above, there are specific criteria any new vaccine must satisfy to make a 
significant impact on disease (target product profile); 
• New vaccines should be highly conserved and develop immunity to all 
pneumococcal serotypes 
• There should be evidence to suggest mucosal immunity and immunity against 
nasopharyngeal colonisation   
• The vaccines should have evidence of immunogenicity with evidence of non-
inferiority to a licensed pneumococcal vaccine  
• The vaccines should induce antibody and cell mediated immune responses  
• The immunity should be long-lasting 
• The vaccine should be designed to prevent disease in the majority of the 
population including children under 2 years of age 
• The vaccine should be low cost to produce  
One possible new vaccine approach is modification of the conjugate vaccine; an 
international non-profit organisation (PATH) is investigating two alternatives; firstly 
to develop a conserved pneumococcal protein which would be used as a carrier for 
a specific number or polysaccharides which could be chosen and changed to meet 
specific geographical needs 124. Secondly, they are looking at ways to accelerate the 
development of vaccines that target serotypes which are more prevalent in 
developing countries and are also developing new strategies to reduce the cost of 
manufacturing 124.   
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An alternative strategy is the use of broadly conserved protein combinations for 
vaccines. The pneumococcus has multiple proteins exposed on its surface which 
could be used as possible vaccine antigens. Well-studied examples of these are 
pneumococcal surface protein A (PspA) and choline-binding protein A (PspC). While 
other virulence factors that are also at the forefront of protein-based vaccine 
development include choline-binding protein (PcpA), pneumolysin (Ply) and 
pneumococcal histidine triad protein D (PhtD) 92 124. Research into these protein-
based serotype independent subunit vaccines have reached varying stages of 
advancement. Recombinant PspA has been studied in a phase 1 clinical trial where it 
was found to be safe in humans and was also immunogenic 126. This study used a 
passive transfer murine challenge model as a surrogate for protection of humans 126. 
Human participants were administered recombinant PspA, pre- and post-immune 
serum samples were examined 126. The authors reported that human antibody to 
PspA could protect mice from pneumococcal infection 126 .   
Another promising area of research is whole cell pneumococcal vaccines, either in 
live attenuated form or killed form, in which many pneumococcal antigens would be 
present at once 92 124. Potential benefits of a killed bacteria whole-cell vaccine 
development would be the very low cost of manufacture and that it could protect 
against all serotypes and could lead to comprehensive mucosal and systemic 
immunity 124 127.  
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1.4.5.1 Controlled human infection studies 
Controlled human infections models (CHIM) involve the experimental infection of 
study participants with a pathogen. They provide the opportunity for researchers to 
study organisms, their incubation periods and clinical disease. More recently these 
studies have been used to accelerate the development of new drugs and vaccines for 
infectious diseases by adding significant data prior to large scale efficacy trials. The 
first controlled infection studies were described in the 17th century. The ethics of 
these preliminary CHIM studies were questionable with the most infamous example 
of Edward Jenner inoculating his gardeners son with cowpox in 1796, and following 
this repeatedly with smallpox lesion material 128.  
There have been significant improvements in ethical considerations of all research 
and specifically CHIM studies since these preliminary studies; CHIM studies must 
conform to a strict ethical framework and go through rigorous independent review 
prior to starting. However, some still argue that CHIM studies are inherently 
unethical due to concerns about non-maleficence 129 130. There are significant global 
health benefits from these studies but to the individuals involved there is an inherent 
risk of illness 128. In addition, similar to phase one studies, there are no direct benefits 
to participants. Due to this, CHIM studies can only be carried out to investigate 
treatable or self-limiting diseases 128.  
The experimental human pneumococcal challenge (EHPC) model is different to the 
majority of CHIM by having colonisation rather than infection as its primary endpoint. 
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Due to this, from an ethical and clinical standpoint, the inherent risks and potential 
for harm is much lower. The Liverpool EHPC team have inoculated over 1000 
participants with pneumococcus over the last 9 years with no related significant 
adverse events.  
 Experimental Human Pneumococcal Colonisation studies and 
their use for vaccine research 
A major roadblock in the process of developing new protein vaccines has been a 
means of prioritising between proposed vaccine candidates 131. Nasopharyngeal 
colonisation is likely the source of pneumococcal transmission into sterile sites and 
therefore is likely a prerequisite for invasive disease 31 131. It has therefore been 
proposed as a marker for vaccine efficacy 31 131. For new vaccines due to come to the 
market, protection against colonisation may predict the overall protective effect 
against mucosal or invasive disease 101. Experimental human pneumococcal 
colonisation (EHPC) can be induced in humans. This was first shown by McCool et al 
29 in 2002; this group successfully induced nasopharyngeal colonisation following 
pneumococcal inoculation with serotypes 6B and 23F and showed that controlled 
human infection with pneumococcus was safe 29 30. 
Following these initial studies in the United States of America (USA), a safe and 
reproducible EHPC model was establish at LSTM, which can be used to test the 
protection induced by vaccination against nasopharyngeal colonisation 101. 
Preliminary studies investigated what the optimal sampling method would be to 
identify nasopharyngeal pneumococcal colonisation. The team compared 
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nasopharyngeal swab (NPS) to nasal wash for the detection of potential respiratory 
pathogens. This study showed that nasal wash was more comfortable for volunteers 
and was significantly more likely to detect pathogens than NPS 132.  
The model allows assessment of the immune responses at the mucosal surface and 
systemically following inoculation with live whole bacteria. It can also be useful to 
help evaluate and compare new vaccines that are possibly coming to market; it could 
evaluate pneumococcal colonisation protection and any change in nasopharyngeal 
flora following vaccination 101. To increase the generalisability of the model and its 
use for vaccine development, it is important to test multiple serotypes of S. 
pneumoniae.  
It has been previously reported that pneumococcal serotype has a significant role in 
determining colonisation. Some serotypes are more likely to be carried but have low 
potential to cause infectious or invasive disease. Conversely others are more 
commonly observed in pneumococcal disease 133. A previous human pneumococcal 
challenge study performed by the Weiser group in the USA used serotype 23F P833. 
They inoculated participants with either 5,000 CFU/naris, 7,000 CFU/naris or 17,000 
CFU/naris to assess if there was a dose dependant relationship to colonisation 
acquisition and achieved colonisation rates of 43% (6/14) with a duration of 
colonisation ranging from 27-122 days 29. Following this, our team (Liverpool EHPC 
team), retested the 23F serotype in addition to serotype 6B in a dose-ranging human 
challenge study. Colonisation rates for 23F in this study were poor for all inoculum 
doses (Figure 6) 134. 
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Figure 6: Dose ranging curve for serotypes 6B and 23F (unpublished work from J. Gritzfeld thesis) 
10 participants were inoculated with either serotype 6B (circle) or 23F (square) for each of the six 
doses from 1x104 CFU/naris to 3.2x105 CFU/naris. Y axis shows percentage of colonisation positive 
participants in each group defined as number of participates found to be an experimental coloniser of 
pneumococcus in nasal washes at any time point following inoculation. 
 
Due to the poor colonisation rates observed above, the 23F serotype used was 
sequenced to look for a cause of these results. It was discovered that this serotype 
differed from the original P833 serotype tested in the USA 29. Murine models had 
previously demonstrated that mutations in amiC gene could significantly affect the 
ability of the pneumococcus to colonise. It was found that there was a frameshift 
mutation in the amiC gene in the 23F serotype used in this initial study, which was 
hypothesised to be the cause of these poor colonisation rates. However, for the ‘new 
serotypes’ study (see below) the serotype used was a naturally-derived isolate of 
P833; P1121. This contained a stable form of the wild-type amiC gene; so we 
expected to be able to reproduce findings from the US-based group of 50% 
colonisation rates at 7,000 CFU/naris and 75% at 17,000 CFU/naris 29.  
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1.5 Project aims 
This project focuses on improving knowledge about the acquisition of S. pneumoniae 
colonisation using controlled human infection trials.  
Aim 1: To investigate whether the hands can be a vector for transmission of S. 
pneumoniae from hands into nasopharynx, leading to colonisation.  
a) We will also investigate whether asymptomatic viral infection at the 
time of exposure to pneumococcus affects acquisition of 
pneumococcal colonisation following transmission from hands to 
nose 
Transmission of S. pneumoniae from person-to-person is thought to occur due to 
airborne respiratory droplets. Epidemiological data provide evidence that 
transmission is influenced by overcrowding and concurrent viral respiratory tract 
infections 8 43. There are no published data investigating specifically how 
Streptococcus pneumoniae is spread and testing different routes of transmission. 
(Chapter 4: HAND TO NOSE STUDY) 
Aim 2: To investigate the propensity for two different pneumococcal serotypes (23F 
and 15B) to cause experimental pneumococcal colonisation in healthy adults 
a) We will investigate whether exposure to pneumococcus or 
pneumococcal colonisation is symptomatic in healthy adults and 
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b) Investigate the host’s polysaccharide specific antibody (IgG) response 
following experimental challenge 
 
To improve our knowledge about nasal pneumococcal colonisation we planned to 
extend the EHPC model by colonising participants’ nasopharynx with different 
serotypes of S. pneumoniae (23F and a non-vaccine type [15B] were tested). Success 
in this would ensure that the model is more generalisable and useful for further 
development of vaccine testing studies. Specifically, the development of a 
colonisation model with a non-vaccine type serotype would be an important step for 
vaccine testing. New pneumococcal vaccines will need to demonstrate an impact on 
reducing colonisation, and protein-based vaccines will need to show efficacy against 
serotypes not covered by PCV13. (Chapter 5: NEW SEROTYPES STUDY) 
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2.1 Overview  
This chapter describes the methods relevant to both studies described in this thesis. 
It covers methodology used to investigate the main aims of the thesis outlined at the 
end of Chapter 1. Specific methods relevant to one study are considered separately 
in each chapter for ease of reading. The chapter is divided into subsections which 
cover study set up, clinical procedures, methodology and laboratory processes.  
2.2 Study set up: Research in the National Health Service (NHS) 
 Sponsorship 
All clinical research undertaken in the NHS requires a sponsor. The definitions of a 
sponsor and roles and responsibilities are detailed in the Research Governance 
Framework, Edition 2 2005 135 (guidelines in place when New Strains study was set 
up) and later by UK Policy Framework for Health and Social Care Research 2017 136 
(see Table 3).The sponsor needs to be an individual, organisation or group which is a 
legal entity involved in either the funding, running, hosting of the research or 
employing the research staff.   
Sponsorship can be sole (in the case of Hand to Nose study- single sponsorship by 
LSTM) or co-sponsored by more than one organisation (in the case of New Serotypes 
study- joint sponsorship between LSTM and Royal Liverpool and Broadgreen 
University Hospital Trust [RLBUHT]). Co-sponsorship involves a pre-agreed division of 
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the sponsor responsibilities prior to initiation of the study. Agreement for LSTM or 
RLBUHT to sponsor a research study involves the research team completing an 
application to the organisation’s research governance department. Initially 
sponsorship in principle is obtained. Full sponsorship is only agreed once the 
organisation receives documentary evidence of ethical and relevant national 
regulatory approvals. No study activities should be completed prior to full approval 
and sponsorship.  
Table 3: Definitions and responsibilities of a sponsor taken from Research Governance Framework 
135 and UK policy for Health and Social Care Research 136 
 
 Research Governance Framework 
for Health and Social Care 
(Second edition, 2005) 135 
UK Policy Framework for 
Health and Social Care 
Research (2017) 136 
 
 
 
 
 
Definition 
 
‘Individual, organisation or group 
taking on responsibility for securing 
the arrangements to initiate, manage 
and finance a study. A group of 
individuals and/or organisations may 
take on sponsorship responsibilities 
and distribute them by agreement 
among the members of the group, 
provided that, collectively, they make 
arrangements to allocate all the 
responsibilities in this research 
governance framework that are 
relevant to the study.’ 135 
 
 
‘The sponsor is the individual, 
organisation or partnership that 
takes on overall responsibility 
for proportionate, effective 
arrangements being in place to 
set up, run and report a research 
project. All health and social care 
research has a sponsor.’ 136 
 
 
 
 
 
Responsibilities 
 
Main responsibility of the sponsor is to assure the quality of the research, 
including ensuring participant’s wellbeing, all legal requirements are met, 
the research team are adequate to carry out the work and have resources 
and arrangements in place for the study to be completed. More detailed 
set of responsibilities are set out in the Research Governance Framework 
for Health and Social Care, Second edition 2005 135 and the UK Policy 
Framework for Health and Social Care Research 2017 136. 
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 Health Research Authority (HRA) 
HRA approval process for research trials was fully implemented in the UK in March 
2016. This new system was designed to combine the independent ethical 
opinion/approval by the Research Ethics Committee (REC) and a review of research 
studies against NHS standards 137. This is an assessment of governance and legal 
requirements needed for each study which is undertaken by specific HRA staff, 
previously undertaken by individual NHS Research Development and Innovation 
(RD&I) offices.   
HRA approval was only required for the Hand to Nose study because the New 
Serotypes study received ethical approval before this new system was fully 
implemented. HRA application is encompassed into the Integrated Research 
Application System (IRAS) form, the research team also provides the HRA with 
Statement of Activities and Statement of Events forms which together aim to capture 
all information about study activities and study related information at a local level.  
There are many steps involved in obtaining HRA approval for a clinical trial.  Figure 7 
below shows the main steps in obtaining approval. The Hand to Nose study gained 
HRA approval in February 2017. For the New Serotypes study which was approved 
pre-implementation of HRA approval, the sole responsibility for ensuring the study 
complied with all legal and governance requirements fell to RLBUHT RD&I 
department, see below section 2.2.4. 
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Figure 7: HRA approval process applies to all research projects taking place in the NHS in England 112 
HRA approval encompasses assessment of governance and legal compliance and independent ethical 
opinion by the Research Ethics Committee.  
 
 Ethics: Integrated Research Application System (IRAS) and 
Research and Ethics Committee (REC) 
One of the HRA’s main functions is ensuring that research undertaken in the NHS is 
ethically acceptable. To do this they have multiple RECs countrywide. They aim to 
protect research participants by ensuring that studies are carried out in an ethical 
way and ensure that participants rights, safety, dignity and wellbeing is protected. In 
addition, they aim to ensure that research being undertaking is of potential benefit 
to science, society and the participants. Both studies in this thesis (Hand to Nose 
[Chapter 3] and New Serotypes [Chapter 4]) required full REC approval because these 
studies involved human volunteers and were carried out in NHS sites.  
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A separate IRAS form was created for each study and was the main basis of the REC 
application. Following this, the research team attended a REC meeting date, this gave 
the REC an opportunity to ask questions about the study and give feedback on 
changes that they would like the study team to make to documents provided or IRAS 
form. Ethical approvals for the studies were granted as shown in Table 4 below.  
Table 4: REC study approvals and other approvals/registrations for research studies within this 
thesis 
Study REC IRAS 
number 
Sponsor  Other 
approvals/registrations 
Hand to Nose 
study 
 
Chapter 3 
Liverpool 
(East) 
 
17/NW/0054 
 
Approved: 
02.02.2017 
221034 LSTM ISRTN: 12909224 registered 
27.06.2017 
 
NIHR portfolio: 33503 
 
HRA approval: 22.02.2017 
 
RD&I: 5376 approved 
17.03.2017 
 
New 
Serotypes 
study 
 
Chapter 4  
Liverpool 
(East) 
 
15/NW/0931 
 
Approved: 
25.01.2016 
 
193680 LSTM and 
RLBUHT 
ISRTN: 68323432 registered 
15.08.2017 
 
NIHR portfolio: 20815 
 
RD&I: 5124 approved 
08.08.2016 
 
 Research Development and Innovation Department (RD&I) 
Both studies discussed in this thesis were carried out in the Clinical Research Unit 
(CRU) based in RLBUHT. As the site of these research studies RLBUHT has a legal 
obligation to ensure that they are aware of all research undertaken on the site and 
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have carried out certain assessments prior to study initiation. The CRU is a Medicines 
and Healthcare Products Regulatory Agency (MHRA) accredited phase one research 
unit at RLBUHT. All participant visits for both studies were conducted in this unit.  
Final RD&I approval was provided for both studies once all other approvals were in 
place including: 
• REC approval 
• Finance team/ RD&I business team approval (contracts finalised) 
• HRA approval (only Hand to Nose study as this step only implemented March 
2016) 
• Directorate managers approval  
• CRU approval  
• Evidence of sponsorship in place 
• Evidence of liability insurance in place 
• Evidence of Principle Investigator/Chief Investigator contract with RLBUHT  
 Patient and Public Involvement (PPI) 
PPI is becoming increasingly important in research, and there are many benefits to 
the research team and public with this involvement. Some of the many benefits 
include: 
• Supporting recruitment and consent 
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• Demonstrating to funders that the research topic is important and relevant 
to the public and patients 
• Demonstrating to funders that the study design and documents are 
acceptable to the public 
• Identifying possible ethical issues with the design of the study 
The EHPC team have been studying pneumococcal colonisation in Liverpool over the 
last 9 years. The clinical and lab EHPC team understand the importance of PPI in 
research and we strived to ensure we had continual PPI events planned throughout 
both study periods. 
We attended many public engagement events; these events gave us the opportunity 
to provide information about the research being undertaken and improve local 
knowledge about research. This included us attending public open days, science fairs 
which are open to the public, having regular display stands and face to face 
engagement with the public at local gymnasiums and libraries. We also created a 
newsletter which was disseminated to previous research participants, colleagues and 
members of the public to which provided updates on findings of finished studies and 
future studies. 
We have also developed a role within the team for research ambassadors; individuals 
who previously participated in one of the EHPC studies. For the studies described in 
this thesis, research ambassadors were used to sense-check promotional and 
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information materials, to provide lay-input into the study protocols and to assist with 
recruitment events. 
A relatively new addition to our PPI work was utilising social media platforms as a 
way of involving the public in the research undertaken. We used multiple platforms 
including Facebook and Twitter to regularly upload information about our face-to-
face research events the public could attend and update followers about current 
trials which were open to recruitment. This has impacted on the demographics of our 
participants; the majority tended to be under 30 years of age who were more likely 
to have an active social media connection 138.   
2.3  Clinical procedures 
 Trial designs  
The two studies in this thesis used a human challenge model study design. 
Participants were challenged with live pneumococcus either intranasally (inoculated) 
or on their hands (exposure). All participants were seen prior to this challenge for 
screening and then were followed up for a period of up to 14 days post challenge. 
Nasal wash and blood samples were obtained to assess for nasopharyngeal 
pneumococcal colonisation and to investigate the immune response to challenge 
with or without colonisation (sample obtained discussed further below). 
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Study specific trial design with study design flow charts are outlined in Chapters 3 
and 4 (sections 3.2.2 and 4.2.2). 
 Ethical considerations 
Autonomy 
The study team ensured that participants were given sufficient information, written 
and spoken, without the use of medical jargon or other language requiring specialist 
knowledge. This ensured that participants could understand the research objectives 
and the risks and benefits of any procedures. Participants were always given enough 
time to consider the information before consenting to any involvement. We ensured 
that all participants did not feel pressured or persuaded into participating in the 
research study. Participants were financially compensated for their participation in 
the studies. Offering this payment was not intended to unduly influence participation 
but to compensate participants for their time and travel expenses incurred due to 
taking part in the trial. 
Participants that were recruited via the Consent4Consent database (see below 
section 2.3.3) were contacted regarding the research as they had previously 
expressed an interest in research. These participants had already given their consent 
to be contacted about future research that they may be eligible for. Participants were 
informed that they had the right to withdraw their consent and therefore withdraw 
from the study at any time without giving reason. 
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Non-maleficence 
The research team had a responsibility to minimise the risk of harm to the 
participants. We ensured that all researchers in the team had sufficient knowledge 
about the proposed interventions and potential risks. In addition, strict safety 
procedures were in place for both studies described in this thesis. See sections 2.3.6 
and 2.3.7 for further details on participant safety during the trial.  
Beneficence 
There are no direct benefits to the participants when taking part in the study. 
However, participants may have benefited from a better understanding of clinical 
research and from a sense of contributing to valuable medical research. 
Justice 
Justice is balanced with non-maleficence. We ensure that the research is open to all 
individuals, but important exclusion criteria are in place, primarily to protect 
individuals from undue risk.  
 Recruitment and advertising 
Prior to the start of the study the research team ensured that there were strategies 
in place to meet recruitment targets. Recruitment strategies used for both studies 
described in this thesis are detailed in Table 5. Figure 8 shows a flow chart of the 
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participant recruitment process. Advertising for the studies was not aimed at any 
vulnerable adults or those that may have lacked capacity to consent to take part in 
research. Participants were asked to gift their samples for use in future studies and 
to share with collaborators internationally. A continuous consent approach was used 
throughout the study; participants were asked at each visit if they were willing to 
continue.   
Table 5: Recruitment strategies for both Hand to Nose study and New Serotypes study 
Recruitment activity Description 
Flyers and 
recruitment posters 
Flyers and recruitment posters were put up on notice boards, 
table displays and around local public areas and local universities 
Social media adverts Facebook and Twitter announcements  
Electronic notice 
boards 
Announcements on local university’s electronic 
notice/announcement boards.  
Face-to-face 
recruitment drives 
Included: local university fresher’s fairs, local university open 
days and events at local halls of residences, libraries and 
gymnasiums.  
Interested people were given study recruitment flyers and were 
briefly spoken to about the purpose of the research and what 
taking part involved.  
Face to face recruitment drives were the most fruitful 
recruitment strategy for our team. During the 2016 fresher’s 
events at local universities we obtained contact details of over 
1400 potential participants. 
Consent4Consent 
Database 
Consent4Consent Database is a secure database of volunteers, 
created by RLBUHT, who had given their permission to be 
contacted about future research projects.  
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Figure 8: Flow chart of participant recruitment 
Following initial expression of interest in taking part in research, participants were given written 
information about the study and all were seen for a face-to-face discussion about the study prior to 
consent.  
 
Recruitment team contacts 
participant if previously given 
contact details at face to face event. 
Via email or phone.  
Potential participants contact 
recruitment team.  
Via email, phone or text.  
If participants happy to consent to 
the research study- the consent 
process and eligibility check was 
done 1:1 with a member of the 
clinical research team following this 
consultation 
Initial recruitment activity – see 
Table 5 above 
Email sent to potential participants with general details about the study and the 
study participant information leaflet (PIL). Invited to attend a face to face 
consultation with the research team.  
Provided we had not exceeded the capacity for recruitment, participants were 
given an unrestricted amount of time to decide whether to participate or not.  
Face-to-face consultation: 
participants met the research team, listen to a presentation about the study and 
asked any questions about their eligibility or the study 
If participants would like time to 
consider the study, they are given 
an un-restricted amount of time to 
consider participation and can re-
contact the team if/when they are 
happy to consent 
Participants details were put on The Over-Volunteering Protection System (TOPS) 
database prior to starting the study. 
This database was used to prevent volunteers from over-volunteering in trials 
which could be detrimental to their health. 
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 Inclusion and exclusion criteria 
Any specific inclusion and exclusion criteria for the Hand to Nose study and New 
Serotypes study are described in Chapter 3 (Hand to Nose) and Chapter 4 (New 
Serotypes).  
 
Inclusion Criteria- common to both studies described in this thesis 
• Adults aged 18-50 years  
 
To minimise the risk of pneumococcal infection, and to allow comparison with previously published 
experimental work done by the EHPC group 
 
• Fluent spoken English 
 
To ensure all participants have a comprehensive understanding of the research project and their 
proposed involvement 
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Exclusion Criteria- common to both studies described in this thesis 
• History of major pneumococcal illness (other severe bacterial infections included if participant fully 
recovered) 
• History of drug or alcohol abuse  
• History of smoking, defined as: 
o Current regular smoker (smokes daily/ smokes > 5 cigarettes per week)  
o Recent smoker i.e. within the last 6 months  
o Ex-smoker with a significant smoking history (>10 pack years)  
• Asthma (current and on treatment or not on treatment but symptomatic) and chronic respiratory 
diseases– both due to propensity to infection and due to possible confounding effect of  
medications such as corticosteroids.  
• Any other acute or chronic medical diagnosis that is known to increase the risk of bacterial  
infections or could lead to hospitalisation during the study period- at the discretion of study team 
• Taking daily medications that may affect the immune system such as steroids, steroid nasal spray, 
or retinoids 
• On any courses of medications which may affect the immune system such as chemotherapy, 
biologics, radiotherapy 
• Current illness, acute illness within 3 days prior to inoculation or antibiotic treatment within 2  
weeks of inoculation- both due to propensity to infection and to minimise any effect on inoculation 
or  
transmission 
• Currently pregnant 
• Diabetes- type 1 and type 2 (current diagnosis) 
• Involved in another clinical trial unless observational or in follow-up (non-interventional) phase- 
both due to propensity to infection and to minimise effect on inoculation or transmission 
• Significant anaemia, thrombocytopenia, neutropenia, neutrophilia, leucocytosis- as per results of full 
blood count test at screening 
• Previously undiagnosed abnormality found on screening clinical examination such as murmur 
 
To minimise risk of possible pneumococcal infection following inoculation or exposure 
 
• Allergy to penicillin/amoxicillin 
 
For safety of the participants- pneumococcal pathogen used in the studies fully sensitive to penicillins  
and are therefore given to participants during the study as emergency supply if unwell or to attempt to 
clear carriage at the end of the study 
 
• Close physical contact with at risk individuals (children under 5 years of age, immunosuppressed 
adults, elderly, chronic ill health) 
 
To minimise pneumococcal transmission and possible subsequent infection risk to others in the  
Community 
• Have been involved in an EHPC clinical trial involving pneumococcal inoculation in the last 3 years 
• Previous pneumococcal vaccination 
• Taking daily medications that may affect the inoculation such as long-term antibiotics  
 
To ensure homogeneity and interpretability of immunological endpoints of the participant population 
 with respect to previous pneumococcal immunisation or disease  
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 Study schedule 
Common parts of the study schedule for the Hand to Nose study and New Serotypes 
study are described below, specific details for each study are detailed in Chapter 3 
for Hand to Nose Study (section3.2.5) and Chapter 4 for New Serotypes study (section 
4.2.2).  
Following consent, participants were given a study schedule by the research team. 
This included an initial screening visit which was scheduled for the week prior to 
pneumococcal inoculation or exposure (see Table 6 for screening safety 
assessments). During the initial screening, additional study samples were also 
obtained to allow for baseline assessment. These included nasal wash to assess for 
natural pneumococcal colonisation and viral throat swab for both studies. A week 
after the screening visit, all participants who had passed screening came back for day 
0 which included pneumococcal challenge (inoculation or exposure).   
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Table 6: Screening safety assessments 
Assessment Rationale Action taken if abnormal 
Focused clinical 
history with 
medication review 
and clinical 
examination 
Ensure no abnormality that 
could increase risk of 
pneumococcal infection or 
would put participant at 
increased risk in the case of 
infection.  
Significant abnormality: volunteer was 
excluded from the study and the study 
doctor arranged appropriate 
investigations or treatment through 
primary care.  
 
Minor abnormality: if no potential to 
increase infection risk, volunteer 
included in study and study team 
informed primary care for follow up.  
 
Urinary pregnancy 
test 
Rule out pregnancy which 
could increase risks 
associated with 
pneumococcal infection  
 
Excluded from study if positive. 
Full blood count 
blood test 
Ensure no abnormality that 
could increase risk of 
pneumococcal infection or 
would put participant at 
increased risk in the case of 
infection. 
No specific cut off values 
were used when evaluating 
full blood count results. 
Results were taken into 
context of clinical history 
and examination.  
Significant abnormality: volunteer was 
excluded from the study and the study 
doctor arranged appropriate 
investigations or treatment through 
primary care.  
 
Minor abnormality: if no potential to 
increase infection risk, volunteer 
included in study and study team 
informed primary care for follow up. 
 Safety  
Pneumococcus is responsible for infections including otitis media, sinusitis, 
pneumonia, bacteraemia and meningitis. Exposing patients to pneumococcus gives 
a theoretical risk to participants of these infections. However, experience from 
previous pneumococcal challenge studies that have been run in Liverpool, suggests 
that the risk to healthy volunteers of developing an infection is very low. 10% adults 
experience natural colonisation at any time; while the incidence of invasive disease 
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is 20/100,000 patient years). Nevertheless, both studies reported in this thesis were 
designed to ensure any risk was minimised as follows: 
• Experienced study team (in pneumococcal human challenge studies) 
undertaking the work. 
• Careful serotype selection and dosing. Serotypes are all fully sequenced and 
have had antibiotic resistance testing by Public Health England. Dosing for 
these studies was based on a previous dose ranging study undertaken by the 
EHPC team 134 139. The team has experience of inoculating volunteers with 
doses of serotype 6B pneumococcus between 10,000-320,000 CFU/naris 134 
139. We have shown that inoculating at these doses is safe and colonisation 
rates are reproducible 134 139. Further information on serotype selection and 
dosing can be found in Chapter 3 and 4.  
• Study design. The New Serotypes study had a dose escalation period built 
into the study design. This ensured safety monitoring of at least 7 days post 
exposure of the first group receiving a new dose prior to any further 
inoculations (see Figure 13, Chapter 4). For both the Hand to Nose study and 
the New Serotypes studies, participants were put into groups of up to 24 
participants. Groups were inoculated at least a week apart to ensure that we 
could minimise exposure if any safety concerns were raised. 
• Participant selection and exclusion criteria. For both studies, strict exclusion 
criteria must be met, and safety screen visit was carried out to ensure 
participants do not have any un-diagnosed conditions which could put them 
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at increased risk (previously explained under the inclusion/exclusion 
heading).  
• Participant education. Participants were educated about potential risks 
involved in the study and signs and symptoms to look out for during the study 
at numerous times. See Appendix A for participant information leaflets. 
• Rigorous safety procedures. Each volunteer received a safety information 
leaflet, business card with emergency contact information, thermometer and 
3-day course of amoxicillin. Participants were advised to keep this pack with 
them at all times during the study. They were advised to take amoxicillin1) in 
the event they were unwell and were instructed to by the research team 2) if 
they were unwell and unable to contact the research team 3) if they had 
carried pneumococcus during the study and did not have 2 clear nasal washes 
prior to the last visit. Daily monitoring was also undertaken; participants were 
required to contact the study team with their temperature reading and any 
symptoms before midday for 7 days post exposure/inoculation. If the study 
team had not heard from a participant by midday, the volunteer was 
contacted to ensure their wellbeing. If they did not respond an allocated daily 
contact person/next of kin was contacted.   
• 24-hour emergency telephone contact available. A member of the clinical 
team was available for participants 24 hours a day, 7 days per week. This 
emergency number was covered by a research nurse during working hours 
and a medical consultant out of hours. Safety queries were either dealt with 
by phone advice or face to face review could be arranged.   
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• Weekly safety report. This report included study number of each participant, 
bacterial dose and serotype, date of inoculation, if they were a carrier of the 
bacteria post inoculation and details of any symptoms or illness that had been 
reported.  
Risks to researchers during the study are also very low. The main potential risks 
include needle stick injury to the clinical staff during venepuncture procedures and 
biological/chemical hazards within the laboratory for the lab staff. Bacterial stock 
preparation is undertaken in a hood to reduce risk of staff pneumococcal 
colonisation. During inoculation/exposure procedure staff also ensure that the 
bacterial stock is only open to the environment for minimal amount of time to ensure 
bacteria are not aerosolised and keep risk of pneumococcal colonisation of staff to a 
minimum. To ensure these risks are at a minimum, only experienced staff carried out 
procedures, within their competencies, in accordance with standard operating 
procedures regulated by good clinical practice and national guidelines. Appropriate 
risk and Control of Substances Hazardous to Health (COSHH) assessments are in place 
for all laboratory procedures. All laboratory work was conducted in an appropriately 
rated laboratory in line with health and safety regulations for research with human 
tissues/infectious agents.  
 Safety monitoring 
The following definitions were used in both Hand to Nose study and New Stains study 
(taken from HRA): 
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• Adverse Event (AE): Any untoward medical occurrence in a participant to 
whom a medicinal product has been administered, including occurrences 
which are not necessarily caused by or related to that product. 
• Serious Adverse Event (SAE) A serious adverse event is any untoward medical 
occurrence that: 
o Results in death 
o Is life-threatening 
o Required inpatient hospitalisation or prolongation of existing 
hospitalisation 
o Results in persistent or significant disability/incapacity 
o Other ‘important medical events’ may also be considered serious if 
they jeopardise the participant or require an intervention to prevent 
one of the above consequences 
 
There are strict guidelines for monitoring safety of participants taking part in 
research studies and reporting any safety concerns; Table 7 details the procedure for 
informing REC of any safety events. The Hand to Nose study and New Serotypes study 
were not clinical trials of an investigational medicinal product (CTIMP). Accordingly, 
the REC was only informed about SAEs that were related to the study and 
unexpected. In addition to this all SAEs were recorded and reported to the DMSC and 
sponsors (within 24hrs). SAE were monitored and reported until the end of the 
participant’s follow-up.  
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Non-serious adverse events were collected systematically during the research and 
recorded in the case report form and in the weekly safety report. Participants in the 
New Serotypes study were also asked to keep a log of symptoms since new serotypes 
of pneumococcus were being investigated. The results were summarised and 
reported to the DMSC. Safety reporting continued until the participant’s last visit. 
Table 7: Safety reporting to REC for non-CTIMP research studies; guidelines taken from the HRA 140  
 
Who When 
SAE CI or sponsor to the REC which 
issued favourable opinion 
 
Within 15 days of the CI becoming 
aware of the event 
Urgent safety 
measures 
CI or Sponsor to the REC which 
issued favourable opinion 
Immediately by telephone and then 
in writing within 3 days 
 
Progress reports To be submitted by sponsor, 
sponsor’s legal representative 
or Chief Investigator. Must 
always be signed by the CI. 
To the REC which issued 
favourable opinion 
 
Annually (starting 12 months after 
the date of the favourable opinion) 
 
Declaration of the 
conclusion or early 
termination of the 
research 
 
CI or Sponsor to the REC which 
issued favourable opinion 
Within 90 days (conclusion). 
Within 15 days (early termination). 
Summary of final 
report 
 
CI or Sponsor to the REC which 
issued favourable opinion 
Within one year of the conclusion of 
the research. 
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 Data Management and Safety Committee (DSMC) 
The EHPC team has an established Data Management and Safety Committee (DMSC) 
who are available for advice and support for the research team. DSMC should be an 
independent group of experts which can advise the study team using their expertise 
and can give recommendations. This committee was used as an additional safety 
measure for our studies. It consisted of 3 members (including at least 1 statistician) 
who are independent of the study team. The DMSC were supplied with a safety 
report at the end of the study, in the event of an SAE, or if requested at any time by 
the PI or DMSC members. Review of this safety report allows for critique of the safety 
of the studies without any possible reporting bias by study staff deciding to only 
escalate certain events to the committee. In the event of a SAE the DMSC and 
sponsor were also informed within 24 hours of PI becoming aware.  
 Nasopharyngeal pneumococcal challenge 
Participants in both the studies reported in this thesis were exposed to 
pneumococcal bacteria (pneumococcal challenge). On the day of pneumococcal 
challenge participants were specifically asked to report any upper respiratory tract 
(URT) symptoms to the clinical team and an oral temperature was taken as an extra 
safety check. If the participant reported any URT symptoms or had an abnormal 
temperature (>38 °C) they would be reviewed by one of the study doctors who would 
undertake a full clinical history and examination and decide about the safety of the 
participant to undergo the pneumococcal challenge. The pneumococcal challenge 
methods are described in Chapter 3 and 4, sections 3.2.7 and 4.2.1.  
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 Nasal wash sampling method 
Nasal wash was used for detection and quantification of pneumococcal colonisation. 
For this procedure, participants were seated, with their head tilted back to 30°, and 
were asked to hold their tongue at the roof of their mouths. Participants were asked 
to take a deep breath in and hold this breath (to avoid lung aspiration). Following 
this, 5mls of sterile 0.9% sodium chloride (saline) was instilled into one nostril, then 
collected into a sterile foil bowl following leaning forward and blowing the saline out 
of the nose while releasing the held breath (see Figure 9). 
This same procedure was then repeated three more times, in total twice in each 
nostril, with a total of 20ml of saline used. The sample was then transferred into a 
50ml centrifuge tube (Falcon, Thermo Fisher scientific, USA) for transportation to the 
laboratory. If less than 10ml of sample was obtained, the procedure was repeated to 
obtain an adequate specimen. Up to 10mls of extra saline was used if needed.  
 
 
Figure 9: Nasal wash procedure 
A syringe is filled with 20mls of saline, this is inserted into the nasal cavity and 5mls of saline is instilled 
into the nasopharynx. The participant has their head tilted back to approximately 30° while the saline 
is expelled and then leans forward to collect the expelled saline into a foil bowl. Picture reproduced 
with permission from EHPC team volunteer. Consent gained prior to photographs taken. 
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 Viral swab sampling method 
Swabs (flock swab, FLOQSwabs™) were taken from the palatopharyngeal arch using 
a tongue depressor, then placed immediately in viral transport medium (universal 
transport medium) and put on ice for transfer to the laboratory. Throat swabs 
preceded nasal washes to minimise oropharyngeal contamination with nasal 
pathogens (Figure 10).  
 
Figure 10: Viral throat swab procedure.  
A sterile medical swab is used to sample the oropharynx. A wooden tongue depressor was used if 
needed. Picture was reproduced with permission from EHPC team. Volunteer consent was gained 
prior to photography. 
 Blood sampling method 
Blood samples were obtained by venepuncture from the arm. The skin was cleaned 
prior to the procedure (CloraPrep® chlorhexidine gluconate 20mg/ml and isopropyl 
alcohol 0.7ml/ml), and samples were collected using a vacutainer system (Becton 
Dickinson, Plymouth, UK) (Figure 11). 
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Figure 11: Venepuncture procedure 
Participant’s blood was usually taken from the antecubital fossa. The skin was cleaned prior to the 
procedure and samples collected using a vacutainer system. Picture reproduced with permission from 
EHPC team. Volunteer consent was gained prior to photography. 
2.4 Laboratory procedures 
 Pneumococcal stock preparation (batch) 
For each serotype (15B, 23F and 6B) a ‘parent’ bead stock was prepared which was 
then used to prepare all subsequent inoculation stocks. For preparation of the 
‘parent’ stock, clinical isolates of each serotype were cultured on Columbia Blood 
Agar with horse blood (Oxoid, UK). This was then incubated overnight at 37°C in 5% 
carbon dioxide CO2. Following this the bacteria growth was added to Microbank™ 
vials (Pro-lab Diagnostics, USA). These cryovials contain ceramic beads and a unique 
cryo-preservative fluid which has been proven to allow for longer survival of 
fastidious cultures and higher quantitative recoveries and stored at -80°C 141. Prior to 
preparing any inoculum stocks from this ‘parent’ stock, it was checked for 
contamination by plating of the stock and checking for any non-pneumococcal 
bacterial growth and colony uniformity.  
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The preparation of the batch pneumococcal stock was undertaken in a fume hood 
with dedicated incubator and pipettes to ensure no contamination. Using the 
‘parent’ stock, each serotype was plated on blood agar and incubated overnight at 
37°C in 5% CO2. Bacterial colonies which grew overnight were then mixed with 
Vegitone broth (a vegetable-based growth medium, Sigma-Aldrich, UK) and grown to 
mid-log phase. These were then stored in aliquots of 1ml following the addition of 
10% sterile glycerol at -80°C.  
The determination of colony forming units (CFU) per ml is carried out using a slight 
modification of the Miles and Misra method 142. A blood agar plate was initially 
divided into 6 sections and labelled as shown in Figure 12. Using a 96 well U-bottom 
plate (Corning Inc, Germany), 180ul of sterile saline was mixed with 20ul of bacteria. 
Serial dilutions were performed to 106. Three 10ul drops from each dilution were 
placed on the corresponding section of the blood agar plate (e.g. 104 in section 4). 
Following time for drying, the plate was incubated for 9-16 hours at 37°C, 5% CO2. 
The following day the number of visible colonies in each section was counted.  
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Figure 12: Miles and Misra plates for determination of CFU/ml 
Three 10µl drops from serial dilution of inoculum were placed into the corresponding section of the 
blood agar plate. The plate was then inverted and incubated overnight. The following day the number 
of visible individual colonies in each section was counted.  
 
 
 
 
Calculation of the final dose (CFU/ml) is determined using the least dilute section 
where the number of individual colonies can be counted using the following formula;  
 
Prior to human challenge, a sample of the bacterial stock was sent to an independent 
reference laboratory (Public Health England, UK) to confirm bacterial stock purity, 
serotype and antibiotic sensitivity.  
(number of visible colonies/3) x (dilution factor of section) 
  volume of the drop plated  
CFU/ml
volume of 
bacteria 
stock used 
for 
challenge 
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 Preparation of pneumococcal stock on day of challenge   
Participants in the Hand to Nose study and New Serotypes studies were put into 
groups. Each group was challenged on the same day in groups of up to 7 participants 
per challenge. This helped to minimise variability between different bacterial 
challenge stocks being used throughout the study. In addition, for all participants the 
bacterial challenge stock came from the same ‘parent’ stock and same pneumococcal 
batch stock made.  
30 minutes prior to the scheduled pneumococcal challenge appointments the 
bacterial aliquot was thawed. This was spun down at 17000g for 3 minutes, followed 
by a wash step in normal saline. The bacterial pellet was re-suspended in 0.9% saline 
to the desired concentration based on prior CFU quantification. Bacterial suspension 
densities were prospectively quantified by Miles and Misra (M&M) serial dilution, 
both from defrosted stock, and from a control sample which was transported to and 
from the clinical site. This established the loss of bacterial viability related to 
transport. Two independent counts were performed per sample. 
 Nasal wash sample processing 
Nasal wash samples were transported to the laboratory and were processed within 
one hour of the sample being taken to minimise loss of viability. Any large pieces of 
mucus were removed (after vortexing to break up the debris or mucus) prior to 
processing with as little loss of saline as possible. The nasal wash sample was then 
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centrifuged for 10 minutes at 3345g, the supernatant volume was recorded and then 
stored as 1ml aliquots at -80°C.  
The nasal wash pellets were mixed with 100µl of skim milk, tryptone, glucose, 
glycerol medium (STGG), and the STGG plus nasal wash pellet volume was recorded. 
20µl of this was then streaked onto a blood agar plate with gentamicin (4µg/ml). 10µl 
was then used for M&M to assess possible colonisation density. The remaining nasal 
wash pellet was diluted with 8.2ml STGG; a further 25µl was streaked onto blood 
agar plates to assess for co-colonising flora. All plates were incubated overnight at 
37°C in 5% CO2. The remainder of the sample was divided into 3 cryovials and stored 
at -80°C.  
 Detection of pneumococcal colonisation by culture 
Pneumococcal growth was confirmed by visual appearance of the colonies 
(draughtsman-like colony morphology), presence of α-haemolysis, Gram-positive 
staining, optochin sensitivity and bile solubility.  
Serotype was assessed using latex agglutination (commercial kit from Statens Serum 
Institute, Denmark). A participant was labelled as colonisation positive if the serotype 
was proven to be the type experimentally challenged with (6B for Hand to Nose and 
23F or 15B for New Serotypes). If there was growth of any other serotypes the 
participant was labelled as a natural carrier of pneumococcus.  
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 Detection of pneumococcal colonisation by quantitative 
polymerase chain reaction (qPCR) 
2.4.5.1 Bacterial DNA extraction 
Stored samples were thawed and 300µl nasal wash pellet suspension was 
centrifuged at 20,238g for 7 minutes. The pellet was re-suspended with lysis buffer 
and protease mix (300µl; 1-part protease to 6-parts of lysis buffer [LGC Genomics 
GmbH, Germany]), 100µl of zirconium beads and 300µl of phenol, and disrupted 
using a TissueLyser (Qiagen, Germany), twice at maximum speed for 3 minutes (with 
cooling on ice in between). Following a further centrifuge for 10 minutes at 9391g to 
ensure separation of phases. The aqueous phase was mixed with binding buffer 
(600µl) and magnetic beads (10µl), then vortexed and incubated for 30-90 minutes 
in a gyratory rocker (Stuart™ SSM3 Gyratory Rocker) at room temperature. The 
sample and magnetic beads were washed twice with 2 washer buffers (200µl each) 
and bacterial DNA was eluted with 63µl of elution buffer. This buffer was the final 
step which detaches the extracted DNA from the magnetic beads and makes it 
soluble for recovery. 
2.4.5.2 Quantification of pneumococcal DNA by qPCR  
Determination of colonisation status and the density of colonisation episode by qPCR 
was performed through partial amplification of the lytA gene. The master mix 
included 12µl of DEEPC-treated water, 0.225µl of forward primer (5’-
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ACGCAATCTAGCAGATGAAGCA-3’), 0.225µl of reverse primer (5’-
TCGTGCGTTTTAATTCCAGCT-3’), 0.125µl probe (5’-(FAM)-
GCCGAAAACGCTTGATACAGGGAG-(BHQ)-3’) and 12.5µl of TaqMan® Universal PCR 
Master Mix (Life Technologies). In each well, 22.5µl of the master mix was mixed with 
2.5µl of extracted DNA. On each plate, two negative controls used 25µl master mix 
only, and each plate contained a standard curve of 10-fold dilutions of genomic DNA 
extracted from S. pneumoniae (106-101). Samples were assayed as duplicates, using 
thermal cycling conditions: 10 minutes at 95°C for DNA denaturation followed by 40 
cycles of 15 seconds at 95°C and then finally 1 minute at 60°C. All qPCR thermal 
cycling was performed in the same ABI 7500 Fast Real-Time qPCR system (Life 
Technologies, UK).  
The lower limit of detection was set at 40 cycles (CT). The qPCR plate was repeated 
if: 1) there was DNA detected in either of the negative control wells or; 2) any of the 
standards between 106-102 were not detected or; 3) both 101 standard wells were 
not detected or 4) the scatter of the standard results around the fitted regression 
line was poor (R2 ≤0.98, slope was not between -3.1 and -3.6) or 5) the efficiency was 
not between 90% and 110%.  
 Detection and identification of upper respiratory tract viruses 
Viral RNA was extracted from 200µl of viral transport medium (VTM), in which the 
oropharyngeal swab was stored and eluted into buffer using standard protocols for 
the QIAcube or QIAsymphony instruments. The samples were analysed for detection 
of viral RNA using four multiplex real-time PCR assays which amplify the viral 
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genome. All PCR assays were run using the Roche LC480 Instrument (Roche 
Diagnostics, UK). The four assay panels cover the detection of: 
1. Influenza A and Influenza B 
2. Parainfluenza 1-4, Adenovirus 
3. Human Metapneumovirus (hMPV), Respiratory Syncytial Virus (RSV), Human 
Rhinovirus (hRV) 
4. Coronaviruses OC43, NL63, 229E, HKU1 
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3 Hand to Nose Transmission of Streptococcus pneumoniae in 
Healthy Participants – Pilot Study (Hand to Nose) 
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This chapter was accepted for publication in a peer review journal (European 
Respiratory Journal) on 1st August 2018 and is currently in press.  
3.1 Introduction 
In pneumococcal epidemiology, transmission routes of S. pneumoniae between 
individuals remains poorly understood. It is hypothesised that transmission occurs 
due to inhalation of contaminated respiratory droplets 8. It is unclear if the hands or 
fomites (inanimate object capable of carrying infectious organisms) have a role in 
pneumococcal transmission. If direct transmission is implicated in the spread of 
pneumococcus the relative contributions of direct and indirect transmission modes 
to pneumococcal colonisation and disease are unknown. Current understanding of 
the transmission of this important clinical pathogen is described in Chapter 1 (section 
1.3).  
The hands have been identified as vehicles for the transmission of respiratory 
pathogens previously. Multiple studies have identified respiratory viral pathogens on 
hands and fomites 62 70 72 143 144,with persistence on dry inanimate surfaces ranging 
from 3 hours for coronavirus and up to 3 months for adenovirus 62. When evaluating 
bacterial respiratory pathogens, Gram-negative species such as klebsiella species and 
Pseudomonas aeruginosa have been shown to survive on inanimate surfaces for 
months 62. However, others only last for days such as Haemophilus influenzae (12 
days) 66.  
Chapter 3: Hand to Nose Study 
 
88 
Evidence is limited on the survival of pneumococcus on hands and fomites. One study 
exposed the hands of 3 adult volunteers, a glass plate and a plastic ball to 
pneumococcus suspended in two different media (Serum broth [10% horse serum in 
Brain Heart Infusion Broth, Oxoid] and Mueller-Hinton broth [Oxoid]) 68. Persistence 
of pneumococcus on the skin was reported for up to 3 hours post exposure when 
suspended in Serum Broth, but with substantially lower pneumococcal counts than 
the initial bacterial stock 68. Viable pneumococcus was also recovered from a glass 
plate at 15 hours post contamination. For the plastic ball there was an 85% average 
loss of pneumococci (266 CFU) at 4 hours but reported ongoing recoverable bacteria 
8 hours post contamination.    
Many epidemiological studies have examined natural pneumococcal carriage in the 
nasopharynx and transmission of infection has been described in case studies of 
outbreaks or epidemics of specific pneumococcal serotypes in communities 54-56. 
Healthy carrier transmission is less well understood. Observational studies suggest 
that person-to-person transmission occurs when in close contact with carriers such 
as within family groups 52 and could be increased with overcrowding for example 
during the Hajj 53.   
There is emerging evidence from murine models which investigate pneumococcal 
transmission from host to host. Most of these models have investigated 
pneumococcal transmission during influenza A co-infection, as this enhances 
pneumococcal shedding and therefore leads to higher acquisition rates by new hosts 
49. More recently evidence from an infant murine model describing shedding and 
Chapter 3: Hand to Nose Study 
 
89 
transmission during pneumococcal mono-infection has been published 51. Using this 
model Zafar et al 51reported that bacterial shedding was highest in pups intranasally 
infected with pneumococcus at age four days and that it peaks over the first four 
days post inoculation. They also reported that transmission was more likely to occur 
when there was a high ratio of colonisation positive pups to colonisation negative 
pups 51.  
We wanted to explore further possible mechanisms of human-to-human 
transmission and acquisition of nasopharyngeal pneumococcal colonisation. To do 
this we have developed our human pneumococcal challenge model to assess the 
feasibility of self-inoculation as a possible mechanism for pneumococcal 
transmission.   
This chapter addresses the following question: Can the hands be vehicles for direct 
transmission of pneumococcus from the hands to nostrils leading to experimental 
pneumococcal colonisation?  
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3.2 Methods  
 Study set up 
Hand to nose study set up procedures and approvals gained can be found in Chapter 
2, section 2.2. 
 Trial design  
Non-specific EHPC trial design information is described in Chapter 2, section2.3.1, 
section and ethical principles which were considered prior to the study initiation are 
outlined in section 2.3.2.  
The Hand to Nose study involved human participants being experimentally exposed 
to Streptococcus pneumoniae on their hands and asked to facilitate transmission of 
bacteria to the nasopharynx. Participants were followed up to evaluate if they had 
acquired nasopharyngeal pneumococcal colonisation using nasal washes at day 2, 6 
and 9. There was an assessment of two different transmission methods and the 
impact of wet bacterial transmission versus transmission following drying.  
The dose of pneumococcus used for the exposure procedures was 3.2 x 106 CFU. In a 
previous EHPC study 139 participants were intranasally inoculated with up to 3.2 x 105 
CFU/naris (6.4 x105 CFU total) with no significant adverse events. Pre-study 
experiments showed that there was a 1-2 log drop in pneumococcal counts 
recovered from the hand after exposure when the bacteria were wet and 
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immediately after drying (data not shown). Therefore, we estimated that we could 
expose participants’ hands to 6.4 x 106 CFU and still be confident that it would be safe 
for participants. However, as this is the first study of this type, we decided to use half 
this dose (3.2x106 CFU) to ensure safety further.  
All participants were exposed to serotype 6B Streptococcus pneumoniae. The first 
forty volunteers were randomly allocated, on the day of exposure, to one of four 
different transmission groups;  
1. Sniffing bacterial residue after air-drying of the hands- Group A/ ‘dry 
sniff’ 
2.  Pick/poke nose with finger exposed to wet bacteria residue- Group B/ 
‘wet poke’ 
3. Sniffing wet bacterial residue- Group C/ ‘wet sniff’ 
4. Pick/poke nose with finger exposed to dried bacterial residue ‘dry 
poke’ 
Randomisation was computer-generated and occurred in blocks of 6. An 
independent co-ordinator from LSTM’s Tropical Clinical Trial Unit produced the 
randomisation schedule. Two members of staff that were not involved in the conduct 
of the study produced sealed envelopes containing the group allocations. On the day 
of exposure, a clinical team member opened the envelope in from of the participant 
and informed them which transmission group they would be in.  
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Following the results from these first 4 groups, the trial steering committee (TSC), 
discussed the results and decided which group would be taken on to complete a 
larger number of participants (see Figure 13). 
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Figure 13:  Study Design Flow Chart 
The first 40 participants were randomly allocated, on the day of exposure, to one of the four 
transmission groups. Rates of colonisation for each of these transmission groups were discussed by 
the trial steering committee following the completion of the first 40 participants. One group was 
chosen to take forward to an extended cohort for better precision of estimated rates of colonisation.  
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 Recruitment 
Recruitment strategies and where the study was advertised is outlined in Chapter 2, 
section 2.3.3.  
 Inclusion/Exclusion criteria 
Inclusion and exclusion recruitment criteria can be found in Chapter 2, section 2.3.4.  
For the Hand to Nose study some additional specific inclusion criteria and exclusion 
criteria are outlined below.  
Table 8: Inclusion and exclusion criteria specific to Hand to Nose study 
Inclusion Criteria 
• Access to their own mobile telephone  
 
To ensure safety and timely communication. Also, to ensure the participants can follow the 
protocol by contacting us daily with temperature and any symptoms during the first 7 days 
post exposure to pneumococcus 
 
• Capacity to give informed consent  
 
To ensure it is clear to the research ethics committee that we will only be undertaking this 
research in adults who have capacity to make their own decision about entering the study 
 
Exclusion Criteria 
• Any acute dermatological illness or skin injury affecting the hands or face 
 
To ensure no confounding effects of topical medications or increased propensity to skin 
infections 
 
• Natural carriers of pneumococcus as determined at screening visit 
 
To minimise the potentially positive or negative effects on pneumococcal challenge 
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 Study schedule 
Non-specific study schedule details are outlined in Chapter 2, section 2.3.5. In the 
Hand to Nose study following pneumococcal exposure, participants were followed 
up for 3 further visits on day 2, 6 and 9 post exposure visits. These follow up visits 
entailed only a nasal wash sample. See Figure 14 for full appointment schedule for 
Hand to Nose study.  
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Figure 14: Hand to Nose study appointment schedule 
Following participants consent to take part in the study, appointments were arranged for all other 
clinical visits. The first visit is a screening appointment for baseline research samples and safety check. 
It also involved a nasal wash to screen for natural colonisation of pneumococcus. The week following 
this screening appointment participants underwent pneumococcal exposure. All participants were 
followed up for 9 days after exposure session. Any participant who was still colonised with 
pneumococcus (6B) at the end of the study was given a three-day course of amoxicillin in an attempt 
to clear colonisation. Clearance of colonisation was not confirmed with repeat nasal wash following 
antibiotics.  
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 Participant safety 
Details of participant safety procedures, safety monitoring and symptom reporting 
are detailed in Chapter 2, sections 2.3.6 and 2.3.7.  
There is a risk of unplanned pneumococcal environmental spread during the 
procedure of exposing participant’s hands to the pneumococcus and while the 
participant attempts bacterial transmission into the nostrils. To reduce this risk, we 
gave the participants full body gowns and eye shields to wear and used a draped area 
for the exposure procedure followed by the area being decontaminated with anti-
bacterial cleaning wipes following each participant.  
To mitigate any potential risk of spreading pneumococcus to vulnerable groups in the 
community, we discussed these risks with our participants and excluded anyone with 
close physical contact with at risk individuals (children under 5 years of age, 
immunosuppressed adults, elderly, chronic ill health) during the trial period. We also 
reduced pneumococcal colonisation burden in all study participants who were still 
colonised with pneumococcus at the end of the study, by giving them oral amoxicillin 
500mg three times daily for 3 days. Clearance of colonisation was not confirmed with 
repeat nasal wash following antibiotics.  
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 Pneumococcal challenge: hand exposure and transmission 
Clinical isolates of serotype 6B BHN418 (GenBank accession number 
ASHP00000000.1), a gift from Professor P Hermans, Radboud University Nijmegen, 
were used to create the ‘parent ‘stock for the Hand to Nose study. See Chapter 2, 
section 2.4.1 for details about how the ‘parent’ stock was made and for general 
aspects of pneumococcal challenge which are common to both studies in this thesis.  
For the Hand to Nose study, challenge involved exposing an area of the participant’s 
hand to pneumococcus, followed by the participant attempting to transmit the 
bacteria into their nose using one of two transmission methods (Figure 15). The 
pneumococcal stock preparation on the day of challenge and the 
exposure/transmission process is outlined in Chapter 2, sections 2.3.9 and 2.4.2.  
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Figure 15: Pneumococcal exposure and transmission process for participants using WHO hand 
hygiene guidelines 145 
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 Clinical sampling processes  
All participant visits were carried out at the CRU in RLBUHT, UK. Samples obtained 
from participants include; nasal wash, throat swab, blood sample and urine samples 
(only women of child bearing age). See Chapter 2, sections 2.3.10-2.3.12 for sample 
collection process. Participants’ full blood count (taken as part of safety procedure) 
and viral throat swabs were analysed by RLBUHT, clinical laboratories. All other 
research samples were processed and stored at LSTM.  
 Sample analysis 
Details of nasal wash sample processing can be found in Chapter 2, section 2.4.3. The 
process for detection of pneumococcal colonisation by culture and by qPCR can be 
found in Chapter 2 sections 2.4.4 and 2.4.5 respectively. The process used for 
detection of concurrent upper respiratory tract viral infection can be found in section 
2.4.6.  
 Endpoints and objectives 
The primary endpoint was experimental pneumococcal colonisation (detection of 6B 
in nasal wash) by classical culture methods at any time point (day 2, 6 or 9) following 
pneumococcal hands to nose transmission. This rate will be expressed as a 
percentage of participants colonised with pneumococcus over the total number 
exposed.  
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The secondary endpoints were (1) Determination of the duration and density of 
pneumococcal colonisation (2) Rates of pneumococcal nasopharyngeal colonisation 
following immediate attempted transmission (3) Rates of pneumococcal 
nasopharyngeal colonisation following attempted transmission following drying of 
bacteria (4) The detection of pneumococcal colonisation by qPCR at any time point. 
 Statistical methods 
As this was a pilot study, with no previously published data pertaining to 
pneumococcal hand to nose transmission rates available, we used proportion 
estimates to ensure the number of participants used in the study was large enough 
to give a specified degree of precision. 
Previous EHPC studies using nasal inoculation of S. pneumoniae bacteria found 
approximately 40% colonisation rates. If our study had the similar rates, 34 people 
would have given 95% confidence that the rate of colonisation lies within 18% on 
either side of this rate (22-58% colonisation). However, as this study does not involve 
nasal inoculation but adds a further step of hand exposure and attempted 
transmission, this rate is likely to be much lower. If we estimate we will get half the 
amount of colonisation observed in other studies (20%), then 34 people would give 
a 95% confidence that the rate of colonisation lies within 14% on either side of this 
(6-34%).  
Taking into consideration the possibility of 10% of participants being natural carriers 
12 and the possibility of 10% drop out/exclusion rate (taken from approximate 
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dropout rates from previous EHPC studies), it was concluded that we would need to 
recruit a maximum of 80 participants to complete 64 participants. This study was not 
powered to compare rates of colonisation between the four different transmission 
methods. The preliminary 40 participants were used to primarily investigate the 
feasibility of the transmission methods to decide which would be taken to the full 
cohort.  
The Fisher’s exact test and the Chi squared test were used to analyse colonisation 
rates. Graphing and statistical analysis were performed using GraphPad prism 
(California, USA). All P values were two-tailed and considered significant if P≤0.05. 
Differences in density were evaluated using one-way ANOVA test. Spearman’s rank 
correlation coefficient was used to assess the correlation of qPCR and culture 
densities.   
 
 
 
 
 
 
Chapter 3: Hand to Nose Study 
 
103 
3.3 Results  
 Screening and recruitment  
Between March and June 2017, 76 participants were recruited for the Hand to Nose 
study, with 63 participants completing all the study visits. 9 participants withdrew 
pre-screening due to personal reasons, 4 participants attended the screening visit; 2 
were excluded due to natural carriage of pneumococcus, 1 had an abnormal full 
blood count and one withdrew for personal reasons (see Figure 16). All 63 
participants were challenged with pneumococcus between April and May 2017, with 
the final participant’s final visit on 1st June 2017.  
The mean average age of volunteers was 22.6 years (range 18-45, median 21) and 
the male:female ratio was 23:40. When evaluating the first 40 participants who were 
randomly allocated to 4 different transmission groups, the mean average ages were 
similar (wet sniff: 23 [range19-28]; wet poke: 21.4 [range 20-24]; dry sniff: 22.5 
[range 19-27]; dry poke: 23.3 [range 19-44]). There were no statistically differences 
when comparing gender ratios of all 4 groups using Chi-squared (P=0.19) or when 
comparing the wet and dry groups using the Fisher’s exact test (P=0.08) (male:female 
ratios: wet sniff 5:5; wet poke 4:6; dry sniff 1:9; dry poke 2:8). 
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Figure 16: Consort flow diagram for Hand to Nose study 
 
 Inoculum doses were compliant with protocol 
All inoculum doses were compliant with the protocol as they fell within half and did 
not exceed double the target amount (3.2x106 CFU; see Table 9). The average 
Completed study = (n=63) 
Recruited (n=76) 
Wet sniff 
extended group 
(n=23 
completed) 
Withdrew after consent 
(n=9) 
Screened (n=67) 
Wet sniff (n=10) Wet poke (n=10) Dry Poke (n=10) Dry sniff (n=10) 
Discontinued (n=4) 
• Abnormal FBC 
• Natural carrier x2 
• Withdrew 
consent 
Total number of wet 
sniff group who 
completed the study 
(n=33) 
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pneumococcal dose participants were exposed to in each of the 4 different 
transmission groups were similar (wet sniff 3.4x106 CFU; wet poke 3.3x106 CFU; dry 
sniff 3.3x106 CFU; dry poke 3.4x106 CFU). To complete the full cohort, a total of 15 
different inoculation sessions were conducted, on 5 different days (See Table 9). The 
first 3 challenge days, in which the first 40 participants were challenged, included 
exposure with the four different transmission methods. For the last 2 challenge days 
only the ‘wet sniff’ transmission method was used to complete the full cohort.  
Table 9: Average pneumococcal challenge dose for all participants groups.  
Date of 
Challenge 
Number of 
participants 
Number of 
challenge 
procedures 
Average dose, CFU 
(SD) 
24/04/2017 22 4 3.50 x106 (4.46 x105) 
02/05/2017 15 3 3.24 x106 (2.00 x105) 
03/05/2017 3 1 2.78 x106 (0) 
16/05/2017 12 4 3.33 x106 (1.00 x105) 
23/05/2017 11 3 3.15 x106 (2.23 x105) 
 
 Hands were vectors for transmission of pneumococcus into the 
nasopharynx- classical culture results 
Initially forty participants were allocated to four different transmission groups. Eight 
individuals (20%) were found to be colonised with 6B serotype pneumococcus at 
follow up visits by culture, with highest rates found in the ‘wet poke’ (4/10, 40%), 
and ‘wet sniff’ (3/10, 30%) groups. Drying of the bacteria on the skin before “sniff” 
or “poke” led to 1/10 (10%) and 0/10 participants becoming colonised respectively 
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(see Figure 17 ). The difference in colonisation rates between groups was not 
significant (first 40 participants P=0.10; Chi-square test).  
Acquisition of colonisation following attempted transmission while the bacteria were 
wet was significantly higher than attempted transmission following drying of the 
bacteria (7/20 vs. 1/20 respectively, two-tailed P=0.04, Fisher’s exact test). The only 
group with no acquisition of colonisation following attempted transmission was the 
‘dry poke’ group. No difference was observed when comparing colonisation rates in 
the sniff groups versus poking groups (4/20 vs. 4/20 respectively, two-tailed P=1.00, 
Fisher’s exact test).  
The ‘wet sniff’ group was expanded to improve precision-estimates of rates. A total 
of 33 participants completed the study in this group. Of these, 6 participants became 
colonised (18.2%, 95% CI, 8.6%-34.4%). This was a lower overall colonisation rate 
than we expected following a colonisation rate of 30% in the initial 10 participants 
exposed. However, this fluctuation in colonisation rates week on week is not 
uncommonly seen in previous EHPC studies. For serotype 6B we have often had 
colonisation rates per group range from 10%-70% but with the overall study 
colonisation rate consistently between 45-55%. Overall experimental pneumococcal 
colonisation was found in 11/63 participants (17.5%, 95% CI, 10.0%-28.6%) at any 
time point, following hand to nose transmission of the pathogen.   
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Figure 17: Colonisation rates following classical culture of nasal wash samples at any time point 
after exposure in each transmission group.  
*No experimental carriers of serotype 6b were found in the dry poke group but 2 participants became 
natural carriers of pneumococci after baseline. 10 participants were exposed to pneumococcus in 
each of the 4 different transmission groups (dry poke, dry sniff, wet poke, wet sniff). Following 
discussion by the trial steering committee it was decided that the wet sniff group should be expanded 
to a total of 33 participants (the end graph includes participants from the initial cohort and extended 
cohort; 10 from initial cohort and 23 from extended). Percentage represents the number of 
participants in the group that were found to be experimentally colonised with pneumococcus at any 
time point following exposure.  
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 Natural Pneumococcal Colonisation 
Overall the natural colonisation rate in our cohort was 6% (4/67). Two participants 
were excluded at baseline due to natural carriage and two participants became 
natural carriers during the study (Error! Reference source not found.). No 
participants were co-colonised with 6B and the naturally acquired serotype when 
assessed using culture. However, 6A/B specific qPCR showed that one participant 
was co-colonised with naturally acquired serotype 19 and 6B at both day 2 and 6. No 
baseline nasal wash samples were positive for lytA qPCR confirming that all 
participants were negative for carriage at time of exposure.  
 
 
Figure 18: Natural pneumococcal colonisation serotypes as found by culture in 4 individuals  
NVT: non-vaccine type, serotypes identified by Statens Serum latex kit; SPN: Streptococcus 
pneumoniae. Pool D NVT serotypes: 16(16F, 16A), 36 and 37.  
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 Pneumococcal colonisation densities were similar in each 
transmission group- classical culture results 
Median post-exposure colonisation densities (CFU/ml of nasal wash) of the ‘wet 
sniff’, ‘wet poke’ and ‘dry sniff’ groups were 5.6x101 (range 4.3x10-1-3.7x106), 4.72 
(range 4.5x10-1-1.25x102) and 2.42 (range 1.16-9.55) respectively. See Figure 19for 
densities at each time point. 
D2 D6 D9 D2 D6 D9 D2 D6 D9
10- 1
100
101
102
103
104
105
106
107
Wet sniff Wet poke Dry sniff
S1
S2
S3
S4
S5
S6
S7
S8
Initial 40 participants:
S9
S10
S11
Larger cohort:
P
n
e
u
m
o
c
o
c
c
a
l 
D
e
n
s
it
y
 C
F
U
/m
l 
o
f 
n
a
s
a
l 
w
a
s
h
 
Figure 19: Pneumococcal colonisation densities, using classical culture method of pneumococcal 
identification, at each time point post exposure to pneumococcus. 
Results from the first 40 participants/subjects are in filled points and participants positive from the 
second part of the wet sniff group are in open points. Nasal washes were performed on day 2, 6 and 
9 post exposure to determine carriage status and density. Density is reported as CFU/ml of nasal wash 
returned. 
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Differences in densities between groups, when comparing the colonisation positive 
participants from the initial cohort (n=8), were not statistically different using a one-
way ANOVA test at any time point. Overall density over time for each participant was 
calculated using area under the curve (AUC). Comparison of AUC of the different 
transmission groups was also not statistically significantly different.  
When the wet sniff group was extended, the AUC appeared statistically significantly 
different between the wet sniff, wet poke and dry sniff groups (one-way ANOVA test) 
(Table 10). However, when applying Dunn’s multiple comparison test, no significant 
differences were observed (Table 11).  
Table 10: Comparison of transmission groups (full cohort) colonisation densities from culture. 
One-way ANOVA test with a P value of <0.05 considered significant. All densities log transformed prior 
to analysis. 
 Wet Sniff 
Mean Densities,  
Log transformed 
(Standard error) 
N=6 total 
Wet Poke 
Mean Densities, 
Log transformed 
(Standard error) 
N=4 total 
Dry Sniff 
Mean Densities, 
 Log transformed 
N=1 total 
P value 
(one-way 
ANOVA 
test) 
D2 1.96 (0.97) 
N=6 
0.21 (0.24) 
N=3 
0.98 
N=1 
0.23 
 
D6 2.09 (0.67) 
N=6 
0.91 (0.28) 
N=3 
0.06 
N=1 
0.20 
 
D9 1.86 (0.44) 
N=6 
1.05 (0.73) 
N=3 
0.38 
N=1 
0.41 
 
AUC  14.57 (3.52) 
N=6 
4.62 (1.62) 
N=4 
4.02 
N=1 
0.04* 
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Table 11: Dunn’s multiple comparison test results from AUC densities from culture of different 
transmission groups 
Dunn's Multiple Comparison Test Difference in rank 
sum 
Significant? P < 
0.05? 
Wet Sniff AUC vs Wet Poke AUC  5.083 No 
Wet Sniff AUC vs Dry Sniff AUC  5.333 No 
Wet Poke AUC vs Dry Sniff AUC  0.250 No 
 lytA qPCR detected pneumococcal DNA in more samples than 
classical culture  
252 nasal wash samples were collected from the 63 participants who completed the 
study; all were tested for the presence of S. pneumoniae by microbiological culture 
and retrospectively using lytA qPCR. The proportion of samples positive for 
colonisation by qPCR was significantly more than the proportion of samples positive 
for carriage by culture (23.8% vs. 13.1%, P<0.0001, Fisher’s exact test) (Table 12). 
There were no samples where pneumococcus was detected by culture but not lytA 
qPCR but in 10.7% of samples pneumococcus was only detected by lytA qPCR.  
Table 12: Comparison of microbiological culture and qPCR in detection of pneumococcus in nasal 
washes. 
 *3 samples culture positive for natural carriage of pneumococcus after baseline included   
Culture 
Positive (%) 
Culture 
Negative (%) 
Total 
qPCR Positive (%) 33 * (13.1%) 27 (10.7%) 60 (23.8%) 
qPCR Negative (%) 0 (0%) 192 (76.2%) 192 (76.2%) 
Total 33* (13.1%) 219 (86.9%) 252(100%) 
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 qPCR detected significantly higher rates of pneumococcal 
colonisation compared to classical culture 
Using molecular methods (lytA qPCR) resulted in higher colonisation detection rates 
compared with culture (35/63 [56%] vs 13/63 [23%] respectively, P=0.0001, Fisher’s 
exact test) (Table 13).  
Table 13: Comparison of microbiological culture and qPCR in detection of participants colonised 
with pneumococcus.  
* 2 participants who were natural carriers of pneumococcus after baseline included  
  
Culture 
Positive (%) 
Culture 
Negative (%) 
Total 
qPCR Positive (%) 13* (20.6%) 20 (31.7%) 33 (52.4%) 
qPCR Negative (%) 0 (0%) 30 (47.6%) 30 (47.6%) 
Total 13* (20.6%) 50 (79.4%) 63 (100%) 
qPCR detected a larger proportion of colonisation positive participants in every 
transmission group and at every time point except for day 9 in the dry sniff group 
compared to culture (Figure 20). The difference was most apparent in dry poke 
group, where 7/10 (70%) volunteers were experimentally colonised at any time 
point, with detectable pneumococcal DNA in nasal washes at 9 days after exposure. 
Of the 24 participants who were only determined as experimental colonisers of 6B 
using qPCR, 5 participants were colonised for more than one time point and 8 further 
participants were found to be colonisers at day 6 or day 9 nasal washes. 
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Figure 20: Comparison of culture (6A/B serotype only) and lytA qPCR results for different 
transmission methods 
Nasal washes performed on day 2, 6- and 9-days post exposure to pneumococcus to determine 
colonisation status. Nasal washes were plated on blood agar plates in real time and read the following 
day. Those participants with confirmed serotype 6B in nasal washes were deemed colonisation 
positive. Filled bar charts represent colonisation rates at each time point for each transmission 
method. At the end of the study all samples were re-run using lytA qPCR method of detecting 
pneumococcus. Striped bars are the additional participants found to be colonised with this molecular 
method. No samples were culture positive and qPCR negative for pneumococcus.  
 
 
 All transmission groups had similar densities of colonisation 
when assessed using qPCR 
Differences in densities between groups were not statistically different at any time 
point or AUC analysis for either the first 40 participants or the full data set (Table 14). 
Samples which were only positive with qPCR tended to have lower densities 
compared to samples which were both qPCR and culture positive (Figure 21).  
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Table 14: Comparison of transmission groups (full cohort) colonisation densities from lytA qPCR.  
One-way ANOVA test with a P value of <0.05 were considered significant. All densities were log 
transformed prior to analysis.  
 Wet Sniff 
Mean Densities, 
Log 
transformed 
(Standard error) 
N=17 total 
colonised 
Wet Poke 
Mean 
Densities, Log 
transformed 
(Standard 
error) 
N=6 total 
colonised 
Dry Sniff 
Mean 
Densities, Log 
transformed 
(Standard 
error)  
N=3 total 
colonised 
Dry Poke 
Mean 
Densities, Log 
transformed 
(Standard 
error) 
N=7 total 
colonised 
P value 
(one-
way 
ANOVA 
test) 
Day 2 1.97 (0.39) 
N=14 
1.13 (0.07) 
N=4 
2.41 (0.40) 
N=2 
1.56 (0.26) 
N=2 
0.34 
 
Day 6 2.99 (0.61) 
N=9 
2.09 (0.32) 
N=6 
1.32 (0.72) 
N=2 
1.65 (0.56) 
N=3 
0.42 
 
Day 9 2.64 (0.58) 
N=9 
2.29 (0.41) 
N=4 
2.75 (NA only 
one positive 
sample) 
N=1 
1.08 (0.28) 
N=3 
0.49 
 
Area Under 
Curve  
10.9 (2.90) 
N=17 
10.4 (2.45) 
N=6 
7.78 (4.58) 
N=3 
3.74 (1.31) 
N=7 
0.41 
 
 
 
Figure 21: lytA qPCR densities for each transmission group  
Nasal washes were performed at days 2, 6 and 9 post pneumococcal exposure. At the end of the study 
all nasal wash samples underwent DNA extraction and lytA qPCR for detection of pneumococcal DNA. 
Densities expressed as copies/ml of nasal wash. Graph shows each participant who was found to be 
colonisation positive following qPCR for each transmission group. Participants who were positive at 
more than one-time point are linked with a line. Open circles represent those samples which were 
only found to be positive using qPCR, filled circles are those samples that were positive with both 
culture and qPCR.  
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When the difference between pneumococcal detection was stratified by qPCR 
density it was clear that qPCR detects more carriers colonised at <101 CFU/ml density 
than classical culture method (Table 15). However, at qPCR densities 103 copies/ml 
and higher there was 100% concordance between qPCR and culture results.  
Table 15: Detection of pneumococci in nasal wash by bacterial culture and qPCR (categorised 
according to qPCR density) 
Density by QPCR 
(copies/ml) 
Number culture positive/number qPCR 
positive (%) 
<10 2/12 (17%) 
101 8/29 (28%) 
102 10/13 (77%) 
103 9/9 (100%) 
104 1/1 (100%) 
105 3/3(100%) 
 
 Density of colonisation reported by qPCR correlated with 
density reported by culture 
The correlation between pneumococcal density found by microbiological culture and 
qPCR was determined for 33 samples. There was a positive correlation between 
density of pneumococcus by culture and qPCR (rs=0.77, P<0.0001) (Figure 22).  
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Figure 22: Correlation between bacterial culture and qPCR in quantifying pneumococci in nasal 
wash.  
Quantification of pneumococci by culture and qPCR were positively correlated. Spearman’s rank 
correlation coefficient for samples positive by both qPCR and culture is 0.77. P<0.05 was considered 
significant.  
 
 No difference in length of time colonised was found between 
transmission groups 
Mean duration of carriage was not significantly different between transmission 
groups by classical microbiology nor by molecular methods of pneumococcal 
detection (1-way ANOVA culture results, P=0.42, qPCR results, P=0.82). Also, no 
significant difference was observed when comparing length of time colonised 
between wet and dry groups (Mann Whitney test culture results, P=1.0, qPCR results, 
P=0.59) or the poke vs sniff transmission methods (Mann Whitney test culture 
results, P=0.36, qPCR results, P=0.67) (Table 16). 
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Table 16: Mean and median days of colonisation for each transmission group, detected by both 
culture and qPCR methods 
Group 
(number 
colonised 
culture and 
qPCR) 
Median – 
culture 
(days with 
interquartile 
range) 
Median-qPCR 
(days with 
interquartile 
range) 
Mean- culture 
(days with 
standard 
deviation) 
Mean -qPCR 
(days with 
standard 
deviation) 
Wet sniff  
n=33 (culture 
n=6, qPCR 
n=17) 
9.0 (9.0-9.0) 9.0 (2.0-9.0) 9.0 (0.0) 6.2 (3.3) 
Wet poke 
(culture n=4, 
qPCR n=6) 
9.0 (3.8-9.0) 9.0 (5.0-9.0) 7.3 (3.5) 7.3 (2.9) 
Dry sniff 
 (culture n=1, 
qPCR n=3) 
9.0 (9.0-9.0) 
 
6.0 (2.0-9.0) 9.0 (0.0) 5.7 (3.5) 
Dry poke 
 (culture n=0, 
qPCR n=7) 
NA 6.0 (2.0-9.0) NA 6.1 (3.1) 
Full wet group 
(culture n=10, 
qPCR n=23) 
9.0 (9.0-9.0) 9.0 (2.0-9.0) 8.3 (2.2) 6.5 (3.2) 
Full dry group 
(culture n=1, 
qPCR n=10) 
9.0 (9.0-9.0) 6.0 (2.0-9.0) 9.0 (0.0) 6.0 (3.1) 
Full sniff group 
 (culture n= 7, 
qPCR n=20) 
9.0 (9.0-9.0) 7.5 (2.0-9.0) 9.0 (0.0) 6.1 (3.3) 
Full poke 
group  
(culture n= 4, 
qPCR n=15) 
9.0 (5.5-9.0) 9.0 (4.0-9.0) 9.0 (3.1) 6.7 (3.0) 
 
 No participants had asymptomatic viral infection at baseline 
We wanted to investigate whether the presence of asymptomatic upper respiratory 
tract (URT) viral infection increases the susceptibility to experimental pneumococcal 
colonisation following hand to nose transmission of the pathogen. Oropharyngeal 
swabs were taken between 4-7 days prior to pneumococcal exposure for all 
participants. At the end of the study we retrospectively analysed swabs from carriage 
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positive participants and negative controls (matched by date of exposure) by PCR for 
the presence of URT viruses. 22 samples were analysed in total due to funding 
constraints. No viral co-infections were found in any samples (tested for Influenza A, 
Influenza B, Parainfluenza 1-4, Adenovirus, Human Metapneumovirus (hMPV), 
Respiratory Syncytial Virus (RSV), Human Rhinovirus (hRV), Coronaviruses OC43, 
NL63, 229E, HKU1).  
3.4 Discussion  
This novel use of a human challenge model allowed for the study of pneumococcal 
colonisation in a controlled environment evaluating transmission of pneumococcus 
from hands into the nose. The study shows, for the first time, that the hands can be 
a vehicle for transmission of pneumococcus leading to acquisition of nasopharyngeal 
colonisation.  
 Success in the model expansion; hands were vehicles for 
transmission of pneumococcus  
We were able to successfully modify the Experimental Human Pneumococcal 
Challenge model 146 to allow for the study of transmission dynamics from the hands 
to the nose. Experimental pneumococcal colonisation was established in 17.4% of 
participants (11/63) when assessed using microbiological culture.  
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The EHPC model was established using nasal inoculation of the pneumococcal 
bacteria. Previous EHPC studies in Liverpool showed an overall colonisation rate of 
63% using this inoculation method (colonisation rates ranged from 55%-70% 
depending on dose of bacterial stock inoculated with) 139. A further study found 
colonisation acquisition was dose dependent with carriage rates ranging from 10%-
60% when inoculated with dose between 1x104-1.6x105, with carriage rates 
stabilising around 50% above 4x104 CFU/naris inoculation dose 10. Lower rates 
observed in this study may be due to the sniffing transmission method causing 
movement of the pathogen out of the nasopharynx. During the inoculation process, 
the inoculum is instilled around the anterior naris and participants are instructed not 
to sniff or blow. Another possible explanation for lower colonisation rates is death of 
the pneumococcal bacteria during the drying process on the hands.  
Epidemiological studies of nasopharyngeal colonisation rates with matched hand 
contamination rates support the findings of this study and suggest that hands could 
be vectors for direct and in-direct transmission of pneumococcus. One study 
reported simultaneous nasopharyngeal colonisation of pneumococcus and hand 
contamination rate of 22%, with serotype concordance of 85% (17/20) 74. A further 
study found hand contamination with pneumococcus is an indicator for risk of otitis 
media in populations at risk for tympanic membrane perforation (relative risk 8.4; 
95% CI 4.6-15.2) 42. 
An association between frequent sharing of drinking glasses or bottles and 
pneumococcal colonisation has also been reported. A significant correlation between 
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colonisation prevalence and self-reported frequency of sharing a drinking 
glass/bottle with 33% of frequent sharing group (sharing a glass/bottle always or 
usually) colonised with pneumococcus versus 16% of infrequent sharing group 
(sharing a glass/bottle half of the time, occasionally or never) 44. The authors 
suggested that these findings indicate pneumococcal transmission through saliva is 
a highly plausible route in young adults. However, the possibility that the hands could 
be vectors for this transmission was not considered or investigated. Following the 
results of this study, it is plausible that hand contamination and hand-to-nose 
transmission could be implicated in the higher rates of colonisation observed in the 
‘frequently sharing group’. 
It is widely known that hand washing is an effective means of preventing 
gastroenteric infections, especially in the developing world and it is a cost effective 
prevention strategy147 148 70. The effect of hand washing for preventing acute 
respiratory tract infections (ARIs) is less well understood. A systematic review of 8 
studies considering this question found a consistent impact of hand washing on ARIs 
with reduction of risk of ARIs by 16% (95% confident interval 11-21%)70. This 
reduction in risk is lower than that observed with the effect of hand washing on 
gastroenteric infection (47% reduction in risk of diarrhoeal illness) 147, but supports 
the results of this study that contaminated hands likely aid in the transmission of 
ARIs. It supports the view that hand washing could be a cost effective and feasible 
option for helping prevent ARIs and other contagious illnesses.  
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 Factors affecting transmission 
When assessing colonisation rates using microbiological culture, results suggested 
that transmission of pneumococcus resulting in colonisation was more likely when 
the bacteria were transmitted while still wet. However, interestingly when evaluating 
colonisation rates using molecular methods (qPCR) this difference disappeared with 
both the wet and dry groups having approximately 50% colonisation rates.  
Drying of the bacteria tended to lead to lower density of colonisation compared to 
transmission while the bacteria were still wet. No significant differences were 
observed between the two different transmission methods; sniffing versus poking. 
Participants who attempted transmission using the sniffing technique tended to have 
higher colonisation densities. This difference is likely due to the dispersion of the 
bacteria into both nostrils and to a larger area of the nasopharynx compared to the 
poking method.  
Little is known or understood about the survival of pneumococcus on the hands and 
the role of contaminated hands and fomites in pneumococcal transmission. One 
study reported a significant drop in pneumococcal counts at 3 minutes post hand 
exposure, but did recover some viable bacteria 3 hours post exposure 68. 
Interestingly, there was significant inter-volunteer variation in pneumococcal 
survival, with the greatest difference (4% recovery to 79% recovery rate at 3 minutes) 
observed between two volunteers exposed to 435 CFU of pneumococcus suspended 
in Serum broth (10% horse serum in Brain Heart Infusion Broth, Oxoid) 68. A limitation 
of this study was that the researchers were unable to assess whether the numbers 
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of pneumococci recovered were sufficient to lead to colonisation or infection. Our 
study confirms that pneumococcus is still viable following drying and can cause 
nasopharyngeal colonisation, albeit at lower densities.  
Transmission models using infant mice have previously been able to give some 
insights into transmission dynamics. Most transmission models have depended on 
influenza A virus co-infection. This has been shown to greatly enhance the 
pneumococcal shedding and leads to more acquisition of colonisation in new hosts 
48 49. Direct contact between pups was not needed for transmission and acquisition 
of colonisation to occur; this suggests that an environmental reservoir may be 
important for the spread of this pathogen 50. When evaluating Streptococcus 
pneumoniae mono-infection similar to all participants in this human challenge study, 
one murine model reported bacterial shedding was highest over the first 4 days post 
challenge 50. This suggests that host-to-host transmission may peak immediately 
following acquisition of pneumococcal colonisation. Epidemiological studies support 
this. A study investigating spread of pneumococcus within families showed rapid 
spread between family members if a new serotype was introduced to the family with 
17/25 transmission episodes took place within 2 weeks of a new serotype entering 
the household 52. 
Transmission in the same murine model was found to be increased when there was 
a high ratio of colonised pups to uncolonised pups in a litter 50. This supports previous 
evidence to suggest close contact increases in transmission of pneumococcus. 
Pneumococcal outbreaks have been reported in nursing homes 58 and prisons 60 and 
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colonisation rates were found to be significant higher at the end of the Hajj where 
close contact and overcrowding is common 53.   
Host and pathogen factors are also likely to impact transmission and the potential 
for the acquisition of pneumococcal colonisation. Murine models have shown that 
transmission is increased with high levels of bacterial shedding 48-50. Shedding is 
increased with acute inflammation in the nasopharynx and is also observed with co-
infection with influenza A virus 48-50. It has also been shown that nasopharyngeal 
inflammation in contact mice lowers their threshold for acquisition of pneumococcal 
colonisation 48. High bacterial load in index mice and capsular type were also found 
to affect transmission 48 69. One study used neutrophil depletion in index mice 
(experimentally colonised with pneumococcus) to investigate this. They found a 
small but significant increase in pneumococcal nasopharyngeal load can increase 
transmission 48. A further study showed that capsular type is correlated with 
transmission rates; capsule types which are better at escaping mucus entrapment 
show increased transmission 69.   
 qPCR detected a higher rate of pneumococcal colonisation 
compared with culture 
The proportion of nasal wash samples positive for colonisation by qPCR was 
significantly higher than the number detected by culture. This is in keeping with a 
previous EHPC study which also found significantly higher colonisation rates using 
qPCR (42.6% vs 27.5%, P<0.0001)149.  
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Culture is considered the gold standard method for detection of upper respiratory 
colonisation of pneumococcus and is recommended by the WHO Pneumococcal 
Carriage Working Group 150. The main advantage of culture is that further tests can 
determine serotype of pneumococcus recovered. Molecular methods of 
pneumococcal detection are increasingly being used either to complement culture 
or on their own to detect pneumococcal DNA. The WHO Pneumococcal Carriage 
Working Group state that there is no current gold standard molecular method of 
pneumococcal detection; they support the lytA PCR assay as widely used and species 
specific. The specificity of molecular methods to detect S. pneumoniae have been 
questioned due to similarities in gene profile of other streptococcal species 151-154. A 
study looking at pneumococcus in cerebrospinal fluid assessed specificity of lytA 
qPCR and reported a specificity of 70% 155. Many studies have showed that qPCR is 
more sensitive at detecting colonisation compared to culture 155-157, with increased 
sensitivity shown when an enrichment step was used 158. However, when the density 
of pneumococcal carriage is of interest, as in our study, this extra step cannot be 
utilised. The most thorough study methodology would utilise both of these methods; 
an initial qPCR could be run with the raw samples on which density could be 
measured then a second qPCR could be run following enrichment.  
The main concern about using qPCR is that this technique cannot confirm the viability 
of pneumococcal DNA detected; a positive PCR result which is culture-negative could 
represent either live bacteria causing low-density colonisation or non-viable/dead 
pneumococcal debris. It has been suggested that using an enrichment step in the 
qPCR method can increase the sensitivity of the method by reducing the impact of 
Chapter 3: Hand to Nose Study 
 
125 
pneumococcal DNA signal originating from possible non-viable bacteria 159. A 
previous study supports our findings; they reported significantly higher rates of 
pneumococcus in saliva using qPCR compared to culture (44/50 [88%] vs. 2/50 [4%] 
respectively) 39. In this study, higher quantities of pneumococcal-specific genes were 
detected in culture-enriched saliva samples. This study also used sham-inoculated 
samples with pneumococcal DNA. These samples were found to be negative with lytA 
qPCR which supports the hypothesis that qPCR detects low density colonisation of 
live bacteria rather than non-viable bacterial DNA 39. A further study reported that 
pneumococci were recovered following re-culturing from the majority of samples 
that were qPCR positive and initially culture negative, further supporting the validity 
of the method 159. 
The results of this study support the hypothesis that qPCR can detect subclinical or 
low-density colonisation rather than detecting non-viable pneumococcal debris. In 
20% of new qPCR colonisers pneumococcus was found at more than one-time point. 
In addition, 33% were found to be colonisers at day 6 or day 9 nasal washes. It is 
unlikely that non-viable or dead bacterial DNA would be still in the nasopharynx 
>6days following initial exposure or be detectable at multiple time points, supporting 
that qPCR likely detects low density colonisation. Using a novel home sampling 
method, the EHPC team have recently examined bacterial movement after 
experimental pneumococcal challenge 160. In this study, the kinetics of pneumococcal 
colonisation or clearance during the first 48 hours following challenge by using self-
collected saliva and nasal lining fluid samples 160. The study showed that at 48 hours 
less than one fifth of non-colonised participants had detectable levels of 
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pneumococcus from nasal lining fluid samples (4/21 (19%) 160. The results suggest 
two distinct profiles of those protected against colonisation;  
1. Saliva clearers; these participants demonstrated a fast-initial 
movement of pneumococcus into the bacteria. With 40% having 
complete clearance of pneumococcus from the nose by 8 hours 
160.  
2. Nasal clearers; these participants show a rapid and strong 
neutrophil baseline activity 160.  
This study supports the hypothesis that dead bacteria do not stay in the nasopharynx 
for prolonged periods of time, with the majority of clearance happening within 24 
hours of exposure or inoculation.  
 Culture and qPCR methods used together improved sensitivity 
of pneumococcal detection  
Our data suggest that using both culture and qPCR to determine pneumococcal 
colonisation is beneficial. By using both methods the chance of missing 
pneumococcal colonisation is likely to be reduced. Higher colonisation rates were 
found using qPCR, but pneumococcal densities measured with both methods were 
positively correlated. All samples that were culture-positive for pneumococcus were 
also positive for lytA in qPCR.  
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We found that culture positivity rate decreased with decreasing densities measured 
by qPCR, suggesting that qPCR may be more appropriate for detecting low density 
colonisation episodes. All the 27 samples that were culture negative and qPCR 
positive had qPCR densities below 103 copies/ml. It has previously been shown that 
culture detected fewer carriers of pneumococcus and S. aureus and H. influenzae at 
bacterial densities of <105 CFU/ml (measured by qPCR) (P<0.0001) 157.  
qPCR has also been shown to be superior at detecting multiple pneumococcal 
serotypes at low carriage densities. One study found 28.7% of participants were co-
colonised with multiple pneumococcal serotypes when using qPCR and only 4.5% of 
these were found to be co-colonised using only culture (P<0.001) 156. The majority of 
additional serotypes only detected by qPCR had a density of <104 CFU/ml 156. This 
correlates with the findings of this study.  We found that one participant who was 
determined to be colonised with only serotype 19 using culture, was co-colonised 
with 6B using molecular methods of detection.  
 Asymptomatic viral carriage and acquisition of colonisation 
We were unable to investigate the relationship between colonisation acquisition and 
concurrent viral infection due to the absence of viral infection in our participants. 
The lack of any concurrent viral infection is likely due to the season in which the study 
was carried out (Spring; April-May)161. Previous EHPC studies, conducted during 
winter months, found that asymptomatic viral co-infection increased odds of 
experimental pneumococcal colonisation (15/20, 75% virus positive volunteers 
became colonised vs. 37/81, 46% virus-negative, P=0.02) 162. In addition, a recent 
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randomised control trial investigated the effect of viral upper respiratory tract 
infections in pneumococcal colonisation using the live attenuated influenza vaccine 
(LAIV) as a surrogate 45. No change in prevalence of colonisation was observed but 
there was evidence of increasing density following vaccination 45.  
Results from murine models have been able to show that viral co-infection can 
increase transmission and colonisation acquisition. One study inoculated index mice 
with pneumococcus and 8 days later inoculated index and contact mice with 
Influenza A; 47% of the contact mice acquired colonisation at day 14. In contrast, 
there were no colonisation episodes detected in any contact mice in the control 
group (no influenza inoculation) 49. Epidemiological studies have also found that viral 
co-infection, such as rhinovirus, facilitate acquisition and transmission of 
pneumococcus between individuals 163.  
Our ability to prevent pneumococcal transmission is limited by the lack of 
understanding about transmission dynamics of pneumococcus and which factors 
promote acquisition of nasopharyngeal colonisation. We have shown that an 
experimental human carriage model can be used to investigate modes of 
transmission. The study shows, for the first time, that the hands can be a vehicle for 
transmission of pneumococcus and lead to acquisition of nasopharyngeal 
colonisation. It also shows that pneumococcus continues to be viable following 
drying. The data suggest that using both culture and qPCR methods for 
pneumococcal detection is important to ensure that low density colonisation 
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episodes are not missed. This is important for further transmission studies where 
carriage density may be an endpoint.  
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4 The Effect of Different Serotypes of Pneumococcus on 
Colonisation in Healthy Participants (New Serotypes) 
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4.1 Introduction 
Epidemiological studies have shown that rates of pneumococcal colonisation and 
disease are dependent on multiple factors. Many of these are host specific including 
age, geographic area, socio-economic factors and viral or bacterial co-infection 14 164. 
The host’s innate and adaptive immune responses have also been shown to effect 
rates of colonisation and disease. Mucosal and systemic antibodies to pneumococcal 
capsular polysaccharides (IgG antibodies) are thought to play a role in pneumococcal 
immunity but the degree of protection against pneumococcal colonisation and 
disease is unclear.  
Current evidence suggests different serotypes may induce different sizes of IgG 
antibody responses to the pneumococcal capsular polysaccharide. During an 
outbreak of pneumococcal pneumonia caused by serotype 1 at a military training 
camp, 27.8% of the men who did not develop pneumonia had serotype-specific IgG 
antibodies detected in sera (systemic blood) compared to 3.6% of controls (3/83, 
controls used were a comparable population of soldiers at a training base with no 
outbreak of pneumococcal pneumonia) 165. A later study showed that for some 
serotypes (9V, 14, 18C, 19F and 23F) a colonisation episode can lead to a significant 
increase in levels of serotype-specific anticapsular IgG 12. However, serotype 6B failed 
to induce the same immune response 12. For serotype 14, higher levels of 
anticapsular IgG at the beginning of the study was also associated with reduced 
chance of colonisation during the study 12. In contrast, in this study antibody 
responses to pneumococcal proteins (PsaA, PsaA and Ply) did not correlate with 
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protection against colonisation. The role of antibodies against the polysaccharide 
capsule and towards proteins in the protection against pneumococcus remain 
unclear. The data suggest that these responses may vary depending on serotype. 
However, more information is needed before this conclusion is made.  
Pneumococcal serotype has also been shown to play a major role in acquisition of 
colonisation or disease. There are over 90 serotypes of Streptococcus pneumoniae. 
Serotypes are defined by biologically different polysaccharide capsules.  Some 
serotypes are more invasive and cause significant disease whereas others mainly 
cause colonisation episodes and are rarely recovered in disease cases 133. A recent 
pneumococcal colonisation surveillance study in the UK showed that the most 
prevalent serotypes causing colonisation are 15B/C, 11A, 23B and 10A in 
2015/2016southern). In addition, serotypes 8, 12F, 3 and 9N caused approximately 
50% of all invasive pneumococcal disease cases in England/Wales during 2016/2017 
166.  
Capsular polysaccharides are understood to play a key part in bacterial physiology 
and are vital in determining the host’s immune response to the pneumococcus. Due 
to differences in the capsular polysaccharides between serotypes, capsule structure 
has been implicated in the varying clearance and acquisition rates observed between 
serotypes 167 168. Specific characteristics of the capsular polysaccharide which affect 
this process are yet to be fully understood. In addition to different capsular 
polysaccharide, multiple other proteins have been suggested to be important in the 
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colonisation process, such as PspC and ChoP 167. The relative contribution of these 
factors is also unknown 167.  
Better understanding of the dynamics of colonisation and systemic immunity for 
different pneumococcal serotypes is vital. This study expanded the current EHPC 
model by re-testing a modified 23F serotype and for the first time tested a non-
vaccine serotype 15B. Investigating the varying propensity of pneumococcal 
serotypes to establish nasopharyngeal colonisation will allow for better 
understanding of transmission dynamics and disease.  
Serotype 6B is currently used in the EHPC model. This serotype consistently colonises 
40-50% of participants. The model is currently limited in generalisability, only having 
one serotype that colonised consistently at a high rate, which is already covered by 
the current PCV (serotype 6B). Expanding the model to include non-vaccine 
serotypes is important for vaccine testing. As colonisation is a likely a pre-requisite 
for invasive infection, it could be used as a surrogate marker of disease risk. 
Protection against colonisation therefore could be used in a vaccine trial to predict 
the protective effect against invasive pneumococcal disease 101. The model has 
previously been used to test the effectiveness of PCV13. A sample size of 100 was 
needed in the study to give power to detect 50% reduction in colonisation rates 
compared to control 169. New serotypes that are able to colonise at similar or higher 
rates than 6B in this EHPC model would allow for further vaccine testing trials.   
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To develop a reproducible model of colonisation with smallest numbers necessary, 
we examined colonisation rates at increasing doses until a colonisation rate of 
greater than 40% was achieved. Following this, to improve the precision of our 
estimates of colonisation potential, one dose was tested in a larger number of 
participants.  
This chapter addresses the following question: What is the capacity of 23F and 15B 
serotypes to cause experimental pneumococcal colonisation in healthy adults?  
 
 
 
 
 
 
 
Chapter 4: New Serotypes 
135 
4.2 Methods  
 Study set up 
New Serotypes study set up procedures and approvals obtained can be found in 
Chapter 2, section 2.2.  
 Trial design  
Non-specific EHPC trial design information is described in Chapter 2, section 2.3.1 
and ethical principles which were considered prior to the study initiation are outlined 
in section 2.3.2. 
The New Serotypes study experimentally exposed human participants to 
Streptococcus pneumoniae: 
Dose-ranging:  
• Group 1: participants were entered into cohorts which were all inoculated 
with the same dose of serotype 23F (P1121). Successive cohorts had 
increasing does of the serotype inoculated if desired colonisation rates were 
not obtained (see Figure 23;n = 33-67). 
• Group 2: participants were entered into cohorts which were all inoculated 
with the same dose of serotype 15B (non-vaccine serotype). Successive 
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cohorts had increasing does of the serotype inoculated if desired colonisation 
rates were not obtained (see Figure 23;n = 33-67). 
• Extended Cohort: To enhance the precision of the estimated colonisation 
rate, a dose and serotype that lead to more than 40% of carriage in the dose 
ranging part of the study was tested in a larger group of volunteers.  
We hypothesised a dose-dependent relationship in probability of colonisation. We 
used the dose escalation method to test this hypothesis, to estimate the optimum 
inoculation dose for these new serotypes and to minimise unnecessary exposure of 
volunteers. Also, to ensure safety of participants, by inoculating small groups we 
monitored for any adverse events before continuing to higher doses and to larger 
groups.   
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Figure 23: Dose escalation study design for New Serotypes study.  
Used for both 15B and 23F serotypes; methodology adapted from Waddington et al 170.  
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 Trial procedures  
General details of trial procedures common to both studies outlined in this thesis are 
described in Chapter 2 Sections pertaining to different trial procedures are outlined 
below in Table 17.  
Table 17: Generic trial procedures outlined in Chapter 2: Methods. 
Trial procedure Section 
Recruitment strategies  Section 2.3.3 
Prevention of over-volunteering process Section 2.3.3 
Inclusion and exclusion criteria Section 2.3.4 
Study schedule Section 2.3.5 
Participant safety procedures Sections 2.3.6, 2.3.7 and 2.3.8 
 
In the New Serotypes study following pneumococcal inoculation, participants were 
followed up for 3 further visits on day 2, 7 and 14 post inoculation. These follow up 
visits involved a nasal wash sample at each visit and bloods for all participants at day 
14. See Figure 24 for full appointment schedule. 
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Figure 24: Flow chart of New Serotypes study participant appointments 
Following participants’ consent to take part in the study, appointments were arranged for all other 
clinical visits. The first visit is a screening appointment for baseline research samples and safety check.  
The week following this screening appointment, participants underwent pneumococcal exposure. All 
participants were followed up for 14 days after exposure session. Any participants who were still 
colonised with pneumococcus (6B) at the end of the study were given a three-day course of amoxicillin 
in an attempt to clear colonisation. Longer follow up was decided for this study compared to the Hand 
to Nose study because we were investigating immunological responses. Previous EHPC studies found 
that serotype 6B induced significant immune response at day 14 post inoculation10 171.  
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 Symptom reporting 
To examine whether experimental colonisation with pneumococcus causes 
symptoms, all volunteers filled out a daily symptom log on inoculation day and for 
each of the following 6 days. For the 23F study a 7-point Likert-type scale was used 
for symptom reporting (nasal and non-nasal symptoms) as published by Spector et al 
172 (recommended to evaluate severity of rhinitis). This scoring system was slightly 
modified with the removal of ‘mental function’ as a possible non-nasal symptom (see 
Appendix B: Daily Symptom Logs) 
For the 15B study, a different daily symptom log was used to cover a larger number 
of potential non-nasal symptoms as a further safety strategy and to ensure 
colonisation did not cause systemic symptoms that we previously did not enquire 
about. A further benefit of this was also to move to a generic symptom log for all 
EHPC studies to allow better comparison of results (see Appendix B: Daily Symptom 
Logs). The numeric scoring system was replaced with descriptive options based on 
participant feedback. Participants felt that the lack of explanation of what 
constituted a score of 2, 4 and 6 made it difficult to use. The study team also believed 
that descriptive options would reduce the subjective variation between participants 
reporting on a numbered scale.  
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 Bacterial Serotypes 
4.2.2.1 23F Serotype  
In 2001 a human challenge experiment was performed in the USA using serotype 23F 
P833.This achieved colonisation rates of 43% (6/14 participants) 29. This serotype was 
transferred to the EHPC group. A repeat study found 23F serotype had a reduced 
ability to colonise humans, maximum colonisation rate of 10%. Upon discussions with 
the USA team it was discovered that the 23F inoculum contained two different cell 
populations, one wild-type for the amiC gene and the other contained an amiC 
frameshift mutation (Dalia and Weiser, personal communication with Ferreira). It 
was confirmed that the inoculum used for the EHPC study containing the amiC 
frameshift mutation. Both genetic serotypes (P833 and P1123) were sequenced using 
an Illumina Hi-Seq and frameshift mutation was determined by PCR amplification and 
sequencing (described in J. Gritzfeld PhD thesis 173).  
AmiC is a pneumococcal transmembrane protein that has been shown to play a role 
in adherence and oligopeptide transport 174 175. Following this discovery, a murine 
model assessed the effect of this mutation on nasopharyngeal colonisation. The 23F 
serotype with amiC mutation did not establish any colonisation, while a 23F serotype 
with a full length amiC gene was able to establish colonisation and is not further 
considered in this thesis (unpublished work, M.de Jonge).  
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In this study we tested a natural derivative isolate of 23F serotype P833; P1121, 
containing a wild-type amiC gene, with no frameshift mutation on amiC gene. Using 
the wild type serotype, we expected to be able to reproduce findings from the USA 
group which established carriage in 75% participants using 17,000 CFU/naris 29. This 
penicillin-sensitive isolate was obtained from a child with otitis media by 
tympanocentesis, gifted from University of Pennsylvania as described below. 
4.2.2.2 Non-Vaccine Serotype 
We also wanted to investigate a pneumococcal serotype not included in the PCV13 
vaccine; no human infection model has tested any such serotype previously. Multiple 
serotypes were assessed using laboratory testing prior to choosing the best 
candidate. 15B P1262 was chosen based on superior pneumococcal survival in 
presence of human blood neutrophils and adherence to human nasal cells compared 
to 6B serotype (Pojar, unpublished work). This penicillin-sensitive isolate was 
obtained from a child during a colonisation episode, gifted from Southampton. 
Collection as described below.  
 Pneumococcal inoculation 
Clinical isolates of serotype 23F serotype P1121 (a gift from Professor JN Weiser, 
University of Pennsylvania. European Nucleotide Archive accession number: 
ERS1072059) and serotype 15B serotype P1262 (a gift from Dr D. Cleary, University 
of Southampton. European Nucleotide Archive accession number: ERS2632437), 
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were used to create two ‘parent’ stocks for the New Serotypes Study. See Chapter 2, 
section 2.4.1 for details about how the ‘parent’ stock was made and for general 
aspects of pneumococcal challenge which are common to both studies in this thesis. 
Prior to human challenge, a sample of the bacterial stock was sent to an independent 
reference laboratory (Public Health England, UK) to confirm bacterial stock purity, 
serotype and antibiotic sensitivity.  
Intra-nasal inoculation with either 15B or 23F serotypes of S. pneumoniae was carried 
out by a research nurse or clinical fellow, trained in the inoculation procedure. 
Participants were sat in a semi-recumbent position with their head tilted back. Using 
a P200 micropipette 0.1ml broth containing the desired dose of pneumococcus was 
inserted into each nostril Figure 25. The pipette tip never touched the nasal mucosa 
during the procedure to ensure the integrity of the epithelium was not disrupted. 
Following inoculation, the participant remained in this position for up to 15 minutes 
without sniffing or blowing the nose.  
               
 
                      
Figure 25: Inoculation of the nasal mucosa procedure  
Participants sat in a semi-recumbent position. Inoculation of the nasal mucosa with pneumococcus 
was undertaken using a P200 pipette. 100µl of the bacterial inoculum was instilled into the anterior 
nasal cavity in a circular motion.  
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 Clinical sampling processes and sample analysis  
All participant visits were carried out at the Clinical Research Facility in the RLBUHT.  
Samples obtained from participants include; nasal wash, blood samples and urine 
sample (only women of child bearing age). Sample collection and processing can be 
found in Chapter 2 (see below for sections in Table 18). Participants’ full blood count 
were analysed at RLBUHT, clinical laboratories. All other research samples were 
processed and stored at LSTM. 
Table 18: Generic clinical sampling process and sample analysis is outlined in Chapter 2 
Process Section 
Nasal wash sampling method Section 2.3.10 
Blood sampling method Section 2.3.12 
Pneumococcal stock preparation (batch) Section 2.4.1 
Preparation of pneumococcal stock on day of challenge Section 2.4.2 
Nasal wash sample processing  Section 2.4.3 
Detection of pneumococcal colonisation by culture Section 2.4.4 
 
Detection of pneumococcal colonisation by q PCR 
Section 2.4.4 
4.2.4.1 Measurement of anti-pneumococcal polysaccharide 
antibodies by enzyme-linked immunosorbent assay (ELISA)  
We measured the levels of serotype 15B specific polysaccharide antibody in 
volunteers’ serum. Initially a 96-well plate was coated with 10µl purified 15B capsular 
polysaccharide (Statens Serum Institute Diagnostica, Denmark) in 10ml of 
phosphate-buffered saline (concentration 5µg/ml) then incubated at 4°C overnight. 
Human anti-pneumococcal capsule reference serum lot 007sp (National Institute for 
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Biological Standards and Control, UK) was used to make a standard curve. The 
standard was serially diluted from a concentration of 271.04ng/ml to 4.235ng/ml.  
In a separate 96-well plate 2.5 µl of serum sample was mixed with 100µl of dilution 
buffer (2ml of 10% heat-inactivated foetal bovine serum blocker in 20ml PBS), 
10µg/ml of cell wall polysaccharide (CPWS Multi, Statens Serum Institute 
Diagnostica, Denmark) was added and incubated at room temperature for 30 
minutes. Following these dilution and absorption steps samples were transferred to 
the pre-coated plates and incubated at room temperature for 2 hours. Bound 
antibodies were detected using goat anti-human IgG (Sigma Life Sciences, UK), 2.5µl 
in 10ml phosphate-buffered saline and incubated at room temperature for 1 hour 30 
minutes. Finally, 100µl of p-nitrophenylphosphate (5mg added to 40ml of distilled 
water) was added to plates and left to develop in the dark for 15-20 minutes, 
following this absorbance was measured at 405nm using FLUOstar Omega plate 
reader (BMG Labtech, Germany). All samples and standard curve were measured in 
duplicate. Between all steps described above plates were washed with PBS-Tween 
0.005% using a microplate washer (ELx50™, BioTek™, USA).  
 Endpoints and objectives 
The primary endpoint was the detection of experimental pneumococcal colonisation 
(serotype 23F or 15B) in nasal wash by classical culture methods at any time point 
(day 2, 7 or 14) following pneumococcal challenge.  
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The secondary endpoints were: (1) Determination of the duration and density of 
pneumococcal colonisation with 23F and 15B serotypes; (2) Rates of colonisation at 
different inoculum doses for both serotypes; (3) The detection of pneumococcal 
colonisation by qPCR at any time point; (4) Quantification of a systemic humoral 
immune response to nasopharyngeal carriage (capsular specific IgG concentration in 
serum). 
 Statistical methods 
Previous EHPC studies using serotype 6B S. pneumoniae bacteria attained 
colonisation rates of approximately 45%. We used this as the basis of our sample size 
calculation; to estimate colonisation rates with 95% confidence (+/-5%) 34 
participants completing the study with a single inoculation dose (2.0x104, 8.0x104 or 
1.6x105 CFU/naris), using 45% colonisation as an estimate for the ‘real rate’. To allow 
for an estimated drop-out rate of 10% and natural colonisation of 10% (who will be 
excluded from primary endpoint analysis) between 34 and 67 participants was 
required for each serotype.  
The Fisher’s exact test and Chi squared test were used to analyse colonisation rates. 
We compared colonisation rates seen between serotype 23F and 15B. In addition, 
comparison was made between colonisation rates found at different inoculation 
doses. Differences in density was evaluated using one-way ANOVA test. Graphical 
and statistical analysis were performed using GraphPad prism (GraphPad Software, 
CA, USA). All P values were two-tailed and considered significant if P<0.05.  
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4.3 Results  
 Screening and recruitment  
4.3.1.1 23F study  
During September 2016, 18 participants were recruited for the 23F group, 16 
participants completed all the study visits. This study was suspended early due to 
poor results, further discussed in section 4.3.3. Two participants were excluded 
following screening both due to abnormal full blood counts (see Figure 26). All 16 
participants were inoculated with pneumococcus in September 2016, with final 
participant, final visit on 11th October 2016. The mean average age of volunteers was 
30.2 years (range 25-47, median 29) and the male:female ratio was 5:11.  
 
Figure 26:Consort flow diagram for 23F group New Serotypes study  
Recruited (n=18) 
Inoculated with 
20,000 CFU 
N=6 
Inoculated with 
160,000 CFU 
N=4 
Inoculated with 
80,000 CFU 
N=6 
Screened (n=18) 
Discontinued (n=2) 
1)Abnormal FBC n=2 
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4.3.1.2 15B study 
Between August-November 2017, 72 participants were recruited to the 15B group, 
with 54 participants completing all study visits. 10 participants withdrew pre-
screening, 7 excluded or withdrew post screening visit and 1 was excluded at day 1 
post inoculation due to starting antibiotics for a non-study related issue (see  
 
Figure 27). All 54 participants who completed the study were challenged with 
pneumococcus between September-November 2017, with the final participants, 
final visits on 13th December 2017. The mean average age of volunteers was 24.6 
years (range 18-49, median 21) and the male:female ratio was 29:25.   
Sequential groups were inoculated with higher doses of bacterial inoculum if optimal 
rates of colonisation were not achieved by day 7 (>40% colonisation rates). This was 
a safety feature to ensure that we were taking forward to an extended cohort the 
lowest inoculum dose possible to achieve adequate colonisation rates. Participants 
were recruited into groups depending on their availability. The inoculation dose 
which achieved the optimal colonisation rates was extended to complete a full 
cohort. This extended cohort would give us statistical confidence to estimate the 
colonisation rate of this serotype.  
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Figure 27: Consort diagram for 15B group of New Serotypes study 
 Inoculum doses were within target range 
All inoculation doses were compliant with protocol as they fell within half or double 
of the target amount. The average inoculation doses per group can be seen below 
(Table 19).  
Table 19: Average pneumococcal challenge dose for all participant groups 
Dose Group 
Target inoculation dose per naris 
Serotype 23F 
Average dose (CFU/naris) 
Serotype 15B 
Average dose (CFU/naris) 
2x104 1.7x104 (SD 0) 1.9x104 (SD 9.9 x102) 
8x104 7.5x104 (SD 0) 8.9x104 (SD 1.3x104) 
1.6x105 1.7 x105 (SD 0) 1.9x105 (SD 0) 
Recruited (n=72) 
Inoculated with 
20,000 CFU 
N=10 
Inoculated with 
160,000 CFU 
N=9 
Inoculated with 
80,000 CFU 
N=10 
Screened (n=62) 
Discontinued (n=7) 
1)Abnormal FBC n=2 
2)Participant wishes n=3 
3)Health issues n=2 
Discontinued (n=10) 
1)Participant wishes n=9 
2)Health issues n=1 
Withdrew at D1 
n=1 due to starting 
antibiotics  Extended cohort 
inoculated with 
80,000 CFU  
N=26 
TOTAL N=36 
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 Dose-ranging study: Serotype 15B lead to more acquisition of 
colonisation compared to 23F serotype  
Naturally colonised participants at baseline were excluded from analysis (see Table 
20). There was no significant difference in colonisation rates between participants 
inoculated with 15B and those receiving 23F (P=0.29, Fisher’s exact test).  
Table 20: Number of participants in each dose-ranging group for each serotype tested, with number 
of naturally colonised participant as baseline who were excluded from primary analysis of data.  
Dose Group 23F group  
Number of 
participants  
 
23F Group 
Naturally 
Colonised at 
baseline 
15B Group  
Number of 
participants   
 
15B Group 
Naturally 
Colonised at 
baseline 
2x104 6 0 10 0 
8x104 6 1 10 1 
1.6x105 4 0 9 1 
 
Overall the colonisation rate with 23F was 13% (2/15; excluding participant naturally 
colonised at baseline). The highest colonisation rates were observed in the group 
inoculated with 8x104 CFU/naris (20%, 1/5) and no colonisation events were 
detected in the 1.6x105 dose group (Figure 28). Due to poor colonisation rates with 
serotype 23F in the dose-ranging portion of the study, this serotype was not taken 
forward to be completed in an extended cohort.   
The 15B serotype led to acquisition of colonisation in each dose group. Initially 
colonisation rates were dose dependent with more participants in the 8x104 group 
becoming colonised compared to the 2x104 group (4/9, 44% vs. 3/10, 30% 
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respectively). However, rates fell from 44% at 8x104 CFU/naris to 13% (1/8) when the 
dose rose to 1.6x105 CFU/naris. This difference was not statistically different (P=0.29) 
(Figure 28). 
 
Figure 28: Colonisation rates (%) for 23F and 15B during dose range portion of the study. 
Participants who were naturally colonised with pneumococcus at baseline were removed prior to 
analysis. Participants were intranasally inoculated with either serotype 23F (blue circle) or 15B (red 
squares) over a range of doses, starting with 2x104 CFU/naris to 1.6x105 CFU/naris. Y axis shows 
percentage of participants experimentally colonised at each dose.  
 Dose-ranging study: Density of colonisation and inoculum dose 
Colonisation rates were not found to rise significantly with increasing inoculum dose 
for either serotype. We wanted to investigate whether colonisation density may 
increase in parallel with this inoculum dose increase. Figure 29 shows the 
colonisation density recovered from nasal washes at each time point (day 2, 7 and 
14) for both 23F and 15B dose-ranging participants. Due to low colonisation rates in 
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the 23F group we cannot confidently analyse differences in colonisation density at 
increasing inoculum doses.  
Participants inoculated with 15B with an inoculation dose of 8x104 CFU/naris had 
significantly higher colonisation density at day 2 compared to those inoculated with 
2x104 (P=0.047, t test). This difference did not continue at later follow up time points 
(day 7 and 14).   
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Figure 29: Density of colonisation for both 23F and 15B groups at each time point tested.  
Results from nasal washes performed at day 2 (A&B), day 7 (C&D) and day 14 (E&F). Density is 
reported as CFU/ml of nasal wash recovered. Data bars represent mean and standard deviation. We 
were unable to compare inoculation groups for 23F as too few were colonised. For the 15B cohort, t-
test was used to compare groups at day 2 as only two inoculation doses lead to colonisation. One-way 
anova was used to compare groups at day 7 and 14. P value of <0.05 considered significant.  
2x104 8x104 1.6x105
-2
0
2
4
6
A
Inoculum dose (CFU/naris)
D
a
y
 2
 N
a
s
a
l 
 W
a
s
h
L
o
g
 o
f 
R
e
c
o
v
e
re
d
 2
3
F
 (
C
F
U
/m
l)
2x10
4
8x10
4
1.6x10
5
-2
0
2
4
6
B
Inoculum dose (CFU/naris)
D
a
y
 2
 N
a
s
a
l 
 W
a
s
h
L
o
g
 o
f 
R
e
c
o
v
e
re
d
 1
5
B
 (
C
F
U
/m
l)
2x10
4
8x10
4
1.6x10
5
-2
0
2
4
6
C
Inoculum dose (CFU/naris)
D
a
y
 7
 N
a
s
a
l 
 W
a
s
h
L
o
g
 o
f 
R
e
c
o
v
e
re
d
 2
3
F
 (
C
F
U
/m
l)
2x10
4
8x10
4
1.6x10
5
-2
0
2
4
6
D
Inoculum dose (CFU/naris)
D
a
y
 7
 N
a
s
a
l 
 W
a
s
h
L
o
g
 o
f 
R
e
c
o
v
e
re
d
 1
5
B
 (
C
F
U
/m
l)
2x10
4
8x10
4
1.6x10
5
-2
0
2
4
6
E
Inoculum dose (CFU/naris)
D
a
y
 1
4
 N
a
s
a
l 
 W
a
s
h
L
o
g
 o
f 
R
e
c
o
v
e
re
d
 2
3
F
 (
C
F
U
/m
l)
2x10
4
8x10
4
1.6x10
5
-2
0
2
4
6
F
Inoculum dose (CFU/naris)
D
a
y
 1
4
 N
a
s
a
l 
W
a
s
h
L
o
g
 o
f 
R
e
c
o
v
e
re
d
 1
5
B
 (
C
F
U
/m
l)
23F Cohort 15B Cohort 
*P=0.047 
P=0.223 
P=0.807 
Chapter 4: New Serotypes 
154 
When evaluating the area under the curve (AUC) of densities for each serotype, no 
differences were observed between 15B and 23F either when looking at all positive 
participants or when this was broken down into inoculum doses (Figure 30). Overall 
colonisation density during the 14 days follow up period was not a function of 
inoculation dose.  
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Figure 30: Area under the curve densities. For 23F and 15B groups at each inoculum dose 
Nasal washes were performed at day 2, 7 and 14 for all participants. Pneumococcus was detected in 
nasal washes using classical culture techniques. Area under the curve was calculated from the density 
of colonisation calculated at each positive time point. Density reported as CFU/ml of nasal wash 
returned. Data bars represent mean ± standard deviation.  
 Dose-ranging study: Majority of the participants colonised up 
to day 14 
Both colonised participants with 23F continued to be positive to day 14. The majority 
(75%, 6/8) of participants colonised with 15B during the dose-ranging portion of the 
study also continued to be positive to day 14. All participants inoculated with 2x104 
and 1.6x105 CFU/naris were colonised up to day 14, but in the 8x104 CFU/naris group 
50% (2/4) cleared colonisation prior to day 14. Those participants who were found to 
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be colonised at either day 7 or 14 received antibiotics at the end of the study to clear 
colonisation.  
 Extended Cohort: Precision of estimated colonisation rate with 
15B improved with extension of cohort to 33 participants  
During the dose-ranging portion of this study, 15B was the only serotype to reach 
colonisation rates above the desired 40% attack rate. Colonisation rates of 44% were 
observed at the 8x104 inoculation dose group; therefore, this was taken forward into 
the reproducibility portion of the study.     
Twenty-five further participants were inoculated with 15B at 8x104 inoculation dose 
in this part of the study. One participant was naturally colonised with pneumococcus 
at baseline; they were removed from the population prior to analysis of the data for 
the primary outcome (modified intention-to-treat). Following challenge, 29% (7/24) 
of participants were experimentally colonised with 15B by microbiological culture. 
Analysis including all participants who were inoculated with 8x104 CFU/naris of 
serotype 15B, indicated an overall colonisation rates were 33% (11/33) (See Figure 
31). 
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Figure 31: Proportion of colonisation positive and negative participants detected by classical culture 
Participants who were naturally colonised with pneumococcus at baseline were removed from 
analysis. Participants were intranasally inoculated in groups with serotype 15B over a range of doses; 
2x104 (10 participants), 8x104 (9 participants) and 1.6x105 (8 participants). We extended the 8x104 
group as this had the best colonisation rates. The extended cohort shows results of a further 24 
participants inoculated with this dose.   
 
 Extended cohort: Half of participants had cleared colonisation 
by day 14  
Of the 11 participants colonised following inoculation with 8x104 CFU/naris of 15B 
serotype, over half cleared colonisation prior to the final visit at day 14 (55%, 6/11), see  
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Figure 32. This was similar to results found in the dose ranging part of the study 
where 50% of participants (2/4) in the 8x104 CFU/naris group cleared colonisation 
prior to day 14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Proportion of participants colonised at each time point following inoculation for 
participants inoculated with 8x104CFU/naris.  
Clearance of colonisation was considered as the first negative nasal wash found by classical culture 
after which all further nasal washes were also negative. All participants in this group who were 
colonisation positive during the study had pneumococcus detected at day 2. By the end of the study 
(day 14) only less than half of participants were still colonised. Any participant that did not have 2 
negative nasal wash results after day 14 visit were given 3 days of amoxicillin in an attempt to clear 
colonisation.  
 
 
 Complete 15B Cohort: No difference found between 
colonisation rates when using lytA qPCR compared to culture  
128 nasal wash samples were collected from 32 participants in the full 15B 8x104 
CFU/naris inoculum group. These were tested for the presence of S. pneumoniae by 
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microbiological culture and retrospectively by lytA qPCR at the end of the study. For 
this analysis, natural carriers (3 participants) were excluded to remove the 
interaction of more than one prominent colonising serotype which might introduce 
wider unexplained variation in responses.  
The proportion of samples positive for carriage by qPCR was higher than by culture, 
but this difference was not statistically significant (29/128 [23%] vs. 21/128 [16%] 
respectively, P=0.27, Fisher’s exact test). LytA qPCR improved detection of 
colonisation and therefore colonisation rate but this was also not statistically 
different from the culture colonisation rate (16/32 [50%] vs. 11/32 [34%] 
respectively, P=0.31, Fisher’s exact test) (Figure 33). Six participants were only 
colonisation positive using qPCR. Of these 5/6 only had pneumococcus detected from 
nasal wash at day 2 post inoculation (Figure 33). In 1.6% samples (2/124), 
pneumococcus was detected by culture but not qPCR (one participant at 2-time 
points), but in 8% of samples (10/128) pneumococci were only detected by qPCR. 
Table 21 shows concordance rates between the two methods of pneumococcal 
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detection. 
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Figure 33: Number of participants colonised at each time point detected by culture and lytA qPCR 
for 15B full cohort.  
For detection by classical culture techniques, nasal wash samples were plated on blood agar. For lytA 
qPCR detection, nasal wash was added to RNA protect and frozen on day of sample collection, DNA 
extraction process was completed retrospectively following completion of the study. Samples with a 
Ct value of <40 were considered qPCR positive. Samples from 32 participants were analysed (naturally 
pneumococcal colonised participants were excluded from analysis). Blocks represent participants who 
were culture positive only (culture +), lytA qPCR positive only (lytA +) and those that were found to be 
colonised by both culture and lytA qPCR. All time points post inoculation are shown and results from 
any time point (any).  
 
Table 21: Concordance between microbiological culture and qPCR in detection of pneumococcus in 
nasal washes. 
3 participants who were natural carriers of pneumococcus either at baseline or during the study were 
excluded from this analysis (modified intention-to treat analysis). 
a Denominator is total number of samples or participants which are positive with either culture or lytA 
qPCR and numerator is number of samples positive by both methods. b Denominator is total number 
of samples or participants which are positive with either culture or lytA qPCR and numerator is number 
of samples negative by both methods.  
 
 
 
Nasal Wash 
Samples 
Number of 
Participants  
Concordance of Positive Results  63% (19/30) a 59% (10/17) a   
Concordance of Negative Results  89% (97/109) b 68% (15/22) b 
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 Natural carriers of pneumococcus 
Overall natural colonisation rates in the 23F group was 1/18 (5.5%) and 15B cohort 
was 6/62 (9.6%). All serotypes found were non-vaccine serotypes (see Figure 34). No 
participants were co-colonised with 23F or 15B and the naturally acquired serotype 
when assessed using culture.  
 
 
 
Figure 34: Natural pneumococcal colonisation serotypes as found by culture.  
NVT: non-vaccine type, serotypes identified by Statens Serum latex kit. Pool C NVT serotypes: 24 (24F, 
24A, 24B), 31, 40. Pool D NVT serotypes: 16 (16F, 16A), 36, 37. Pool G NVT serotypes: 29, 34, 35 (35F, 
35A, 35B, 35C), 42, 47 (47F, 47A). Pool H NVT serotypes: 13, 28 (28F, 28A). 
 
 Levels of polysaccharide 15B (PS15B) IgG in serum at baseline 
were not associated with protection against colonisation 
acquisition. 
We measured pneumococcal antibody levels in serum samples from 34 participants 
before inoculation with 8x104CFU/naris of serotype 15B to assess whether levels 
correlated with protection against colonisation. Levels of PS15B IgG at baseline were 
similar between colonisation positive (those who acquired colonisation following 
14% 
29% 
43% 
14% 
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inoculation) and colonisation negative participants (those who did not acquire 
colonisation) (Figure 35). Median 15B IgG levels in colonisation positive volunteers 
was 3787ng/ml (interquartile range [IQR] 1607-6465) compared to 3681ng/ml (IQR 
1927-6008) in colonisation negative participants (P=0.78, unpaired t test).  
In addition, no association was observed between baseline PS 15B IgG levels and 
colonisation density (Figure 36) (RS= -0.21 Spearman’s rank correlation coefficient, 
P=0.54). Baseline levels of PS 15B IgG were therefore not predictive of colonisation 
status nor associated with colonisation density.   
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Figure 35: Baseline polysaccharide15B (PS15B) IgG levels prior to experimental human 
pneumococcal challenge.  
IgG specific ELISA’s in serum were performed against pneumococcal PS15B. levels of antibody were 
determined from colonisation-positive participants (colonisation+ n=11) and colonisation negative 
participants (colonisation – n=23). Serum samples were taken at screening visit (day -5). Horizonal 
bars represents geometric mean and error bars represents the 95% confident intervals. Comparison 
of colonisation positive and negative participants carried out using unpaired t test. P value of <0.05 
where considered significant.  
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Figure 36: Correlation between baseline anti-PS 15B IgG levels and AUC density of colonisation 
positive participants.  
Spearman’s rank correlation coefficient is -0.21 with P value of 0.54.  
4.3.10.1 PS 15B IgG levels are increased post inoculation in colonisation 
positive participants  
Paired baseline and final follow up (day 14) serum samples from 33/34 participants 
from this cohort were evaluated. In colonisation positive participants we observed a 
significant rise in levels of PS 15B IgG at day 14 post inoculation compared to baseline 
(mean 4693ng/ml at baseline vs 18164ng/ml at day 14, P=0.0005 paired t-test). In 
contrast, colonisation negative participants levels of PS 15B IgG at day 14 were 
comparable to those at baseline (mean 4059ng/ml at baseline vs. 3866ng/ml at day 
14, P= 0.31 paired t test). See Figure 37.  
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Figure 37: Levels of polysaccharide 15B (PS 15B) IgG before and after pneumococcal inoculation. 
IgG specific ELISA in serum were performed against pneumococcal PS15B. Levels of antibody were 
determined from colonisation positive participants (colonisation +) and colonisation negative 
participants (colonisation -). Serum samples taken at screening visit (day -5) labelled as ‘Pre’, serum 
samples taken on final follow up visit (day 14) labelled as ‘Post’. A) Measurement of PS 15B IgG levels 
was carried out in all samples as duplicate. Horizonal bars represents geometric mean and error bars 
represents the 95% confidence intervals. B) Pre and Post PS 15B IgG levels are linked for each subject.  
Comparison of antibody levels ‘Pre’ and ‘Post’ exposure was carried out using paired t test. P value of 
<0.05 was considered significant.  
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 Active symptom reporting 
All participants in the 23F study group completed the daily symptom logs (16/16), 
and 98% (53/54) participants in the 15B study group completed the daily symptom 
logs. Within the 23F study, two participants became experimentally colonised with 
pneumococcus. One participant was naturally colonised with pneumococcus at 
baseline and throughout follow up visits. For the 15B study, 15 participants became 
experimentally colonised and a further 4 participants who were either naturally 
colonised at baseline or during the study. The only participant who did not complete 
the daily symptom log, was not colonised with pneumococcus throughout the study.    
In both scoring systems, a score of 1-2 (no symptoms-occasional limited symptom) 
was considered asymptomatic. This was to limit the impact of participants reporting 
an isolated event of short duration such as one sneezing episode. Participants who 
reported symptoms prior to inoculation where only considered symptomatic if they 
reported a score which was higher than the baseline score.   
4.3.11.1 23F group symptom analysis 
There were 5 categories relating to nasal symptoms (sneezing, runny nose, 
congestion/stuffiness, itchy nose and post-nasal drip) and 5 categories relating to 
non-nasal symptoms (eye symptoms, throat symptoms, cough, ear symptoms and 
headache) (see Appendix B: Daily Symptom Logs). Overall 19% (3/16) of participants 
reported either nasal or non-nasal symptoms (score ≥3) during the 7 days following 
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inoculation. These symptoms consisted of one participant reporting each of the 
following; sneezing, nasal congestion and throat symptoms. All were reported on day 
7 post inoculation and no symptoms were scored as 4 or more (mild steady 
symptoms).  
Due to small number of positively colonised participants we are unable to definitively 
determine whether colonisation with 23F is symptomatic. However, of the 3 
participants who reported symptoms, none were experimentally colonised with 23F, 
and one was a natural carrier of pneumococcus at baseline and up to day 7.  
4.3.11.2 Colonisation with 15B does not increase likelihood of nasal 
symptoms but may cause coughing 
There were 5 categories related to nasal symptoms (sneezing, runny nose, 
congestion/stuffiness, itchy nose and post-nasal drip) and 15 categories related to 
non-nasal symptoms (cough, chest pain, breathlessness, coughing up phlegm, 
sweating, chills, headache, nausea/vomiting, muscle pain, anorexia, trouble 
concentrating, fatigue, trouble sleeping due to breathlessness, waking at night due 
to breathlessness and wheeze) (see Appendix B: Daily Symptom Logs). Naturally 
colonised participants were included in the colonisation positive group for this 
analysis.  
Overall 25% (13/53) of participants reported nasal symptoms (score ≥3) during the 7 
days following inoculation and 13% (7/53) reported non-nasal symptoms. Similar 
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rates of colonisation positive participants reported nasal symptoms (26%, 5/19) 
compared to colonisation negative participants (24% 8/34). For non-nasal symptoms 
21% (4/19) of colonisation positive participant reported symptoms compared to 9% 
(3/34) of negative participants. No statistically significant difference was observed 
between number of participants who reported symptoms in colonisation positive or 
negative groups (nasal symptoms P=1.00, non-nasal symptoms P=0.23, Fisher’s exact 
test). When evaluating the number of episodes of each symptom being reported 
(number of times over 7-day period), the only statistically significant difference found 
was that colonisation positive participants reported more episodes of cough (9/19 
colonisation positive participants reported cough vs 0/34 non-colonised, P<0.0001, 
Fisher’s exact test), see Figure 38.  
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Figure 38: Number of symptom episodes reported over 7/7 period post inoculation.  
Only symptoms that have been reported as ≥3 score on the daily symptom log are shown. *Cough is 
the only symptom in which colonisation positive participants reported significantly more than non-
colonised participants (9/19 vs 0/34 P<0.0001, Fisher’s exact test).  
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Five participants scored symptoms 4 or 5 (“moderately” or “quite a bit” bothered 
with symptom). Three of which were colonisation positive, all from the 8x104 dose 
group; all complained of cough and one complained of wheeze. Of the two non-
colonised participants both from the 1.6x104 dose group; one complained of sneezing 
and one complained of runny nose, sneezing and congestion. During the study no 
participants had any serious adverse events due to any symptoms reported. This 
included no hospital admission, no extra visits for clinical review and no participants 
were advised to take antibiotics due to clinical need.  
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4.4 Discussion  
The use of the experimental human pneumococcal challenge model allowed us to 
directly study the propensity of two pneumococcal serotypes to cause colonisation.  
The study successfully determined which inoculation dose of 15B, a non-vaccine 
serotype, achieved colonisation rates of >40% and tested the precision of estimated 
colonisation rates at the chosen dose.  
 Success in the model expansion; experimental colonisation of 
non-vaccine type was successful and reproducible 
Colonisation dynamics of a non-vaccine type pneumococcal serotype (15B) was 
evaluated. Experimental pneumococcal colonisation was established in 40% (4/10) 
when inoculated with 8x104 CFU/naris and was shown to be reproducible in the 
extended cohort where colonisation rates were found to be 30% (7/23, overall 
colonisation rate of 33%, 11/33).  
Despite the small number inoculated, the data suggest that a non-linear increase 
exists in colonisation acquisition rates for serotype 15B with increasing inoculum 
doses. The EHPC model has previously used serotype 6B for experimental challenge; 
with this serotype colonisation rates of 40-50% have been achieved in multiple 
studies 139. We hypothesised that colonisation rates would be higher than this for the 
15B serotype following promising in vivo testing which showed superior survival in 
the presence of human blood neutrophils and adherence to human nasal cells 
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compared to the 6B serotype (not discussed further in this thesis). We expected to 
see a dose dependent increase in colonisation rates; in previous EHPC studies 
following inoculation with serotype 6B, colonisation rates were found to be dose 
dependent between a dose of 1x104-4x104 CFU/naris. Following this the colonisation 
rates plateaued after 4x104 up to a dose of 3.2x105 CFU/naris. However, in this study 
following inoculation with serotype 15B, colonisation rates dropped after 8x104, with 
lowest colonisation rates of 13% observed with 1.6x105 CFU/naris dose.  
Better understanding of the dynamics of colonisation of non-vaccine pneumococcal 
serotypes is of growing importance with recent epidemiologic evidence of significant 
serotype replacement following the introduction of PCV13. A cross-sectional study in 
the USA analysed serotype data from children under 7 who were colonised with 
pneumococcus between 2004 and 2014 176. They found that 15B emerged as the 
most common colonisation serotype in 2014 overtaking 19A which was the 
predominant serotype in 2004 but substantially reduced following the introduction 
of PCV13 176. Two UK studies further evaluated the impact of the PCV on 
pneumococcal colonisation and invasive disease. A cross sectional study of 
nasopharyngeal colonisation rates in children under 5 between 2006-2011 found 
that the overall prevalence of pneumococcal colonisation remained stable following 
introduction of PCV7 in 2006 and PCV13 in 2010 177. Vaccine efficacy was good with 
a significant reduction in vaccine serotypes but with a simultaneous increase in non-
vaccine serotypes 177. A further UK observational cohort study reported a 37% 
reduction in overall invasive pneumococcal disease incidence in 2016/17 compared 
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to pre-PCV7 incidence, however a concurrent doubling of invasive disease due to 
non-PCV13 serotypes was observed with an acceleration since 2013/14 166.  
 No difference in colonisation rates found with lytA qPCR 
compared to classical culture  
The proportion of participants who were positive for colonisation and the number of 
positive samples were apparently higher using lytA qPCR for pneumococcal detection 
compared to culture. But these differences were not statistically significantly 
different. When evaluating the whole cohort, irrespective of inoculation dose, 8 
participants (8/37 previously colonisation negative participants, 22%) were found to 
be new colonisers with lytA qPCR only. The majority of these were only found to be 
colonised at day 2 post inoculation (7/8, 88%, one participant found to be positive 
only at day 14). As previously discussed, higher rates of colonisation using qPCR 
method could be explained by this method detecting more low-density colonisation 
episodes.  
Turner et al 178 suggested that the World Health Organisation’s suggested 
methodology of culture and serotyping with the use of latex agglutination (one 
colony used for latex agglutination test) can significantly underestimate multiple-
serotype colonisation. This study found that using sweep serotyping (a sweep of 
colonies are taken from the culture plate and serotyped using latex agglutination) 
identified 1.4 times the number of pneumococci compared to culture and S. 
pneumoniae molecular-serotyping microarray found 1.6 times the number 178. qPCR 
has also been identified as a method of improving pneumococcal detection during 
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co-colonisation episodes with one study reporting a co-colonisation rate of 28.7% 
with qPCR compared to 4.5% detected by culture alone 156. It has previously been 
suggested that non-vaccine serotypes such as 15B, may have been more prevalent, 
prior to introduction of PCV than previously described. These non-vaccine serotypes 
may be low density colonisers which were not detected if co-colonised with a vaccine 
type serotype (likely high-density colonisers). Following the introduction of conjugate 
vaccines, the prevalence of vaccine types reduced and true rates of non-vaccine 
serotypes may have been unmasked with the possibility of no real increase in non-
vaccine type colonisation rates 105.  
 Baseline levels of PS 15B IgG in serum were not associated with 
protection against colonisation acquisition  
We evaluated levels of PS 15B IgG in serum of participants in the 15B extended cohort 
who were inoculated with pneumococcus (8x104 CFU/naris). All participants had 
measurable levels of IgG to 15B capsular PS at screening. No relationship was found 
between levels of serum IgG at screening and colonisation outcome after intranasal 
inoculation. This result is in keeping with previous EHPC studies assessing 
experimental colonisation with 6B serotype. Two studies found no association 
between pre-exposure 6B specific polysaccharide IgG levels and protection against 
colonisation acquisition 10 171.  
The protective effect of pneumococcal capsular-specific antibodies against disease 
has been well established. As early as 1938 published data showed that serotype-
specific anti-pneumococcal serum passively transferred to patients with 
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pneumococcal pneumonia could improve survival rates 179. In addition, the ability of 
vaccine-induced serotype specific antibodies to protect against pneumococcal 
disease has been well established. It is still unclear what amount of circulating serum 
antibodies are sufficient to protect against disease. Research suggests that generally 
higher levels are needed for protection against mucosal endpoints in comparison to 
invasive pneumococcal disease and that there is a degree of variation between 
serotypes 111 180 181.  Being able to estimate the minimum antibody concentrations 
needed for protection against pneumococcal disease is of critical importance for 
assessing new vaccine efficacy. A meta-analysis pooled the data from three double 
blinded controlled trials which evaluated the immunogenicity of the PCV 
immunisation 182. The protective effect of the PCV immunisation is mediated 
exclusively or primarily by antibodies, therefore, the authors sought to find the 
specific concentration of antibody which is estimated to lead to protection against 
pneumococcal disease. This correlate of protection level was reported as an antibody 
level of 350ng/ml 107 182-185. The results of this study showed baseline levels much 
higher than this; median of 3787ng/ml in participants who went on to become 
colonisation positive and 3681ng/ml in those who were protected against 
colonisation.  
 Nasopharyngeal colonisation with 15B found to boost 
immunity by day 14 
Murine models and experimental human challenge models have improved the 
understanding of immune responses to pneumococcal colonisation episodes; 
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colonisation protects against re-colonisation with homologous serotypes and against 
disease 26 186. The role of antibody-mediated immune responses targeting serotype-
specific pneumococcal polysaccharides has been well researched. It is believed that 
protection against pneumococcal disease involves antibody mediated immune 
responses which target serotype-specific capsular polysaccharides 187. We have 
demonstrated that intranasal exposure to 15B serotype, without acquisition of 
colonisation, did not boost serum IgG levels to the 15B capsular PS. Conversely in 
participants who acquired experimental pneumococcal colonisation (with serotype 
15B) during the study a significant increase in serum IgG levels to 15B capsular PS 
was observed.  
Our data are consistent with previous EHPC studies, in which inoculation with 
serotype 6B was not associated with a change in 6B specific IgG levels in serum 24. 
One study showed that nasopharyngeal pneumococcal exposure alone may be 
immunising; capsular specific IgG levels were found to significantly increase in nasal 
wash and broncho-alveolar lavage samples following intranasal inoculation without 
colonisation 24. The EHPC team have previously demonstrated colonisation infers 
100% protection against re-acquisition of a homologous serotype, up to 11 months 
following the first colonisation episode 10. In this study during the initial colonisation 
episode a significant rise in serum anti-6BPS IgG levels were observed which is 
consistent with the finding for serotype 15B demonstrated in this thesis 10.   
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 Low colonisation rates observed with 23F serotype 
We were unsuccessful in expanding the EHPC model with a further vaccine type 
serotype. Colonisation rates remained low with escalating inoculum doses between 
2x104-1.6x105 CFU/naris, with highest colonisation rates observed of 20% in 8x105 
CFU/naris inoculation group. No participants became colonised following inoculation 
with 1.6x105 CFU/naris dose. This serotype (P833, inoculum doses ranging from 
2x104- 3.2x105 CFU/naris) had previously been tested by our group, poor colonisation 
rates were observed with a maximal colonisation rate of 10%. Following investigation 
of the serotype used in this study (23F P833), an amiC frameshift mutation was found 
and investigated in a murine pneumococcal challenge, results suggesting this 
mutation was the cause of the poor colonisation rates. 
For the current study we ensured the isolate used, 23F P1121, contained a wild-type 
form of the amiC gene. This isolate change did not lead to significantly better 
colonisation rates. The amiC gene may have contributed to poor colonisation rates 
in the initial study but it is clear now that either another factor or multiple factors 
may be implicated in a serotype’s ability to colonise the host. As previously discussed, 
host factors may affect colonisation rates. Epidemiological data suggest that 23F 
serotype was highly prevalent in UK prior to the introduction of PCV7 into the 
childhood immunisation schedule 15. Recent studies suggest that rates of 23F 
serotype have significantly fallen over the last decade 176. Previous colonisation with 
this serotype may have induced immunity and impacted on colonisation rates 
observed. Using the experimental human pneumococcal carriage model, it has been 
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shown that protection from colonisation (with 6B serotype) was associated with a 
high number of circulating 6B specific IgG-secreting memory B cells at baseline 171. 
Alternatively, other bacteriological differences observed between 23F and 6B 
(known to have high experimental colonisation rates) may have impacted on this 
serotypes ability to colonise the nasopharynx.  
Poor colonisation rates with the 23F serotype are likely multifactorial and may be 
due to a combination of serotype and host factors. Pneumococcus is a pathogen that 
grows in chains, it has been suggested that serotypes grow in long-chain formation 
may be more successful in colonising the nasopharynx 188. In vitro and in vivo analyses 
have shown that pneumococcal adherence is increased proportionally to the average 
size of the chain 188. The ability for serotypes or specific isolates to grow in chains and 
the average length of chains may be an important predictor for determining 
successful colonisation. Longer chains may improve adherence of pneumococcus to 
the mucosal service and therefore give an advantage in colonisation through a larger 
number of possible adhesive events per particle. Assessing chain formation of any 
future serotypes prior to experimental inoculation may be beneficial for any future 
experimental pneumococcal human challenge studies.  
It has also been suggested that the biochemical structure of the capsular 
polysaccharide of different serotypes of pneumococcus may impact on their success 
at colonising the nasopharynx. In vitro assays have shown an association between 
resistance to neutrophil-mediated killing and colonisation prevalence; serotypes 
which were more heavily encapsulated were more resistant to this neutrophil- 
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mediated killing 189. Further research showed that surface charge of Streptococcus 
pneumoniae may affect colonisation potential. It has been shown that serotypes 
which are more negatively charged also have a higher resistance to killing by 
neutrophils in vitro 190. Using previous epidemiological studies, it was also shown that 
the more negatively charged serotypes were associated with higher colonisation 
rates in human populations 190. Understanding better the factors which may explain 
why serotypes have varying colonisation potential is important for predicting 
serotype replacement and can support the identification of serotypes to be used in 
future human challenge models.  
 Experimental colonisation does not cause nasal symptoms but 
increased cough 
We actively sought symptom data using a daily symptom log on the day of inoculation 
and 7 days following. We were unable to compare symptoms reported in the 23F 
group due to small numbers of colonisation positive participants. In the 15B group, 
due to small numbers in individual inoculation dose groups, we combined all 
colonisation positive and negative participants. The number of participants reporting 
nasal symptoms in both groups were similar, suggesting that colonisation is an 
asymptomatic process in adults. Interestingly of the non-nasal symptoms reported 
cough was found to be more common in colonisation positive group, in terms of both 
number of participants reporting the symptom and the frequency with which it was 
reported over a 7-day period.  
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Nasopharyngeal colonisation is generally considered an asymptomatic event in 
adults. However, there is little definitive research looking at this question. Cross-
sectional studies in children report a strong association between a history of upper 
respiratory tract infection (URTI) symptoms, cough or coryza (in the weeks preceding 
sampling) and the detection of nasopharyngeal pneumococcal colonisation 164 191. 
Unfortunately, due to this study design the causality of symptoms is not clear. 
Pneumococcal colonisation may cause URTI symptoms or coryza may increase the 
rate of pneumococcal colonisation acquisition or there may be a third factor that 
both colonisation and viral URTIs are independently associated with.  
One study did report that for serotype 19F, colonisation was strongly associated with 
children who complained of symptoms such as coryza, sneezing, cough and 
expectoration 192. These children were recruited from the emergency room of a local 
paediatric hospital. The study did not report on the diagnosis given to these patients 
therefore an independent cause is possible for the symptoms reported 192. The same 
study also recruited participants from a day care centre; for this group the results of 
symptom reporting was not published 192.  
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We investigated factors affecting nasopharyngeal pneumococcal colonisation using 
an experimental human carriage model.  
The two main aims were: 
Aim 1: To investigate if the hands can be a vector for transmission of S. 
pneumoniae from hands into the nasopharynx, leading to colonisation.  
Aim 2: To investigate the propensity of serotypes 23F and 15B to cause 
colonisation following experimental human challenge. 
These projects used the Experimental Human Pneumococcal Carriage model to 
investigate these research questions. This model offers a novel and feasible method 
of investigating pneumococcal transmission in a controlled environment. The 
expansion of this model during this project to include a non-pneumococcal vaccine 
serotype (15B), further supports the model’s potential for use in vaccine 
development.  
A discussion of the main findings was provided at the end of each chapter; therefore, 
the aim of this general discussion is to provide an overall summary of the findings of 
these research studies. It also outlines some limitations of the research studies which 
may impact on interpretation of the results. Finally, it details implications of this work 
and how future work could provide deeper insights.  
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5.1 Main findings 
 Chapter 3- Hands were vectors for hand to nose transmission 
of pneumococcus 
Chapter 3 reports the results from a pilot study we conducted to investigate 
pneumococcal transmission using a human challenge model 146. It is generally 
thought that transmission of S. pneumoniae occurs primarily by indirect contact via 
inhalation of infected airborne droplets. Previously it has been unclear if hands or 
fomites have a role in pneumococcal transmission. We found that the hands can be 
vectors for transmission of pneumococcus leading to acquisition of colonisation. 
When using a combination of microbiological culture and lytA qPCR for 
pneumococcal detection, colonisation rates following hand to nose transmission are 
comparable to rates observed following intranasal pneumococcal inoculation in 
previous studies 149.                                                         
We demonstrated that pneumococcus can be transmitted leading to colonisation 
even after drying on the skin. Molecular methods of detecting pneumococcus 
showed similar rates of transmission when the bacteria were wet and immediately 
after visual drying on skin (50%). In addition, significant direct contact with the nasal 
mucosa (such as picking/poking the nose) is not needed for colonisation to occur 
following pneumococcal transmission. Overall rates of colonisation following 
transmission using the rubbing and sniffing method were comparable to the poking 
nose method. Direct contact with the mucosa was an important factor in enhancing 
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acquisition of colonisation in the dry bacteria sub-groups. Dry poke group had an 
overall colonisation rate of 70% (7/10) compared to 30% (3/10) in the dry sniff group. 
Streptococcus pneumoniae is a leading bacterial cause of infections worldwide; 
transmission, colonisation and invasion are the key stages in the pathogenesis of this 
bacteria. Our understanding of the process of transmission has profited recently by 
new models of transmission in rodents. In addition, experimental pneumococcal 
human challenge studies have greatly improved our understanding of the 
colonisation process. The Hand to Nose study described in Chapter 3 sought to build 
upon previous work by using this human challenge model to study pneumococcal 
transmission for the first time in humans. The results are in keeping with murine 
models which suggest that an environmental reservoir of pneumococcus may be an 
important source of transmission 47 50. Pneumococci have been shown to be able to 
survive days outside the human host, in nutrient-sufficient conditions, and have been 
cultured from common objects 193 194. It has been proposed previously that 
pneumococcus could be acquired from fomites and that bio-film growth 
characterises may be a key factor in length of time it remains infectious in the 
environment 193. Transmission during colonisation episodes is crucial to the 
infectious life cycle of pneumococcus. Future use of human infection studies 
investigating mediators of pneumococcal transmission could identify interesting 
targets for prevention of pneumococcal spread. 
Finally, the data from this chapter suggest that using both microbiological culture and 
a molecular method such as lytA qPCR for the detection of pneumococcal 
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colonisation can reduce the chance of missing low-density pneumococcal 
colonisation episodes. We found that all culture-positive samples were also qPCR 
positive. Interestingly the culture positivity rate decreased with decreasing densities 
measured by qPCR. All samples that were culture negative but qPCR positive had 
qPCR densities below 103 copies/ml. This suggests that qPCR may be more 
appropriate for detecting low density colonisation episodes.  
This study adds to the growing body of evidence suggesting that traditional culture 
methods may be suboptimal for detecting low density pneumococcal colonisation 
episodes. Our findings were in line with Olwagen et al 156 who found that qPCR was 
more sensitive in detecting concurrent colonisation with multiple pneumococcal 
serotypes. They reported that the majority of additional serotypes detected by the 
molecular method had bacteria load of <104 CFU/ml156. The use of qPCR method in 
addition to classical culture for detection of pneumococcal colonisation could help 
improve our understanding of the process and the effect of interventions such as PCV 
immunisation. Evaluation of PCV13 immunisation using the experimental human 
pneumococcal challenge model suggested that the success of this vaccine lies in 
reduction of colonisation acquisition 169. Using culture methods of detection, a 78% 
reduction in colonisation rates was found using PCV13 compared to control 169. 
Reduction of on average three logs in colonisation density in volunteers vaccinated 
with PCV13 was also observed. These results suggest the efficacy of PCV vaccine may 
be partially mediated by controlling pneumococcal colonisation density rather than 
solely stopping acquisition of colonisation.  
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 Chapter 4 – The EHPC model was successfully expanded to 
include non-pneumococcal vaccine serotype  
Chapter 4 demonstrated the propensity of serotypes 23F and 15B to cause 
nasopharyngeal colonisation in health adults. Colonisation rates for serotype 23F 
remained at or below 20%, regardless of dose. For serotype 15B acquisition of 
colonisation was dose-dependent until 8.0x104 CFU/naris, at this dose the highest 
colonisation rates were observed. An extended group of participants were inoculated 
with this dose to give a better precision of estimated colonisation rates (overall 
colonisation rate of 33% [11/33]). At the higher dose of 1.6x105 CFU/naris lower 
colonisation rates were observed. A previous human challenge study using serotype 
6B found that colonisation rates plateaued at inoculum doses higher than 8.0x104 
CFU/naris 139. This adds to previous data from human challenge studies and murine 
models which have showed a lack of relationship between dose of inoculated 
pneumococcus and colonisation densities 139 195. 
Pneumococcal serotype affects pneumococcal pathogenesis and the bacteria’s 
ability to colonise the host. It has been shown that serotypes differ in their 
prevalence, tendency to cause disease or outbreaks and their age distribution 89 133 
196. The New Serotypes study did not investigate possible bacterial factors which may 
have impacted on colonisation potential.  
This chapter also reported that nasopharyngeal colonisation does not cause nasal 
symptoms when symptom data are actively sought from participants for 7 days post 
inoculation. However, the data suggest that participants who are colonised are more 
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likely to develop a cough during a colonisation episode. Cross-sectional studies in 
children have reported that upper respiratory tract symptoms can be a significant 
risk factor for pneumococcal colonisation 164 191. It is unknown from this type of study 
design if colonisation causes symptoms or if concurrent symptomatic viral infection 
increases risk of colonisation.  
Chapter 4 demonstrated that for serotype 15B pre-exposure levels of anti-capsular 
antibodies were not associated with protection against colonisation acquisition. This 
was in keeping with previous experimental human challenge study results where 
baseline levels of 6B specific IgG levels were similar in all participants and did not 
predict colonisation status following exposure to serotype 6B 10 171. The role of these 
antibodies and levels needed to protect against colonisation are still unclear. Murine 
models have shown that passive transfer of anti-capsular polysaccharide IgG to 
contacts pups could stop acquisition of colonisation 197. Pre-exposure PS 15B IgG 
levels of all participants were ten times higher than the previously established and 
accepted threshold antibody level which is thought to protect against IPD of 
350ng/ml. Protection against mucosal colonisation may be better associated with IgG 
or IgA which are produced by B cells at the mucosal surface rather than serum levels 
171.  
This study corroborated observations from previous experimental human challenge 
studies, demonstrating that a colonisation episode increases serum capsular-specific 
antibody levels 10 171. We did not assess the function of the anti-PS responses 
observed here. However, previous research found that colonisation induced a 
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significant increase in opsonophagocytic killing activity 10. In addition, a significant 
increase in mucosal IgG to PspA levels was observed 28 days following exposure in 
colonisation positive participants 10. These results suggest that colonisation may be 
beneficial and could lead to immune boosting to provide protection against 
subsequent pneumococcal disease and colonisation. This protection is likely to be 
serotype-specific as shown by two experimental human challenge studies; one 
showed 100% protection when participants were re-challenged with a homologous 
serotype10. Whereas the second study demonstrated that heterologous challenge 
lead to 50% colonisation rates which comparable to conisation rates observed in 
previous experimental challenge studies using the same serotype (6B) 171.  
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5.2 Methodological criticisms  
One area which could impact the generalisability of results from both studies lies 
within the recruitment of individuals. All participants were healthy young adults. It is 
unknown if the rates of results from the two studies described in this thesis would 
be predictive of results in children, the elderly, or the immunocompromised. 
Understanding of the drivers of pneumococcal colonisation in these cohorts is 
important for prevention strategies as they are known to be high risk for 
pneumococcal infection. Due to concerns about safety, using a human infection 
model in children is likely unethical and its use in immunocompromised adults or 
adults with chronic medical complaints would need significant consideration and 
enhanced safety protocols. Controlled human infection model (CHIM) studies in 
these groups would allow for a unique opportunity for the investigation of host-
pathogen interactions in these groups which are high risk for disease. We could also 
investigate how differences in the microbiome of these groups effects the dynamics 
of mucosal colonisation of pneumococcus.   
In children higher rates of colonisation would be expected in human infection model 
studies. Previous studies have shown that the highest rates of pneumococcal 
colonisation are observed in infants and that rates of colonisation fall with increasing 
age. Evidence also suggests shorter duration of colonisation episodes occur with 
increasing age but that children are colonised at high densities 198. Children are also 
believed to be the primary reservoirs for community pneumococcal transmission. 
Therefore it could be hypothesised that the Hand to Nose study may have shown 
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higher rates of transmission and colonisation in a paediatric population 199. Multiple 
epidemiological studies have shown that in family transmission was a key source of 
new episode of nasopharyngeal colonisation; results suggest that children tend to 
initiate this by bringing pneumococcus into the household 15 198 200. Higher densities 
of colonisation observed in children would likely impact on transmission, this may 
lessen the impact or need for direct contact for transmission to occur.  
Conversely in the elderly many studies have reported low rates of pneumococcal 
colonisation 201. One study that sampled over 3000 participants, with a mean age of 
74, reported a colonisation rate of just 1.8% 202. Due to this we would hypothesise 
that experimental colonisation would also be lower with increasing age. 
Paradoxically,  this reduction in colonisation coincides with an increase in the 
prevalence of pneumococcal disease in this age group with causes significant 
morbidity and mortality 201. The mechanisms for this are unclear. One hypothesis is 
that in the elderly, increased levels of proinflammatory cytokines may lead to 
clearance of colonisation before a natural boosting of pre-existing immunity can take 
place. A further hypothesis is that the elderly have lower density pneumococcal 
colonisation episodes and therefore colonisation is undetected but is highly 
prevalent in this age group.   
There are some general limitations of the model which may impact on the studies 
described in this thesis. The bacteria stock used for exposure is derived from culture 
media and is mid-log phase, these experimental conditions may influence 
pneumococcal viability and colonisation potential. In addition, it is unknown if the 
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dose we expose participants to is similar to what the nasopharynx may be exposed 
to naturally. Due to this our experimental carriage model may overestimate or 
underestimate the potential for hand to nose transmission of pneumococcus or the 
potential for 23F and 15B to colonise the nasopharynx. For both studies described in 
this thesis we investigate the dynamics of mucosal colonisation with only one 
serotype of pneumococcus. In the community it is likely that we are exposed to 
multiple pneumococcal serotypes simultaneously and there is evidence to suggest 
that pneumococcal co-colonisation is not uncommon. One study found that 28.7% of 
participants who were known to be colonised with pneumococcus using classical 
culture, were co-colonised with multiple pneumococcal serotypes when using qPCR 
to detect the serotype 156.   
One possible methodological criticism could be the use of nasal washes for detection 
of nasopharyngeal colonisation. This method has been validated by our team 
previously; it was found that nasal wash detected significantly more pathogens 
compared to nasopharyngeal swab and was more comfortable for volunteers 132. 
More recently, it has been suggested that for adults trans-oral sampling may be 
superior for detecting colonisation 159. No trans-oral samples were taken in either 
study described in this thesis, using a combination of nasal wash and oropharyngeal 
swab may have increased detection of pneumococcal colonisation further 159.  
Another possible methodological criticism may be the cycle threshold (CT) value of 
40 that was used for the qPCR experiments. Many of the culture-negative samples, 
that were found to be positive for pneumococcal colonisation using qPCR, had an 
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average Ct value >38, which is very close to the assay limit of 40. This amplification 
of samples that are culture negative has also been reported previously 155 203-205. 
There is no consensus about these borderline positive results; we could attribute 
these to the superior sensitivity of PCR over culture or it could be attributed to 
detection bacterial DNA from dead organisms or contamination 151 203-205. In these 
studies, our strict laboratory procedures regarding qPCR reduces the possibility that 
these results are due to contamination by PCR amplicons. In addition, as our samples 
are from non-sterile sites and the known difficulties of pneumococcal culture, the 
increased rates of pneumococcal colonisation using qPCR is not unexpected and have 
been seen in previous studies 149 151.  
A further methodological criticism may be that patients were followed up for a 
maximum of 14 days post pneumococcal exposure and colonisation positive 
participants completed a course of antibiotics after this final visit to clear 
colonisation. This limits the ability for us to comment on duration of colonisation 
episodes in either study. The short follow up period of participants limits our ability 
to assess how duration of colonisation and different transmission methods affect 
longevity of colonisation. To confidently answer these questions participants would 
need to be followed up at regular intervals until they naturally cleared the 
pneumococcus.   
For the Hand to Nose study one possible criticism may be the investigation of only 
potential transmission of pneumococcus by self-inoculation. There was also no 
investigation of pneumococcal shedding from a colonisation episode. Recent murine 
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models have highlighted the importance of understanding pneumococcal shedding 
to understand transmission, we need to better understand the process of 
pneumococcal exit from the colonised host 20 49. Examining the relative risk of 
pneumococcal spread via aerosolised bacteria, direct contact or indirect contact 
would be beneficial similar to previous studies investigating transmission of 
respiratory viruses 206-209. One study described multiple experiments to investigate 
the transmission of rhinovirus using laboratory infected participants (donors) and 
susceptible participants (recipients) 206. These experiments included: 
• Investigation of spread by aerosol. The infection rate of recipients who were 
not allowed to touch their faces during contact with donors was analysed.  
• Investigation of a combination of spread by aerosol, indirect contact and 
direct contact. Infection rate of recipients who were in contact with donors 
with no restrictions. 
• Investigation of possible transmission through infected fomites. The only 
contact between donors and recipients in this experiment was potential 
fomites/objects which had been heavily used by donors for 12 hours. 
Finally, neither study investigated the potential effects of the URT microbiome on 
pneumococcal colonisation. To successfully colonise the nasopharynx, the 
pneumococcus must compete with many other micro-organisms including 
Staphylococcus aureus and coagulase-negative staphylococci. It is still unclear why 
some individuals are at lower risk of pneumococcal colonisation and subsequent 
disease. It is hypothesised that competition and co-operation between the 
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pneumococcus and other bacteria which colonise the nasopharynx likely influences 
the incidence of colonisation episodes 210 211. Investigating and comparing the 
microbiome of participants in our model who become colonised and those who do 
not could provide potential new strategies to limit pathogenesis.  
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5.3 Implications and future work  
 Chapter 3: Hand to Nose 
The hands have been implicated as vehicles for transmission of many pathogens and 
viruses. The results from Chapter 3 suggest that pneumococci can be transmitted by 
a similar process. Due to the high burden of disease caused by pneumococcus and 
the rise in antibiotic resistance, strategies to prevent pneumococcal infection are 
more important than ever. Better understanding of how pneumococcus is 
transmitted from person-person is crucial and can inform more effective prevention 
strategies. There is clear evidence that handwashing reduces transmission of many 
bacterial and viral pathogens and can save lives. This study adds to this knowledge 
base by specifically looking at hand transmission of pneumococcus. Unlike many 
other pathogens, the person colonised with pneumococcus is generally clinically well 
and asymptomatic which often relates to lower rates of hand washing. Our results 
suggest that regular hand washing, and cleaning of potential fomites could be an 
important approach to reducing the transmission of pneumococci via these routes. 
This is particularly important in care setting such as child care centres and hospitals 
where transmission and colonisation have a higher risk of leading to disease. These 
findings can be useful in health education campaigns and in the event of further 
epidemics of pneumococcal disease can inform containment strategies. Gavi, the 
Vaccine Alliance, in 2017, partnered with Unilever to promote handwashing with 
soap and immunisation together as they believe that promoting these two cost-
effective child survival interventions together could save many lives 212.  
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We have developed a human infection model which can investigate transmission 
dynamics in a controlled environment. Following this pilot study, the international 
consumer goods company Unilever have funded the use of this modification of the 
EHPC model. Our group has recently concluded a randomised control trial to 
investigate the effectiveness of their anti-bacterial soap, Lifebuoy. In future the 
model could be in the product development phase of new hand cleaning products to 
ensure reduction in transmission of this important bacterial pathogen. On the other 
hand, future work could show that soap universally stops pneumococcal 
transmission, irrespective of formulation which could advise public health 
interventions in the developing world.  
This chapter’s results also add to the growing amount of research suggesting that 
molecular methods of pneumococcal detection have an important role to play in the 
detection of colonisation episodes. Culture is considered the gold standard method 
for detection of upper respiratory colonisation of pneumococcus and is 
recommended by the WHO Pneumococcal Carriage Working Group 150. We have 
demonstrated that using microbiological culture and lytA qPCR methods are 
complementary. Simultaneous use improves detection rates of pneumococcus, 
especially in low density colonisation episodes and improves detection of 
simultaneous colonisation with multiple pneumococcal serotypes. This is important 
for any future transmission studies and for vaccine efficacy studies using 
experimental colonisation as a primary endpoint. If the endpoint used in future 
studies is a reduction in colonisation rates or density, the sensitivity of methods used 
to accurately detect these changes becomes increasingly important. The results from 
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our study suggest that using culture only may overestimate or underestimate the 
effect of any intervention if low density colonisation episodes are missed. From the 
current research, the significance and natural history of low density colonisation 
episodes is unclear. Future research investigating the dynamics of mucosal 
colonisation in participants who are qPCR positive culture negative would be 
beneficial to further inform this issue.  
One way in which this research could be taken forward is to investigate how long 
pneumococcus continues to be viable at high enough numbers to cause colonisation 
following drying on the hands. In addition, better understanding of pneumococcal 
survival duration in nasal secretions would help to understand the dynamics of 
pneumococcal transmission. Pneumococcal shedding in humans during a 
colonisation episode has yet to be researched. Understanding how the 
pneumococcus exits the colonised host and which factors increase this process is also 
important for prevention of transmission.  
 Chapter 4: New Serotypes 
Chapter 4 increases the scope of the EHPC model, this study showed the success of 
a non-pneumococcal vaccine type serotype for the first time in a human infection 
model. The results of this study improves current understanding of colonisation 
dynamics of serotype 15B, which is one of the most prevalent serotypes causing 
invasive pneumococcal disease currently in England and Wales 166. Understanding of 
non- vaccine serotypes is increasingly important. The widespread use of 
pneumococcal conjugate vaccines has significantly reduced invasive pneumococcal 
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disease caused by serotypes covered by the vaccine. It has been estimated that 
nearly 40,000 invasive pneumococcal disease cases have been prevented in England 
and Wales since PCV was introduced 166. However, the rapid increase in some non-
vaccine serotypes highlights the importance of improved understanding of these 
non-vaccine serotypes. Using the EHPC model we can investigate colonisation 
dynamics of different pneumococcal serotypes which represent a variety of capsular 
types and protein expression profiles. Evaluating how serotype specific factors effect 
colonisation and immune responses, especially for serotypes not included currently 
in vaccines, may help aid in the development of new vaccines. This MD project 
focuses predominantly on the clinical aspects of the model, a number of other 
analyses and mechanistic work were undertaken by the wider EHPC team but are not 
discussed in this thesis.  
The success in developing the EHPC model to include this non-vaccine serotype 
further supports its use for the testing of novel vaccines. Colonisation is a 
prerequisite for invasive disease and is the primary reservoir for pneumococcal 
transmission in the community. Herd immunity has been observed following the 
introduction of PCV into childhood immunisation programmes; control of 
nasopharyngeal colonisation has been suggested as the mechanism for this 
phenomenon. Due to this, it has been suggested that the EHPC model can use 
prevention of colonisation, or reduction in colonisation density as a surrogate of 
vaccine-induced immunity and potential for herd immunity. If this is true, it would 
allow for a cost-effective method of down-selecting pneumococcal vaccine 
candidates early in development. Using the controlled human infection model 
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(CHIM) early in vaccine development timeline, allows for preliminary efficacy testing 
to be carried out in a small number of participants. Early results suggesting poor 
efficacy can minimise the risks of a late clinical failure in following expensive phase 2 
and 3 clinical trials 128.  
Extending this model to investigate other serotypes and testing of a mixed serotype 
inoculum may provide important information about interspecies competition and 
how different serotypes with different capsules and expressed proteins effect 
colonisation. A recent study which used both standard culture methods and qPCR for 
pneumococcal detection found that culture alone significantly underestimated the 
rate of simultaneous colonisation of multiple serotypes 156. This study highlighted the 
need for better understanding of the dynamics of interspecies competition and 
simultaneous colonisation. This may help to identify steps during transmission, 
colonisation or infection, where pneumococci must pass through a microbiological 
bottleneck and may help understanding of vaccine escape mechanisms. A study in 
which healthy adult participants are inoculated with a mixed inoculum could 
investigate this, either multiple serotypes, or similar serotypes with different gene 
expression, genome sequencing could be used to support identification of serotype 
recovery. 
5.4 Overall considerations 
The work conducted for this thesis adds to the current understanding of what drives 
nasopharyngeal pneumococcal colonisation. Results from the Hand to Nose project 
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uncovered the role of the hands as vehicles for the transmission of pneumococcus 
and acquisition of colonisation. This has never been shown in humans before, this 
modification of the human challenge model can in the future build upon recently 
developed murine models investigating pneumococcal transmission dynamics. 
Future studies should aim to investigate bacterial shedding during colonisation 
episodes and identify potential factors that promote shedding. Identification of 
factors that must be inhibited in order to effectively reduce pneumococcal 
transmission is key in prevention of pneumococcal disease.  
The growing prevalence of serotypes not included in the PCV immunisation is a major 
concern. In children serotype 15B/C was a common coloniser prior to the 
introduction of PCV (2001) and its prevalence has continued to expand since the 
vaccine was introduced into many childhood immunisation programmes worldwide 
176. The use of the novel human challenge model used in this project has allowed for 
better understanding of this serotype and how host and bacterial factors can affect 
pneumococcal colonisation. A major challenge of new potential vaccine candidates 
is the huge costs involved in large scale phase II and III studies. The successful 
development of the EHPC model to include serotype 15B, which PCV 13 
immunisation does not protect against, would support the models use in future 
vaccine testing, aiming at down-selecting candidates that failure to show an impact 
on colonisation. An area which needs further study prior to this is the question of 
how we measure vaccine efficacy with colonisation; what level reduction in 
acquisition is needed for protection, or can a reduction in colonisation density suffice 
to infer protection and herd immunity by reducing transmission?
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7 Appendices 
7.1 Appendix A: Safety information leaflets 
Hand to nose transmission of streptococcus  
pneumoniae in healthy participants – pilot study 
 
 
Safety Information Sheet 
 
If you are very 
unwell  
Contact your GP or Emergency Department  
Simultaneously inform the research team tel: 
07912 053 981 
If you have mild 
or moderate 
symptoms   
Contact the Respiratory Research team 
Land line:  0151 706 3381 
Mobile: 07912 053 981 
Royal Liverpool Hospital 0151 706 2000  
If you are well   For safety monitoring we ask you to text us daily 
for the first 7 days before 12.00 (inc weekends) 
Tel: 07912 053 981 
 
If you are unwell:  
Pneumococcus bacteria may cause infection. Although this is very unlikely we ask you to 
familiarise yourself with early symptoms or signs that may indicate infection to make sure 
they are recognised and treated. Please contact the research team who are available day 
and night if you have any symptoms as follows:  
 
If you have these symptoms 
Contact the research team:  
 
Fever (temp>37.5 ˚C) (if below 36 ˚C please recheck) 
Shivering 
Headache 
New rash 
Drowsiness 
Cough 
Earache 
Signs of skin infection: pimples, blisters or raised red 
itchy bumps with redness or swelling 
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If you are very unwell or 
concerned about your 
health 
 
Caution: it is possible that 
you may be unwell for 
another reason not related 
to these bacteria. 
Seek urgent care from your GP or hospital 
Start taking the antibiotic (one tablet of amoxicillin three 
times a day)  
Tell the doctor:  
You were exposed to live Streptococcus pneumoniae on 
your hand and attempted to transmit this into your nose.      
It is sensitive to amoxicillin  
Your GP records say you have no history of allergy to this 
antibiotic. 
 
What if I am not near a phone? 
 
If you are unwell and you are unable to make contact with the research team, we would 
advise that you start taking your antibiotics straight away. If you have any concerns we 
recommend you attend your nearest GP, Walk in centre or Emergency Department. 
 
What do I tell the doctor? 
 
If, for any reason you have to attend your doctor or the hospital you need to inform them that 
you have had live Streptococcus pneumoniae inoculated into your nose which is can be 
treated by amoxicillin as it is sensitive to this antibiotic).  Please contact us as soon as you 
can.  
 
What if I have a general cough or cold? 
 
Please contact us and we can advise you whether we would like to assess you in the clinic. In 
some cases, we may ask you to have a throat swab to confirm if you have an infection or 
advise you to take the amoxicillin antibiotic or advise you to see your GP.  
 
Safety monitoring  
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To ensure you are not experiencing any problems we ask you to contact us daily after we 
have put bacteria in your nose for week and to inform us at any time in the study if you are 
unwell for any reason.  
For the first 7 days please: 
Set an alarm on your phone  
Take your temperature each morning 
Text your temperature and if you are well any time before 12.00  
If we do not hear from you, we will text then phone you.  
 
Provide contact details of someone that can contact you if we have not heard from you 
(housemate etc)  
 
Explain to them that you are in this research and that we may contact them if we are unable to 
contact you...  
 
Record symptoms daily on the diary provided and return this at your clinic appointment 
Keep your antibiotics and our contact details with you at all times during the study (return the 
antibiotic if unused on your last visit).  
 
At any time in the study: 
If you feel unwell, please contact us to let us know we are available day and night   
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Do you have any of the following? 
Fever (>37.5 ˚C) 
Headache 
Rash 
Drowsiness 
Cough 
Earache 
Generally Unwell 
YES 
NO 
Contact Research Team 
by 12 noon every day 
for first 7 days on  
07912 053 981 
 
Call the Emergency Research Team on        
07912 053 981                                    24 hours/ 
day 
Or Call 0151 706 2000 and Ask for 
Respiratory Research  
If you are unable to get to a telephone 
start taking your antibiotics 
immediately 
Inoculation LEAFLET 
Experimental Human Pneumococcal 
Carriage (EHPC) Model Using New 
Serotypes 
 
Information Sheet 
EMERGENCY RESEARCH TEAM 
07912053981 24 hours/ day 
OR CALL 
0151 706 2000 
Hospital Switchboard 
Ask for Respiratory Research 
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Do I need to do anything if I feel well? 
 
We ask that for the first 7 days you text or phone the research nurse by 12noon every day on the 
following number: 07912 053 981 
This is to ensure that you are not experiencing any problems. If we do not hear from you by 12noon we 
will contact you to make sure you are not experiencing any problems. In the event that we cannot contact 
you, your next of kin will be contacted.  
 
Things you should know........Following inoculation with pneumococcus 
 
After the pneumococcus is put into your nose it is possible that it may cause an infection. Although this is 
very unlikely it is sensible that you familiarise yourself with symptoms or signs that may indicate infection 
to make sure they are recognised and treated early. Keep your thermometer, antibiotics and contact 
numbers with you at all times during the study.  
 
WHAT SHOULD I LOOK OUT FOR? 
If you feel generally unwell or have any of the following: 
Fever (temp>37.5 ˚C) 
Shivering 
Headache 
New rash 
Drowsiness 
Cough 
Earache 
 
If you have any of the symptoms or signs marked in bold please call the emergency number immediately. 
 
07912 053 981 24 hours/ Day 
OR 
Phone 0151 706 2000 and ask for Respiratory Research 
What should I do? 
 
If you have any of the above symptoms we would ask that you should contact the research team on the 
following numbers without delay 07912 053 981  24 Hours/ Day 
0151 706 2000 Hospital switchboard - ask for Respiratory Research. The Consultant will be available by 
telephone 24 hours a day for advice. 
 
What if I feel very unwell? 
 
In the unlikely event you feel very unwell we advise you to start taking the antibiotics immediately and 
phone the emergency research team (xxxxx xxx xxx).  In the unlikely situation that you are unable to make 
contact with the team we recommend you attend your nearest Emergency department. 
 
What if I am not near a phone? 
 
If for any reason you are unable to make contact with the emergency research team, we would advise that 
you start taking your antibiotics straight away. This is one tablet (500mg) of AMOXICILLIN to be taken three 
times per day. If you have any concerns we recommend you attend your nearest Emergency Department. 
 
What do I tell the doctor? 
 
If, for any reason you have to attend your doctor or the hospital you need to inform them that: You have 
had live Streptococcus pneumoniae type _______ inoculated into your nose on ___/___/_______ as part of 
a randomised control trial into nasal carriage and vaccination. The bacteria you carry are fully sensitive to 
amoxicillin and you have no history of allergy to this antibiotic. 
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7.2 Appendix B: Daily Symptom Logs 
Daily symptom log used for all participants inoculated with 23F serotype. Adapted 
from modified Likert Score from Spector et al 172. 
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Daily symptom log for all participants inoculated with 15B serotype  
 
 
 
 
